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General introduction
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General inTroducTion and aim of The Thesis 
Due to a high number of chemicals with only limited data on toxicity, there is a high 
demand for performing toxicological hazard identification and risk assessment of 
those chemicals. One toxic effect of great concern is developmental toxicity, i.e. adverse 
effects produced prior to conception, or during pregnancy and childhood. Exposure 
to agents affecting development can result in a wide range of adverse developmental 
effects, such as spontaneous abortions, stillbirths, malformations, early postnatal 
mortality, reduced birth weight, mental retardation, sensory loss, and other adverse 
functional or physical changes that are manifested postnatally [1]. Due to the high 
impact developmental toxicants exert on human society, the need for efficient methods 
to screen chemicals, drugs and environmental pollutants for their developmental 
toxicity is obvious.
in vivo developmental toxicity study
According to current international guidelines, developmental toxicity can be evaluated 
through exposure of pregnant animals, mostly rats and rabbits, and subsequent 
assessment of toxic effects in their fetuses [2-4]. A concurrent control group treated 
with the vehicle used for agent administration is a critical component of a well-designed 
study. At a minimum, a high dose, a low dose and one intermediate dose are included. 
Ideally, the high dose is selected to produce some minimal maternal or adult toxicity. The 
low dose is generally a no observed adverse effect level (NOAEL) for adult and offspring 
effects and if the low dose produces a biologically or statistically significant increase in 
response, it is considered the lowest observed adverse effect level (LOAEL). Normally, 
the test substance is administered to pregnant animals at least from implantation to 
one day prior to the day of scheduled sacrifice, which should be as close as possible to 
the normal day of delivery without risking loss of data resulting from early delivery [2, 
3]. Evaluation of maternal responses is examined throughout pregnancy using clinical 
evaluations, as well as gross necropsy and histopathology. A number of endpoints that 
may be characterized as possible indicators of maternal toxicity include mortality, 
change in body weight, organ weights, food and water consumption. Shortly after 
caesarean section, the fetuses are evaluated. Endpoints of developmental toxicity include 
preimplantation loss, change in offspring body weight and the incidence of external, 
visceral, and skeletal malformations and variations that may indicate the organs or 
organ systems have been affected [2, 3]. 
The need for alternatives to animal studies
Recently, the European Commission has implemented the REACH (Registration, 
Evaluation, Authorization and restriction of CHemicals) legislation, aiming at greater 
protection of human health and the environment towards the adverse effects of 
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industrial chemicals. This REACH legislation aims at completing a comprehensive 
safety evaluation for existing and new commercial chemicals that are produced, 
imported and traded in Europe at amounts of more than one ton per year. However, 
implementation of the regulation may require 54 million vertebrate animals and 
testing costs of 9.5 billion euro [5]. Another estimation by the European Chemicals 
Bureau has shown that the developmental toxicity studies will require large amounts of 
animals and resources within REACH (23% of animals, 24% of resources) [6]. Because 
of the large number of animals needed, there is an urgent need for the development, 
validation and application of reliable alternative assays to in vivo developmental 
toxicity studies, which is in concordance with the replacement, reduction and 
refinement (3Rs) principle of animal use in toxicological research. The aim of the 
present thesis is to evaluate the applicability of an integrated in vitro-in silico approach 
for prediction of developmental toxicity using a series of antifungal compounds as 
the model compounds.
antifungal compounds   
The chemicals studied in the present thesis belong to the class of antifungal compounds. 
Antifungal compounds are widely used in agriculture and in human therapy. Their 
antifungal activity is based on their ability to inhibit cytochrome P450 (CYP) 51, a 
key enzyme in the formation of fungal wall components [7]. Human epidemiologic 
investigations have reported that antifungal compounds can pose a developmental 
toxicity hazard, with the evidence of inducing a lower birth weight and pregnancy loss, 
but without showing an increased risk of congenital malformations when administered 
at low therapeutic doses during pregnancy [7]. Several antifungal compounds tested 
in laboratory animals have been found to possess a common teratogenic potential 
to induce facial, axial skeleton, and limb defects. Although no evidence exists that 
shows that antifungal compounds induce malformations in human, some, but not all 
antifungal compounds have an effect on altering normal embryonic development leading 
to teratogenesis in animals indicating a possible teratogenic hazard in humans [7], which 
merits attention. Overall, assessment of the developmental toxic potential of antifungal 
compounds is of importance. 
Two sets of antifungal compounds were studied in the present thesis. Our first 
set includes five reference antifungal compounds, i.e. ketoconazole, tebuconazole, 
propicoanzole, prothioconazole and fenarimol, with four of these being azoles (Fig.1). 
The azole family represents the largest family of antifungal compounds, which can be 
subdivided into the imidazole and triazole groups. We selected these five compounds, 
because of their widespread use as antifungal agents in medicine and crop protection and 
because they are known to cause developmental toxicity. For these chemicals an extensive 
toxicity data base is available, required for the evaluation of the predictions made in 
11
1
In
tr
o
d
u
ct
io
n
the present thesis on their toxicity based on in vitro and in silico approaches [8-16]. 
The reference compounds used have demonstrated a varying degree of developmental 
toxicity in vivo (Table 1), allowing for a quantitative assessment of potency, which is the 
basis of the validation of the predictions of potency made in the present thesis based on 
the results from the in vitro assays.
The second set of compounds consists of six novel triazoles. For these novel triazoles, 
in vivo data are presented for the first time and are not available in the literature. 
In vivo studies were performed in addition to the framework of the present project 
at BASF SE, experimental toxicology and ecology, in the context of new fungicide 
development. All six novel triazoles showed to some degree a potential to cause prenatal 
developmental toxicity, including post-implantation loss, fetal weight decrease and 
skeletal malformation. Because of these findings development of these compounds 
was terminated and the compounds were made available as a second set of compounds 
for validation purposes of predictions made by in vitro developmental toxicity assays. 
After the in vitro assays have been validated in first instance using the five reference 
compounds, the evaluation of these assays is extended by testing the six novel triazoles 
and comparing the results obtained with in vivo findings.
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Fig. 1 Chemical structures of five reference antifungal compounds  
Ketoconazole Tebuconazole
Propiconazole Prothioconazole Fenarimol
Fig. 1. Chemical structures of five reference antifungal compounds
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Table 1. Developmental toxicity induced by antifungal compounds in rats upon oral 
administration.
Compound
Dose  
(mg/kg bw/day)
Exposure 
duration Fetal effects Ref.
Ketoconazole
25, 75 PI 6-17 Increased incidence of cleft palate [8] 
80 GD 6-15 Increased embryolethality, decrease of fetal body 
weights, and fetal defects including cleft palate, 
frontal, parietal and interparietal incomplete 
ossification, limb anomalies, absent fibula and 
pubis, short femur, tibia and pubis 
[9]  
[10] 
Tebuconazole
30, 60, 120 GD 6-15 Increased incidences of skeletal variations. [11] 
10, 30, 100 PM 6-15 Facial alteration dysplacia of scapula and 
long bones, exencephaly + spinia bifida, 
encephalomeningocele + macroglossia and other 
external alterations.
[12] 
Propiconazole
30, 90, 300 GD 6–15 Increased incidence of rudimentary ribs, cleft 
palate, unossified sternebrae, as well as increased 
incidence of shortened and absent renal papillae 
[13] 
Prothioconazole
20, 80, 750 PC 6-19 Marginal increase in the incidence of fetal 
supernumerary rudimentary (comma-shaped) ribs
[14] 
80, 500, 1000 PC 6-19 Increased incidence of microphthalmia [14] 
Fenarimol
5, 13, 35 GD 6-15 Increased hydronephrosis without maternal 
toxicity. (This minor effect of delayed 
development is not of particular concern.)
[15]
150, 300 GD 
15–21 
Increased neuromuscular and behavioral deficits 
in nursing pups 
[16] 
Note. PI = post-insemination; GD = gestational day; PC=post coitum; PM=post mating
- Data not available
The choice of the in vitro assay for developmental toxicity
The ES-D3 cell differentiation assay
Several in vitro methods have been developed to evaluate the developmental toxic 
potential of chemicals, such as the embryonic stem cell test (EST), the rodent whole 
embryo culture test and ex ovo assay of chicken embryos [17-19]. Among these tests 
the EST is the only validated in vitro assay that does not require the use of primary 
animal tissues. In the European Centre for the Validation of Alternative Methods’ 
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validation study on 20 different chemicals with different in vivo embryotoxic potencies 
(classified as non, weak or strong embryotoxic), the EST provided a correct classification 
of the embryotoxic potential of 78% of the test chemicals, based on a prediction model 
that integrates effect data on ES-D3 cell viability, ES-D3 cell differentiation and 3T3 
cell viability [20]. When only the strong embryotoxic chemicals were taken into 
account, a predictivity of 100% was obtained. However, in a second study, only 2 out 
of 13 test chemicals were correctly classified in the EST. Therefore, the applicability of 
this prediction model was questioned [20]. Several studies have used the ES-D3 cell 
differentiation assay as a stand-alone assay, using the chemical-induced inhibition of 
ES-D3 cell differentiation into functional (contracting) cardiomyocytes as a readout 
parameter, and have shown that the in vitro potency ranking of chemicals in this assay 
can be used to predict in vivo potency rankings within selected chemical classes for 
most of the investigated chemicals, including a set of antifungal compounds [21-23]. 
Despite the above-stated good predictive ability of the ES-D3 cell differentiation 
assay, the assay has also drawbacks. First of all it is relatively lengthy because it requires 
the exposure of cells to test chemicals for 10 days. Besides, a main weakness of the assay 
is the process of monitoring changes in the differentiation of the formed embryoid 
bodies (EBs) upon exposure to the test chemical, i.e. effects on the differentiation of 
the embryonic stem cells into contracting cardiomyocytes. Although an individual 
microscopic inspection of the 10-day differentiated EBs is performed to determine if 
they are functional (contractile), other relevant circumstances, such as the total beating 
area and beating intensity, are not taken into consideration for the toxicity assessment 
[20]. Another disadvantage is that in its present form, the ES-D3 cell differentiation assay 
focuses only on embryotoxicity and does not model any specific morphogenic events 
[24], so it is not able to detect the multitude of specific structural alteration events that 
may occur during pregnancy. However, since the assay is a cell-based assay, it holds 
promise for use in the high throughput testing of chemicals. Moreover, given the fact 
that ES-D3 cell differentiation assay as stand-alone has been shown to predict quite well 
the relative in vivo potencies of chemicals within chemical classes [21-23], we have used 
the ES-D3 cell differentiation assay in the present thesis to evaluate its applicability on 
predicting developmental toxicity of antifungal compounds. 
The ex ovo assay of chicken embryos
Although the ES-D3 cell differentiation assay has been shown to be useful to predict 
the developmental toxicity potency of compounds, it is limited to the evaluation of the 
phenotypic endpoint, i.e. the differentiation of embryonic stem cells into contracting 
cardiomyocytes, and can therefore not be used to detect structural alterations induced by 
chemicals. Antifungal compounds have shown to possess a teratogenic potential, causing 
specific morphological alterations, such as craniofacial changes and inter alia cleft palate 
[25]. The mechanism of action of antifungal compounds on skeletal development has 
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been reported to result from alterations during hindbrain segmentation and branchial 
arches formation [26]. Since the teratogenic potential of chemicals is an important 
toxicological endpoint considered to be of high importance in risk assessment, it is 
important to employ an alternative assay that is capable of investigating structural 
alterations induced by antifungal compounds. 
The ex ovo assay of chicken embryos can be used as such an assay as it assesses 
chemicals with regard to their developmental toxic potential based on morphological 
changes [27]. The ex ovo assay of chicken embryos was first established in 1976 by 
Jelinek et al. as a fast and cheap teratogenicity test [28]. Later on, their protocol has been 
modified by different researchers. In general, the culture duration (2 or 3 days) of the 
chicken embryos covers the major parts of organogenesis, offering the assessment of 
survival, growth and various morphological endpoints including specific development 
of different organ anlagen, i.e. head region with different brain -, eye -, ear anlagen 
and branchial arches, using microscopic inspection. The chicken embryos have been 
revealed to possess their own basic metabolic capacity, such as activities of CYP450 
and glutathione S-transferases (GSTs), providing the possibility to screen for adverse 
effects of potential metabolites [29]. However, the ex ovo assay of chicken embryos has 
been criticized for the absence of mammalian maternal–fetal relations [30]. Moreover, 
although this assay has a short duration, i.e. 2 or 3 days, it is labor intensive and special 
equipment and highly educated and trained staff are needed. 
Despite its disadvantages, in several inter-laboratory validation studies [31-33], the 
ex ovo assay of chicken embryos was found to be able to distinguish specific patterns of 
growth perturbations and anomalies induced by different chemicals in a concentration-
dependent manner. At the present time, some laboratories in academia and industry are 
using the ex ovo assay of chicken embryos for routine embryotoxicity screening purposes 
and mechanistic studies. BASF SE has been using this assay for 10 years and obtained 
a good correlation to in vivo studies, within the limits of the applicability domain 
(compounds should not be toxic and/or irritant / corrosive) (Ben van Ravenzwaay, 
personal communication, October 1, 2015). Meanwhile, it has been reported that 
teratogenic potentials of tested compounds detected by the ex ovo assay of chicken 
embryos were similar to those determined in vivo [29, 34]. Therefore, the ex ovo assay 
of chicken embryos seems to be a suitable tool to study the potential to cause structural 
alterations of the antifungal compounds to gain additional information about their 
embryotoxic potential.
The importance of toxicokinetic information for predicting in vivo 
toxicity based on in vitro toxicity data
Although the ES-D3 cell differentiation assay and the ex ovo assay of chicken embryos 
have exhibited their usefulness in predicting developmental toxicity of chemicals [21-23]
[31-33], these in vitro systems have the generic limitations of most in vitro systems 
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with regard to the lack of in vivo kinetic processes, phenomena that are of influence 
in the in vivo situation. Toxicokinetics (TK), which is typically defined as absorption, 
distribution, metabolism and excretion (ADME) processes of a chemical, describes 
the fate of a toxic substance within the body. For the risk assessment using in vivo 
animal testing, TK data are key information for various extrapolations needed in risk 
assessment, such as interspecies extrapolation, route-to-route extrapolation and for 
mechanistic considerations [35]. Therefore, TK information is important in the in vivo 
animal testing based risk assessment.
With the implantation of the REACH legislation, in vitro tests are being developed 
to reduce the use of animals for REACH chemicals. There is a general consensus that 
the TK information is necessary to convert the in vitro results, generated at tissue/cell 
or sub-cellular level, into dose response curves or potency levels for the entire target 
organism [36]. More and more attention has been paid in recent years to the (further) 
development and implementation of in vitro or/and in silico models to measure the 
various ADME [37-39]. In the present thesis, we have developed and validated an in 
vitro cell-based model to obtain kinetic information on placental transfer, and combined 
that with data from in vitro developmental toxicity tests, in order to assess whether the 
prediction of in vivo developmental toxicity using in vitro models improves by adding 
kinetic data on placental transfer.
Placental transfer
The placenta is an important organ required for the development of the embryo or 
fetus. During normal pregnancy, the placenta attaches to the uterine wall and serves as 
a structure separating the maternal and fetal blood circulations. The functions of the 
placenta include signaling, production and release of hormones and enzymes, transfer 
of nutrients and waste products, implantation, cellular growth and maturation [40]. 
Placental transfer plays a crucial role in developmental toxicity. Only a few decades ago, 
it was still commonly believed that the placenta protects the conceptus from harmful 
agents [41]. However, the thalidomide catastrophe in the 1960s made people start to 
consider that chemicals can cross the placenta and give rise to serious developmental 
toxicity [41]. Ever since this catastrophe, several studies have been conducted providing 
evidence that toxicants, such as alcohol, nicotine or harmful drugs, can pass the placental 
barrier, reach the conceptus and induce toxicity [42-47]. It is important to note that 
different chemicals may transfer through the placental barrier to a different extent 
[42, 44, 46-51]. Several in vitro developmental toxicity studies using the ES-D3 cell 
differentiation assays have suggested that discrepancies of toxicity potencies between 
in vitro and in vivo could be due to the lack of a measure of placental transfer in the in 
vitro system [21-23]. The inclusion of data on placental transfer may therefore provide 
additional information, leading to the improvement of the predictive values of in vitro 
developmental toxicity tests. 
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Chemicals cross the placenta mainly by simple passive diffusion. Other possible 
mechanisms of placental transport are facilitated diffusion, active transport, pinocytosis 
and filtration. Important influencing factors on the rate and extent of placental transfer 
by passive diffusion include molecular weight, ionization (pKa), lipid solubility and 
protein binding. The passage through placental membranes can be also influenced by 
transporter proteins as many chemicals have been shown to be substrates of transporters 
in the placenta [51].
Placental transfer of compounds can be studied in the human ex vivo placental 
perfusion model, which is one of the main techniques for investigating transport of 
compounds across the maternal-fetal barrier. This model uses human term placenta, and 
therefore resembles the in vivo situation in human best. However, since the placentas 
used are donated by mothers and collected when they give birth, the number of available 
placentas is limited and the planning of experiments is difficult. An in vitro model using 
BeWo cells may provide an easier and faster method for predicting placental transfer 
of compounds [52]. BeWo cells are derived from a human choriocarcinoma that has 
retained cell properties and hormonal profiles of mononucleated cytotrophoblasts [53]. 
The BeWo b30 clone has a cell layer forming ability and has been used to study placental 
distribution of drugs and nutrients [54]. When grown on transwell inserts, the cell layer 
separates an apical maternal compartment from a basolateral fetal compartment and the 
cells get polarized with respect to the expression of functional transporters specific to 
the apical and basal membranes, such as P-glycoprotein [55], although P-glycoprotein 
expression levels in BeWo b30 cells have been reported to be lower than those in primary 
trophoblasts [56]. In the present study, the BeWo cell transport model is evaluated by 
comparing relative transport rates in this model to relative transport rates in the ex vivo 
human placental model, using a series of compounds that show low, middle and high 
transfer rates in the human ex vivo placental model [57]. Further, in the present thesis 
the BeWo model is used to study placental transfer of chemicals and to evaluate whether 
inclusion of placental transfer data may improve predictions of in vivo developmental 
toxicity based on in vitro developmental toxicity data. 
The use of physiologically based kinetic modeling facilitated in vitro‐in 
vivo extrapolations using a reverse dosimetry approach to apply in 
vitro toxicity data for risk assessment
With the help of the in vitro kinetic assays, such as the BeWo cell transport model, the 
predictive value of in vitro developmental toxicity tests may be improved. However, the 
challenge of predicting developmental toxicity using in vitro assays still remains that 
the effect concentrations obtained from those assays cannot be used for risk assessment, 
because risk assessment requires dose response curves from which points of departure 
to define safe levels of exposure for humans can be derived. The quantitative conversion 
of in vitro effect concentrations of compounds into in vivo effect doses, using in silico 
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approaches such as physiologically based kinetic (PBK) modeling, is a promising strategy 
in developing alternatives for toxicity testing for risk assessment [35, 58]. 
PBK modeling
With PBK modeling the fate of compounds in the body can be simulated and can be 
used to relate external (toxic) doses to internal (toxic) concentrations [58]. Briefly, in a 
PBK model the animal or human is described as a set of tissue compartments and these 
basic compartments can each be depicted as a single box. Then this conceptual model is 
translated into a mathematical model, describing the ADME kinetic processes in each 
compartment by differential equations. In the next step model parameter values need 
to be determined, including values for 1) physiological and anatomical parameters (e.g. 
cardiac output, tissue volumes and tissue blood flows), 2) physico-chemical parameters 
(e.g. tissue/blood partition coefficients) and 3) other kinetic parameters (e.g. kinetic 
constants for transport as well as for biotransformation reactions of the chemical and/
or its metabolites). The values for physiological and anatomical parameters of a species 
can be obtained from the literature. Physico-chemical and kinetic parameter values 
may be obtained using in vivo data or using in silico or in vitro techniques. After the 
mathematical model has been defined and the parameter values have been obtained, 
simulations can be made using computational software, such as Berkeley Madonna 
(Macey and Oster, UC Berkeley, CA, USA), to calculate the concentrations of the chemical 
and its metabolites in the different compartments over time as a function of the dose. In 
order to examine the validity of the model and the reliability of subsequent predictions, 
the performance of the model is evaluated by comparing the predictions made to 
experimental in vivo kinetic data. This evaluation process helps discover discrepancies 
between the model predictions and the in vivo experimental data, which may point out 
if a certain important kinetic process has been overlooked or its model parameter value 
imprecisely incorporated in the model, requiring a new hypothesis and improvements 
of the model [58]. 
In vitro to in vivo extrapolations with a reverse dosimetry approach 
After the PBK models have been developed, the application of so-called PBK modeling-
facilitated reverse dosimetry enables the translation of in vitro concentration–response 
curves into in vivo dose–response curves, providing a platform to use in vitro toxicity data 
for risk assessment [37, 39, 59]. In reverse dosimetry approaches aiming to predict in vivo 
toxic dose levels, in vitro toxic effect concentrations are considered as surrogate tissue 
or blood concentrations that could cause an adverse effect in the in vivo situation. The 
corresponding in vivo toxic dose levels can be predicted using a PBK model to calculate 
the doses that are needed to reach these internal effect concentrations, indicating that 
PBK modeling-facilitated reverse dosimetry is an adequate method for the quantitative 
translation of in vitro data to the in vivo situation. Therefore, there is increased interest 
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in using the reverse dosimetry approach to define dose–response curves that enable the 
definition of reference values for risk assessment, such as Benchmark Dose (BMD) values, 
based on the translation of in vitro concentration–response data obtained from in vitro 
toxicity assays [35, 60]. Our group has shown that reverse dosimetry of developmental 
toxicity data obtained in the ES-D3 cell differentiation assay resulted in the correct 
prediction of in vivo dose–response curves of glycol ethers, phenol and retinoic acid [37, 
39, 59]. No proof-of-principles of chemicals from other chemical categories are available 
so far. In the present thesis, the use of the PBK modeling-facilitated reverse dosimetry 
approach with the antifungal compound tebuconazole is applied to extrapolate in vitro 
concentration-response curves obtained in the ES-D3 cell differentiation assays and the 
ex ovo assay of chicken embryos into in vivo dose-response curves, in order to assess 
whether the in vitro developmental toxicity data of antifungal compounds can be applied 
in toxicological risk assessment. 
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ouTline of Thesis
In Chapter 1 of the thesis, background information on the topic is given and the aim of 
the thesis is presented. As outlined above the aim of the present thesis is to evaluate the 
applicability of integrated in vitro and in silico approach for prediction of developmental 
toxicity using a series of antifungal compounds as the model compounds.
Chapter 2 presents the assessment of the usefulness of an in vitro BeWo cell 
transport model to predict placental transfer. To this end, BeWo cells, derived from a 
human choriocarcinoma, were grown on transwell inserts to form a confluent cell layer, 
separating an apical maternal compartment from a basolateral fetal compartment. For 
a set of nine selected model compounds, including the reference compound antipyrine, 
the transport velocity from the apical to the basolateral compartment is determined. 
Relative transport rates obtained were compared with the relative transport rates of 
these compounds derived from data of ex vivo placental perfusion studies reported in 
the literature. 
Chapters 3 investigated the applicability of the ES-D3 cell differentiation assay 
combined with the in vitro BeWo transport model to predict relative in vivo developmental 
toxicity potencies. To this purpose, the in vitro developmental toxicity of five antifungal 
compounds is investigated by characterizing their inhibitory effect on the differentiation 
of ES-D3 cells into cardiomyocytes. The BeWo transport model is used to determine 
the relative placental transport velocity. The ES-D3 cell differentiation data, combined 
with the relative transport rates obtained from the BeWo model, were compared to in 
vivo developmental toxicity data of the compounds studied, as reported in the literature. 
Chapter 4 extended the evaluation on this combined approach by testing another 
set of six antifungal compounds. To this end, we combined ES-D3 cell differentiation 
data of the six compounds with relative transport rates obtained from the BeWo model 
and compared the obtained ranking to the developmental toxicity ranking as derived 
from in vivo data.
In Chapter 5 we investigated the applicability of the ex ovo assay of chicken embryos 
to predict the potential to cause alterations in development of five antifungal compounds 
also studied in Chapter 3 and investigated if the combination of the ex ovo assay with 
the kinetic information on placental transfer would improve its predictive capacity. 
To this end, the toxicity data inducing the increase in the incidence of the number of 
structurally altered embryos, combined with the relative transport rates obtained for 
the various model compounds in the BeWo model, were compared with in vivo data on 
developmental toxicity of the compounds studied as reported in the literature. 
In Chapter 6 the in vitro concentration‐response curves of the antifungal compound 
tebuconazole, obtained in the ES‐D3 cell differentiation assay (Chapter 3) and the ex ovo 
assay of chicken embryos (Chaper 5), were translated into in vivo dose‐response curves 
for developmental toxicity of tebuconazole in rat, using the reverse dosimetry approach. 
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The PBK model for tebuconazole developed and used for this purpose is solely based 
on kinetic parameter values derived using in vitro and in silico techniques. To assess 
whether in vivo developmental toxicity could be predicted for this chemical, using the 
reverse dosimetry approach, predicted dose‐response curves for in vivo developmental 
toxicity in rats were compared with literature data on tebuconazole‐induced in vivo 
developmental toxicity in rats.
Finally, Chapter 7 summarizes and discusses the results of the present thesis and 
provides future perspectives. It discusses possible implications of the use of the integrated 
in vitro-in silico approach for toxicological risk assessment and gives directions for 
future research in the field. 
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absTracT
The human ex vivo placental perfusion model has regularly been used to study the 
transplacental transport of compounds. However, this method is laborious and dependent 
on the presence of fresh human placenta, hampering its use for the assessment of large 
numbers of compounds. An in vitro model for the placental barrier using BeWo b30 
cells may provide an alternative to the ex vivo system. The present study aims to assess 
whether such an in vitro model could be used to reliably predict placental transfer. 
To this end, BeWo b30 cells, derived from a human choriocarcinoma, were grown on 
transwell insert to form a cell layer, separating an apical maternal compartment from a 
basolateral fetal compartment. For a set of nine selected model compounds, including the 
reference compound antipyrine, the transport velocity from the apical to the basolateral 
compartment was determined. Relative transport rates obtained were compared with the 
transfer indices (a measure for the transport relative to antipyrine) of these compounds 
obtained in ex vivo placental perfusion studies as reported in the literature. The relative 
transport rates in the in vitro BeWo model were in good correlation (R2=0.95) with the 
transfer indices reported for the ex vivo model. This indicates that the BeWo model 
could be a valuable in vitro model for prediction of placental transfer of compounds. 
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inTroducTion 
The implementation of the REACH legislation results in the increased use of animals 
for toxicity testing, especially for reproductive and developmental toxicity testing [1]. 
Therefore, the development and validation of in vitro and in silico alternatives for these in 
vivo studies are urgently needed [2]. A number of in vitro methods have been developed 
to screen compounds for possible developmental toxicity, using primary cultures of 
embryonic cells or embryonic stem cell lines, such as the Embryonic Stem cell Test (EST), 
as well as test methods using whole embryos, such as the rodent Whole Embryo Culture 
(WEC) test and the Chicken Embryotoxicity Screening Test (CHEST) [3-5]. Although 
these assays have been proven to be useful in ranking compounds in relative potency, they 
are at present not used in risk assessment. An important reason is that in vitro assays only 
provide in vitro concentration-response curves, whereas in vivo dose-response curves are 
required for setting safe exposure levels in risk assessment. The application of so-called 
reverse dosimetry enables the translation of in vitro concentration-response curves into 
in vivo dose-response curves, providing a platform to use in vitro toxicity data for risk 
assessment [6]. In the reverse dosimetry approach, in vitro toxic concentrations are set 
as internal concentrations in a physiologically based kinetic (PBK) model, which is used 
to calculate which doses result in these internal concentrations [6, 7]. In a simple reverse 
dosimetry approach, it can be assumed that concentrations in the maternal circulation 
equal the concentrations in the conceptus, implying that placental transfer is not taken 
into account in the PBK modeling [6]. However, this is not true for all compounds, due 
to restricted or enhanced transport across the placenta, which is for example the case 
for B vitamins, vitamin E, vaccenic acid and cotinine [8-11]. It is therefore important to 
obtain information on the transport of compounds across the placenta, in order to enable 
incorporation of placental transfer in PBK models used for reverse dosimetry when 
predicting in vivo developmental toxicity dose levels based on in vitro toxicity assays.
Placental transfer of compounds can be studied in the human ex vivo placental 
perfusion model, which is one of the main techniques for investigating transport of 
compounds across the maternal-fetal barrier. This model resembles the in vivo situation 
in humans best. Furthermore, the size of the human placenta enables a great number 
of different parameters to be studied, e.g. placental metabolism, hormones and enzyme 
production and release [12, 13]. However, since the placentas used are donated by mothers 
and collected when they give birth, the number of available placentas is limited and the 
planning of experiments is difficult. 
An in vitro model using BeWo cells may provide an easier and faster method for 
predicting placental transfer of compounds [14]. BeWo cells are derived from a human 
choriocarcinoma that has retained cell properties and hormonal profiles of mononucleated 
cytotrophoblasts [15]. The b30 BeWo clone has a monolayer forming ability and has been 
used to study placental distribution of drugs and nutrients [16]. Furthermore, these 
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cells express placental differentiation markers, such as human chorionic gonadotrophin 
(HCG) [17] and the major cytochrome P450 isoforms (CYP1A1 and 1A2) present in 
placenta [18]. When grown on transwell inserts, the cells get polarized with respect to 
the expression of functional transporters specific to the apical and basal membranes, 
such as P-glycoprotein [19], although P-glycoprotein expression levels in BeWo b30 cells 
have been reported to be lower than those in primary trophoblasts [20]. Although the 
BeWo model may possess these characteristics of a functional placenta, it represents a 
simplification of the in vivo situation. It is therefore important to obtain information on 
the comparison of the in vitro BeWo model with the ex vivo placental perfusion model, 
in order to assess the usefulness of the BeWo model. 
The objective of the present study was to evaluate the ability of the in vitro BeWo 
model in predicting placental transfer of compounds. To this end, the transport rates of 
a set of nine selected model compounds (amoxicillin, antipyrine, digoxin, indomethacin, 
ketoprofen, levofloxacin, lidocaine, ofloxacin and spiramycin), which exhibit a wide range 
of transport indices (TIs) in the ex vivo placental perfusion model, were determined in 
the BeWo model and compared with data reported for the ex vivo model, as reported 
in the literature. In addition, the influence of protein binding on the transfer of the test 
compounds was studied.
maTerials and meThods
reagents and chemicals
Digoxin, spiramycin, antipyrine, amoxicillin, ofloxacin, levofloxacin, ketoprofen, 
indomethacin, lidocaine, human placental collagen, bovine serum albumin (BSA), and 
Dulbecco’s modified Eagle’s medium (DMEM) were purchased from Sigma-Aldrich 
(Zwijndrecht, the Netherlands). Fetal calf serum (FCS) was obtained from HyClone-
Perbio (Etten-Leur, the Netherlands) and dimethyl sulfoxide (DMSO) was purchased 
from Acros Organics (Geel, Belgium). Penicillin, streptomycin, L-glutamine, trypsin-
EDTA, phosphate-buffered saline (PBS), and Hank’s balanced salt solution (HBSS) were 
obtained from Invitrogen (Breda, the Netherlands). Trifluoroacetic acid was purchased 
from J.T. Baker (Deventer, the Netherlands) and acetonitrile was obtained from Biosolve 
(Valkenswaard, the Netherlands).
cell culture
The BeWo cell line (clone b30) was kindly provided by the Institute of Public Health 
of the Faculty of Health Sciences of the University of Copenhagen (Denmark) with 
permission from Dr. Alan Schwartz (Washington University, St. Louis, MO), and 
confirmed to be mycoplasma negative. BeWo b30 cells (passages 27 to 45) were 
cultured in DMEM supplemented with 10% (v/v) heat-inactivated FCS, 10,000 U/ml 
penicillin, 10 mg/ml streptomycin, and 2 mM L-glutamine. The cells were maintained 
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in polystyrene cell-culture flasks (Corning, USA), under a humidified atmosphere of 5% 
CO2 at 37 °C. The cells were harvested by exposure to a 0.05% trypsin-EDTA solution 
and transferred to transwell® polycarbonate membranes (12 mm diameter, 0.4 µm 
pore size) (VWR International BV, Amsterdam, the Netherlands) coated with human 
placental collagen. Cells were seeded at a density of 100,000 cells/cm2 and the medium 
(0.5 ml apical compartment, 1.5 ml basolateral compartment) was replaced daily. At 
day 6 post-seeding the BeWo b30 cell layers were used for transport experiments. 
According to the findings of Liu et al., a confluent monolayer has been formed on 
day 6 post-seeding [21].
determination of transepithelial electrical resistance values
The barrier forming capacity of the BeWo b30 cell layers was evaluated by measuring 
the transepithelial electrical resistance (TEER) of the cell layer using a Millicell ERS-2 
Volt-Ohm Meter (Millipore, USA) at day 2 to 7 post-seeding. The TEER value was 
determined after replacing culture medium with HBSS and was corrected for the TEER 
of the collagen-coated filters in the absence of BeWo b30 cells. 
Transport experiments
At day 6 post-seeding, following the examination of cell layer integrity using TEER 
measurements, the cells were equilibrated in transport buffer (HBSS) in both the apical 
and basolateral compartment for 30 min at 37 °C. Only the cell layers showing TEER 
values between 80 and 100 Ω∙cm2 were used for transport experiments. Transport 
experiments were initiated by adding 0.5 ml of transport buffer containing the test 
compound, added from a 200 times concentrated stock solution in DMSO, to the apical 
compartment and 1.5 ml transport buffer to the basolateral compartment. Subsequently, 
the plate was incubated in a humidified atmosphere with 5% CO2 at 37 °C. After 15, 30, 
60, and 120 min a sample of 0.2 ml was taken from the basolateral compartment and 
replaced by an equal volume of transport buffer. At the end of each experiment, a 0.2 ml 
sample was also taken from the apical compartment. Subsequently, the filters with the 
BeWo b30 cell layers were washed 3 times with PBS, cut out of the insert, dissolved in 
0.25 ml 65% (v/v) methanol and sonificated for 15 min in a Bandelin Sonorex RK100 
(Berlin, Germany) in order to determine the amount of compound accumulated in the 
cells. After each experiment mass-balance calculations were performed. The transport of 
levofloxacin, indomethacin and antipyrine was investigated using apical concentrations 
of 50, 100 and 200 µM. The transport of digoxin, amoxicillin, ofloxacin, ketoprofen and 
lidocaine was studied at a concentration of 100 µM. In each transport study, amoxicillin 
was included allowing data comparison of different studies.
In the ex vivo placental perfusion studies performed with indomethacin, 
levof loxacin, of loxacin, ketoprofen and lidocaine described in literature, albumin 
was added to maternal and fetal perfusates. Therefore, the effect of protein addition 
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to the transport buffer on the transfer rates of these compounds was investigated in 
the BeWo model in the present study. To this end, BSA was added to the transport 
buffer, present in the same concentrations as the albumin concentration reported 
to be added in the perfusates of the respective human ex vivo placental perfusion 
studies. The albumin concentrations used in these experiments are presented in 
Table 1.
Table 1. Albumin concentrations (g/l) in transport buffer in the BeWo model and albumin 
concentrations in the perfusates in human ex vivo placental perfusion studies.
Test compound
Transport buffer BeWo model Human placental perfusion perfusate
Apical Basolateral Maternal Fetal ref
Indomethacin 2 2 2 2 [22]
Levofloxacin 3 3 3 3 [23]
Ofloxacin 3 3 3 3 [23]
Ketoprofen 8.7 10.2 8.7 10.2 [24]
Lidocaine 35 40 35 a 40 [25]
a 100% fresh frozen plasma was used as maternal perfusate [25]. The physiological serum albumin 
concentration in late pregnancy is 35 g/l [26].
high Performance liquid chromatography analysis
Samples were analyzed using High Performance Liquid Chromatography (HPLC) to 
quantify the amount of test compound present in the collected samples in order to 
determine the transport rate. The HPLC system used consisted of a Waters (Milford, 
MA) 600 controller and a 600 pump, equipped with a photodiode array detector set 
to record absorption of wavelengths between 200 and 400 nm. A Waters 717 plus 
autosampler was used for sample injection. The temperature of the autosampler 
was kept at 7 ˚C. Sample (50 μl) was applied to a C18 5μm reverse phase column 
(150mm×4.6mm I.D.) with a guard column (7.5mm×4.6 mm I.D.) (Alltech, Bergen 
op Zoom, the Netherlands). Prior to analysis, collected samples containing BSA were 
mixed with 0.4 ml methanol. After centrifugation at 16,000 g for 5 min, the supernatant 
was injected for HPLC analysis. After sonification, the samples containing cells and 
filters were centrifuged at 16,000 g for 5 min, after which the supernatant was used 
for HPLC injection. 
The mobile phase used for analysis of all the test compounds consisted of (A) 0.1% 
trifluoroacetic acid in nanopure water and (B) HPLC-grade acetonitrile. For analysis 
of amoxicillin, ofloxacin, spiramycin, levofloxacin, indomethacin, ketoprofen and 
antipyrine, elution was applied at a flow rate of 1 ml/min, starting at 10% B with a 
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linear increase to 100% B in 20 min. Subsequently, the gradient returned linearly to 
the initial condition in 2 min and remained 10 min at this condition prior to the next 
injection. For analysis of digoxin and lidocaine, the solvent gradient started at 22% B 
at a flow rate of 0.8 ml/min for 2 min, followed by a linear increase to 100% B in 8 min. 
Subsequently, the gradient returned to the initial conditions by a linear gradient over 
2 min, followed by an equilibration of 10 min. In each experiment, calibration curves 
were included for quantification.
data analysis
For each compound, the linear appearance rate in the basolateral compartment was 
determined. These linear appearance rates were used to calculate apparent permeability 
(Papp) coefficients (Papp coefficient (cm/s) = (ΔQ/Δt) / (A∙C0)), where ΔQ is the amount 
of test compound (μmol) transported to the receiver chamber in a certain time span 
(Δt (s)), A is the cell surface area (cm2) and C0 is the initial concentration of the test 
compound (mM). To calculate ΔQ for the second, the third and the fourth time point, 
a correction was made to compensate for the removal of compound at the earlier time 
points (ΔQ at tx+1 = amount measured at tx+1 (nmol) (basolateral concentration at tx+1 
(µM) * 1.5 (mL)) supplemented with the amount removed at tx (nmol) (basolateral 
concentration sample at tx (µM) * 0.2 (mL))). Subsequently, relative Papp ratios were 
determined by expressing the Papp coefficient as a fraction of the Papp coefficient obtained 
for antipyrine. Relative Papp ratios can be written as (Af, compound X (t) * Am, antipyrine (t0)) 
/ (Af, antipyrine (t) * Am, compound X (t0)), in which Af, compound X (t) = amount of compound X 
in the fetal (basolateral) compartment at time point t, Am, antipyrine (t0) = amount of 
antipyrine added to the maternal (apical) compartment at time point t0, Af, antipyrine (t) 
= amount of antipyrine in the fetal compartment at time point t, and Am, compound X (t0) 
= amount of compound X added to the maternal compartment at time point t0. The 
relative Papp ratios were used for the comparison with TIs reported for the ex vivo 
placental perfusion model.  A TI value represents the transfer of the compound of 
interest as a fraction of the transfer of the reference compound antipyrine in ex vivo 
human placental perfusion studies [22-25, 27-30]. In the original studies, different 
formulas for TI values are reported, of which most can be rewritten as (Af, compound X 
(t) * Am, antipyrine (t)) / (Af, antipyrine (t) * Am, compound X (t)), in which Af, compound X (t) = amount 
of compound X in the fetal compartment at time point t, Am, antipyrine (t) = amount of 
antipyrine in the maternal compartment at time point t, Af, antipyrine (t) = amount of 
antipyrine in the fetal compartment at time point t, and Am, compound X (t) = amount of 
compound X in the maternal compartment at time point t. In the ex vivo study of 
lidocaine, however, the TI value was expressed slightly different, and can be rewritten 
as (Af, compound X (t) * Am, antipyrine (t0)) / (Af, antipyrine (t) * Am, compound X (t0)), being equal to the 
in vitro relative Papp values. 
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resulTs
Teer values of beWo b30 cell layers
BeWo b30 cells grown on collagen-coated polycarbonate membranes demonstrated 
a gradual increase in TEER value in time, with the maximal TEER value of 95 Ω∙cm2 
being reached at day 6 post-seeding (Figure 1), indicating an increasing integrity of 
the cell layer until day 6 post-seeding. The TEER value decreased to 64 Ω∙cm2 at day 
7 post-seeding indicating that the integrity of the barrier decreased. This finding was 
similar to the results reported by Poulsen et al. [29],  showing that day 6 post-seeding 
is the optimal time point to perform transport experiments. 
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Fig. 1 Transepithelial electrical resistance (TEER) of BeWo b30 cell layers at different days post-seeding. Data are presented as 
mean ± standard deviation (n=6) 
Transfer of test compounds in the in vitro BeWo model 
For all transport experiments, the mass balances were between 91 and 99%. Figure 2a shows the 
amount of levofloxacin, indomethacin and antipyrine in the basolateral compartment of the BeWo model 
with increasing time, after adding 50 nmol to the apical compartment (0.5 ml of a 100 µM solution). Up to 
60 min, the transport of all compounds to the basolateral compartment was linear in time. Therefore, the 
linear appearance rate of mass in the basolateral compartment could be determined using data at 60 min for 
the calculation of Papp coefficients (Table 2). Furthermore, the amount transported to the basolateral 
compartment was linearly related to the amount added to the apical compartment (Figure 2b). 
The effect of albumin on the transport of levofloxacin, ofloxacin, ketoprofen, indomethacin and 
lidocaine was studied by adding albumin in both compartments at the same concentrations as in the 
perfusates used in the ex vivo perfusion studies (Table 1). The obtained Papp coefficients for these studies 
are shown in Table 2 and were between 2.0- and 8.4-fold lower than the values obtained in the absence of 
BSA. Figure 3 shows the transport of antipyrine and ketoprofen in the BeWo model in the absence or 
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Fig. 1. Transepithelial electrical resistance (TEER) of BeWo b30 cell layers at different days post-
seeding. Data are presented as mean ± standard deviation (n=6)
Transfer of test compounds in the in vitro beWo model
For all transport experiments, the mass balances were between 91 and 99%. Figure 
2a shows the amount of levofloxacin, indomethacin and ntipyrine in the basolateral 
compartment of the BeWo model with increasing time, after adding 50 nmol to the 
apical compartment (0.5 ml of a 100 µM solution). Up to 60 min, the transport of all 
compounds to the basolateral compartment was linear in time. Therefore, the linear 
appearance rate of mass in the basolateral compartment could be determined using 
data at 60 min for the calculation of Papp coefficients (Table 2). Furthermore, the amount 
transported to the basolateral compartmen  was linea ly related to the am unt add d 
to the apical compartment (Figure 2b).
The effect of albumin on the transport of levofloxacin, ofloxacin, ketoprofen, 
indomethacin and lidocaine was studied by adding albumin in both compartments 
at the same concentrations as in the perfusates used in the ex vivo perfusion studies 
33
2
B
eW
o
 t
ra
n
sp
o
rt
 m
o
d
e
l f
o
r 
p
la
ce
n
ta
l t
ra
n
sf
e
r
(Table 1). The obtained Papp coefficients for these studies are shown in Table 2 and were 
between 2.0- and 8.4-fold lower than the values obtained in the absence of BSA. Figure 
3 shows the transport of antipyrine and ketoprofen in the BeWo model in the absence 
or presence of BSA, using BSA concentrations as used in the ex vivo placental perfusion 
study on ketoprofen (and antipyrine as reference compound). The results presented 
show that the presence of 8.7 g/l BSA in the apical and 10.2 g/l BSA in the basolateral 
compartment reduced the transfer of antipyrine by 31% (Figure 3a), while the transfer 
of ketoprofen was reduced by 88 % under these conditions (Figure 3b), indicating that 
the addition of BSA can affect the transfer of different compounds to different extents. 
Table 2. Papp coefficients (10-6 cm/s) of 9 test compounds in BeWo model in the presence and 
absence of BSA.
No BSA With BSA
Digoxin 4.6
Spiramycin 5.7
Amoxicillin 7.2
Levofloxacin 8.7 3.1
Ofloxacin 10.3 4.4
Indomethacin 23.2 9.9
Ketoprofen 23.6 2.8
Lidocaine 36.1 17.4
Antipyrine 38.0
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Fig. 2 Amount of levofloxacin (circle), indomethacin (triangle) and antipyrine (square) in the basolateral compartment in the in 
vitro BeWo model (a) with increasing time using initial concentrations of 100 µM in the apical compartment and (b) at 60 min 
with increasing initial concentrations of 50, 100, 200 µM in the apical compartment. Data are presented as mean ± standard 
deviation (n=6) 
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Fig. 2. Amount of levofloxacin (circle), indomethacin (triangle) and antipyrine (square) in the baso-
lateral compartment in the in vitro BeWo model (a) with increasing time using initial concentrations 
of 100 µM in the apical compartment and (b) at 60 min with increasing initial concentrations of 50, 
100, 200 µM in the apical compartment. Data are presented as mean ± standard deviation (n=6)
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comparison of the placental transfer in the in vitro beWo model and 
the transport in the ex vivo human placental perfusion model
The selection of the compounds tested in the BeWo model was based on the broad 
range of TI values as reported for these compounds in the ex vivo human placental 
perfusion studies (ranging from 0.13 to 0.83) (Table 3). Table 3 presents the TI values 
of the selected model compounds reported for the ex vivo placental perfusion model 
as well as the relative Papp values obtained in the in vitro BeWo model in the absence 
and presence of BSA. In order to extend the dataset for comparison between the ex 
vivo and in vitro models, transport data of caffeine, benzoic acid and glyphosate 
obtained in both placental transport models reported by [29] were included in the 
comparison. The relative transport rates in the in vitro BeWo placental transport 
model showed a high correlation (R2=0.95) with the ex vivo TI values (Figure 4a) 
when in vitro transport studies were carried out in the absence of BSA. In the 
presence of BSA, the correlation to ex vivo placental perfusion was slightly lower 
(Figure 4b; R2=0.92). 
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Fig. 3 Amount of antipyrine (a) and ketoprofen (b) in the basolateral compartment of the BeWo model with increasing time using 
initial concentrations of 100 µM in the apical compartment in the absence (open circle) or presence (closed circle) of BSA in the 
apical and basolateral compartment. The concentrations of BSA used were 8.7 g/l in the apical compartment and 10.2 g/l in the 
basolateral compartment, similar to what was applied in  the corresponding ex vivo placental perfusion study [24]. Data are 
shown as mean ± standard deviation (n=6) 
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Fig. 3 Amount of antipyrine (a) and ketoprofen (b) in the basolateral compartment of the 
BeWo mo el with increasing time using i itial concentrations of 100 µM in the pical co -
partment in the abse ce (open circle) or resence (closed circle) of BSA in the apical and 
basolateral compartment. The concentrations of BSA used were 8.7 g/l in the apical com-
partment and 10.2 g/l in the basolateral compartment, similar to what was applied in  the 
corresponding ex vivo placental perfusion study [24]. Data are shown as mean ± standard 
deviation (n=6)
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discussion
The objective of the present study was to evaluate the ability of the in vitro BeWo model 
to predict placental transfer of compounds. To this end, the relative transport rates of a 
set of  nine model compounds obtained in the in vitro BeWo model, supplemented with 
the transport data of three compounds in this model reported by Poulsen et al. (2009), 
were compared with TIs of these compounds in the ex vivo human placental perfusion 
model as reported in the literature. The study shows that the relative transfer rates of the 
selected compounds in the in vitro BeWo model correlated well with the TIs reported 
for the ex vivo human placental perfusion model (R2=0.95), indicating that the in vitro 
BeWo model is a useful tool to predict placental transfer of compounds. 
The relative transport rates in the in vitro placental transport model correlated 
strongly with the ex vivo TIs in absence of BSA in the in vitro studies. A good correlation 
(R2=0.92) was also found for the in vitro transport rates obtained under experimental 
conditions in which BSA was present. When albumin was present in the transport buffer, 
the transport rates of the six test compounds (Table 2) were lower than when albumin 
was absent, showing that the placental transfer of these compounds was influenced by 
the presence of proteins. It may be expected that in general only the free fraction of 
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Fig. 4 Correlation between TIs from the ex vivo placental perfusion model and relative transport rates from the in vitro BeWo 
model for selected model compounds. A: all in vitro studies were carried out in the absence of albumin in the transport medium. 
B: in vitro studies were carried out in the presence of albumin in the transport medium, when the respective ex vivo studies were 
performed in the presence of albumin in the perfusates (closed symbols). Ex vivo data were taken from literature. In vitro data 
were obtained in present study for 9 test compounds (circles) and taken from [29] for 3 compounds (triangles). amo=amoxicillin, 
ant=antipyrine, ben=benzoic acid, caf=caffeine, dig=digoxin, gly=glyphosate, ind=indomethacin, ket=ketoprofen, 
lev=levofloxacin, lid=lidocaine, ofl=ofloxacin, spi=spiramycin 
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Fig. 4. Correlation between TIs from the ex vivo placental perfusion model and relative transport 
rates from the in vitro BeWo model for selected model compounds. A: all in vitro studies were 
ca ried out in th  absence of albumin in the transport medium. B: in vit o studies were carried
out in the presence of albumin in the transport medium, when the respective ex vivo studies 
were performed in the presence of albumin in the perfusates (closed symbols). Ex vivo data were 
taken from literature. In vitro data were obtained in present study for 9 test compounds (circles) 
and taken from [29] for 3 compounds (triangles). amo=amoxicillin, ant=antipyrine, ben=benzoic 
acid, caf=caffeine, dig=digoxin, gly=glyphosate, ind=indomethacin, ket=ketoprofen, 
lev=levofloxacin, lid=lidocaine, ofl=ofloxacin, spi=spiramycin
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the compound will be able to cross the placenta [31]. Binding to proteins decreases the 
free drug concentrations in maternal and fetal compartments. It has been shown in ex 
vivo studies that changes in protein concentrations in the maternal and fetal perfusates 
affect placental transfer [32, 33]. In the ex vivo perfusion study of ketoprofen, which 
has a high binding affinity for albumin [24], the TI decreased 2.1-fold, from 0.80 in 
the absence of albumin to a TI of 0.38 in the presence of albumin [24]. Using the same 
conditions regarding albumin concentrations in the BeWo model, the in vitro transport 
rate of ketoprofen relative to antipyrine decreased 4.9-fold, from 0.54 in the absence of 
albumin to 0.11 in the presence of albumin (Table 3). This indicates that the effect of 
protein binding on the transport of ketoprofen relative to the transport of antipyrine 
appears to be larger in the in vitro BeWo model than in the ex vivo placental perfusion 
model. This may be related to the fact that the in vitro BeWo model is a static system, 
without flows of perfusates, whereas the ex vivo model is a dynamic system consisting 
of flows of maternal and fetal perfusates controlled by peristaltic pumps [34]. 
Although we found a good correlation between the relative Papp ratios in the in vitro 
BeWo model and the TIs obtained in the ex vivo placental perfusion model, a difference 
between relative Papp ratios and TI values is that with TI values, the change in the amount 
of compound in the maternal circulation is included in its calculation. This implicates 
that a TI value does not exactly represent a relative transport rate, whereas the relative 
Papp ratio does. Therefore, a better correlation may be found between relative Papp ratios 
and relative transfer rates of the compounds in the ex vivo model. Unfortunately, the 
data reported for the ex vivo studies did not allow the calculation of relative transfer rates 
of the compounds in this model. However, if the decrease in the amount of compound 
in the maternal compartment is relatively low compared to the amount added at t0, the 
TI value will be close to the actual relative transfer rate. 
Although the data obtained in the in vitro BeWo model was in good correlation with 
data obtained in the ex vivo placental perfusion model, it must be noted that it is not 
clear how well both models predict placental transfer at early stages of pregnancy. The 
ex vivo human placental perfusion method uses term placenta [34] and the obtained 
data may therefore be especially relevant for the last period of pregnancy. Since many 
structural abnormalities occur at early stages of pregnancy [35], it is important to predict 
placental transfer at these early stages. Therefore, knowledge is needed on whether 
placental transfer in early stages of pregnancy differs from placental transfer in the last 
period of pregnancy, in order to determine how well the BeWo model predicts placental 
transfer in these critical stages of pregnancy.
Since we found a good correlation between the relative transport rates in the in vitro 
BeWo model and the TIs in the ex vivo placental perfusion model, the BeWo model 
may be a useful tool to predict whether compounds are likely to reach the fetus when 
being present in the maternal circulation. Together with data on in vitro developmental 
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toxicity of these compounds, for example obtained in the EST, the BeWo transport data 
may give indications which compounds would be of highest concern for the developing 
conceptus. This information could be used for prioritization for eventual further testing. 
Furthermore, the transport data generated from the BeWo model may be used in future 
studies to make quantitative predictions of fetal exposure, if the data would be integrated 
in PBK models that describe placental transfer from the maternal circulation to a fetal 
compartment. This addition of placental transfer in PBK modeling may improve the 
prediction of in vivo toxic dose-response curves for developmental toxicity when 
translating in vitro concentration-response curves to the in vivo situation using reverse 
dosimetry, enabling a non-animal based developmental toxicity testing strategy.
conclusion
The present study shows that the in vitro BeWo model is capable of predicting similar 
relative placental transfer of compounds compared to the ex vivo placental perfusion 
model. The in vitro BeWo model may therefore provide an alternative to the ex vivo 
placental perfusion model, as an easier and faster method to predict placental transfer, 
enabling the assessment of a larger number of compounds. The data obtained in the BeWo 
model may be useful for the prioritization for eventual further testing of compounds. 
Furthermore, the parameters for placental transfer generated from this in vitro model 
may be used in future studies to establish parameter values for placental transfer in 
PBK models that can be used for reverse dosimetry, enabling the translation of in vitro 
concentration-response curves into in vivo dose-response curves that can be used for 
risk assessment, thereby contributing to the replacement, reduction and refinement of 
animal use in toxicity testing.
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We investigated the applicability of the ES-D3 cell differentiation assay combined 
with the in vitro BeWo transport model to predict the relative in vivo developmental 
toxicity potencies. To this purpose, the in vitro developmental toxicity of five antifungal 
compounds was investigated by characterizing their inhibitory effect on the differentiation 
of ES-D3 cells into cardiomyocytes. The BeWo transport model, consisting of BeWo 
b30 cells grown on transwell inserts and mimicking the placental barrier, was used to 
determine the relative placental transport velocity. The ES-D3 cell differentiation data 
were first compared to benchmark doses (BMDs) for in vivo developmental toxicity 
as derived from data reported in the literature. Correlation between the benchmark 
concentration for 50% effect (BMCd50) values, obtained in the ES-D3 cell differentiation 
assay, with in vivo BMD10 values showed a reasonable correlation (R2 = 0.57). When the 
ES-D3 cell differentiation data were combined with the relative transport rates obtained 
from the BeWo model, the correlation with the in vivo data increased (R2 = 0.95). In 
conclusion, we show that the ES-D3 cell differentiation assay is able to better predict 
the in vivo developmental toxicity ranking of antifungal compounds when combined 
with the BeWo transport model, than as a stand-alone assay. 
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inTroducTion
The implementation of the REACH legislation results in the increased use of animals for 
(eco) toxicity testing, especially for developmental toxicity testing [1, 2]. Therefore, it is 
urgently needed to develop and validate in vitro and in silico alternative methods for in 
vivo developmental toxicity studies [3]. Several in vitro methods have been developed to 
evaluate the developmental toxic potential of chemical substances, such as the embryonic 
stem cell test (EST), the rodent whole embryo culture test and the chicken embryotoxicity 
screening test [4-6]. Among these tests only the EST does not require the use of primary 
animal tissues. The EST uses the blastocyst-derived mouse embryonic stem cell line D3 
(ES-D3) that spontaneously differentiates into contracting cardiomyocytes when cultured 
as embryoid bodies. The inhibition of the ES-D3 cell differentiation into contracting 
cardiomyocytes by test compounds is the in vitro endpoint for developmental toxicity 
[7]. In the European Centre for the Validation of Alternative Methods’ validation study 
on 20 different chemicals with different in vivo embryotoxic potencies (classified as non, 
weak or strong embryotoxic), the EST provided a correct classification of the embryotoxic 
potential of 78% of the test chemicals, based on a prediction model that integrates effect 
data on ES-D3 cell viability, ES-D3 cell differentiation and 3T3 cell viability. When only 
the strong embryotoxic chemicals were taken into account, a predictivity of 100% was 
obtained. However, in a second study, only 2 out of 13 test chemicals were correctly 
classified in the EST. Therefore, the applicability of this prediction model was questioned 
[8]. Several studies that have used the ES-D3 cell differentiation assay as a stand-alone 
assay, have shown that in vitro potency ranking of chemicals in this assay can be used 
to predict in vivo potency rankings within selected chemical classes for most of the 
investigated chemicals [9-11]. Any incorrect ranking was pointed out to be possibly 
due to the lack of in vivo kinetic processes in this in vitro assay, phenomena that are of 
influence in the in vivo situation. A further point is that some chemicals may be tested 
at higher concentrations in the EST than could be achieved in vivo. Therefore, it is of 
importance to combine the in vitro model for developmental toxicity with data on in 
vivo kinetics, to better predict in vivo developmental toxicity potencies. 
One of the main in vivo kinetic processes involved in developmental toxicity is 
placental transfer, as the transport of compounds through the placental barrier may 
differ, thereby influencing the final concentrations of compounds that could reach the 
fetus. Placental transfer of compounds can be studied in the human ex vivo placental 
perfusion model, which is a useful model for investigating transport of compounds across 
the maternal-fetal barrier [12-15]. However, this method is laborious and dependent on 
the presence of fresh human placenta, hampering the use for the assessment of large 
numbers of compounds. Another method to study placental transfer is the in vitro BeWo 
transport model, which is easy, fast and cheap [16]. In this model, BeWo b30 cells, derived 
from a human choriocarcinoma, are used. When grown on a transwell insert, the cells 
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get polarized and form a cell layer, separating an apical compartment from a basolateral 
compartment, representing maternal and fetal compartment in vivo, respectively [17]. 
Besides transmembrane diffusion, compounds can be transported across the BeWo 
cell membrane via active transport or paracellular diffusion. These different transport 
mechanisms have been elucidated in inhibition and specific substrate studies which 
demonstrated the expression of specific transporters such as the P-glycoprotein[18], 
and the multidrug resistance-associated proteins, as well as the breast cancer resistance 
protein (Mitra and Audus, 2010). We have previously shown that this in vitro model 
is capable of predicting relative placental transfer of a set of 9 model compounds with 
a good correlation to the transport observed in the ex vivo placental perfusion model 
(R2=0.95), indicating the in vitro BeWo transport model is useful to study placental 
transfer of compounds [19]. 
The aim of the present study was to determine the usefulness of combining the 
ES-D3 cell differentiation assay of the EST with the in vitro BeWo transport model 
to predict the relative in vivo developmental toxicity potencies of a series of five 
antifungal developmental toxicants, being ketoconazole, tebuconazole, propiconazole, 
prothioconazole and fenarimol. The five compounds have shown to be developmental 
toxicants in animal studies as they cause, e.g., increased embryolethality, cleft palate, 
reduced fetal weight, and skeletal malformations [20, 21]. The in vitro developmental 
toxicity data of the five test compounds obtained in this study were compared to the 
historical in vivo data.
maTerials and meThods 
chemicals
Ketoconazole, tebuconazole, propiconazole, prothioconazole and fenarimol (with purity 
for the five compounds all > 98%) were purchased from Sigma-Aldrich (Steinheim, 
Germany). Dimethyl sulfoxide (DMSO) was purchased from Acros Organics (Geel, 
Belgium). Hank’s balanced salt solution (HBSS) was obtained from Invitrogen (Breda, 
the Netherlands).
es-d3 cell culture
The murine ES-D3 cell line was purchased from ATCC (Wesel, Germany). The cells were 
maintained in polystyrene cell culture flasks (Corning, the Netherlands) in Dulbecco’s 
Modified Eagle Medium (DMEM, Invitrogen, Breda, The Netherlands), supplemented 
with 20% heat-inactivated fetal calf serum (Lonza, BioWhittaker, Verviers, Belgium), 
50 U/ml penicillin with 50 μg/ml streptomycin (Invitrogen), 2 mM L-glutamine 
(Invitrogen), 0.1 mM β-mercaptoethanol (Sigma-Aldrich) and 1% (v/v) non-essential 
amino acids (Invitrogen), at 37°C and 5% CO2 in a humidified atmosphere. Cells 
were kept undifferentiated with 1000 U/ml murine leukemia inhibiting factor (LIF) 
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(Sigma-Aldrich) and subcultured every 2 to 3 days using non-enzymatic cell dissociation 
solution (Sigma-Aldrich) to detach the cells.
cytotoxicity assay with es-d3 cells
To determine cytotoxicity of the compounds, a WST-1 assay was performed. This 
assay measures the influence of test compounds on mitochondrial activity, by using 
WST-1 reacting with the mitochondrial succinate-tetrazolium reductase forming the 
water-soluble formazan reaction product. The cytotoxicity of a test compound inversely 
correlates to the absorbance of the produced formazan quantified spectrophotometrically 
as described previously [22]. ES-D3 cells were exposed to test compounds for the duration 
of one day or five days. Briefly, cells were seeded in 96-well plates (Greiner bio-one) 
at concentrations of 20 x 104 cells/ml (one-day exposure) or 1 x 104 cells/ml (five-day 
exposure) in 100 μL culture medium in the absence of LIF and incubated for one day to 
allow cell adherence. Then the cells were exposed to the test compounds at concentrations 
up to 200 μM (final solvent concentration: 0.2% DMSO) and subsequently cultured 
for one or five days at 37°C and 5% CO2 in a humidified atmosphere. Solvent DMSO 
(0.2%) was used as a negative control and Triton X-100 served as a positive control in all 
cytotoxicity assays. After incubation of one or five days, 20 μL WST-1 reagent (Roche, 
Woerden, the Netherlands) was added to each well and the plates were incubated for 
another 3 hours. Then absorbance was measured at 450 nm using SpectraMax M2 
(Molecular Devices, Sunnyvale, USA). Three wells were used per treatment in each 
independent experiment. Three independent experiments were done for each compound. 
The cell viability was expressed as % of control, with the solvent control set at 100% 
viability. Reproducible results were obtained from the treatments of negative and positive 
controls in all of the cytotoxicity assays.
differentiation assay with es-d3 cells
Differentiation assays were carried out to detect the effects of test compounds on the 
differentiation of ES-D3 cells into contracting cardiomyocytes using culture medium in 
the absence of LIF. On day 1, droplets of 20 μl cell suspension (3.75 x 104 cells/ml) were 
placed as hanging drops, to which the test compounds were added at concentrations up 
to 100 μM (final solvent concentration: 0.2% DMSO), on the inner side of the lid of a 
96-well plate. Sterile lids of eppendorf tubes were placed on the corner wells of the plates 
to prevent contact of the drops with the plate. The wells of the 96-well plate were filled 
with 250 μl phosphate buffered saline (PBS) (Invitrogen) and the plate was sealed with 
Micropore tape (3M, Neuss, Germany) to prevent evaporation of the hanging drops. 
Plates were incubated for three days at 37°C and 5% CO2 in a humidified atmosphere. 
In the drops, cells formed embryonic bodies (EBs), which were transferred to non-tissue 
culture treated Petri dishes (diameter 6 cm, Greiner) with 5 ml of medium with test 
compound. On day 5, the EBs were transferred to a 24-well plate (Corning) with 1 ml 
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of medium with test compound, with one EB per well. On day 10, the number of wells 
containing contracting EBs was determined by visual inspection using a light microscope. 
Solvent control (DMSO) was included in each experiment. The solvent control was also 
used to assess the quality of the batch of ES-D3 cells used in each individual test (cells 
being randomly distributed over test groups and solvent control). Tests were accepted for 
further analysis if at least 21 of the 24 wells of the solvent control contained contracting 
cardiomyocytes. For each test compound, three independent assays were performed, 
at concentrations ranging from 0.1 to 100 µM. The results were expressed as “fraction 
of total”, with 1.0 implying all EBs in one 24-well plate differentiated into contracting 
cardiomyocytes.
beWo transport experiments
To study placental transfer of test compounds, BeWo transport experiments were 
performed as described previously [19]. Briefly, BeWo b30 cells (passages 27–45) were 
cultured in DMEM (Zwijndrecht, the Netherlands), supplemented with 10 % (v/v) heat-
inactivated FCS (HyClone-Perbio, Etten-Leur, the Netherlands), 10,000 U/ml penicillin, 
10 mg/ml streptomycin and 2 mM l-glutamine. The cells were seeded at a density of 1 x 
105 cells/cm2 on transwell® polycarbonate membranes (12 mm diameter, 0.4 μm pore size) 
(VWR International BV, Amsterdam, the Netherlands) coated with human placental 
collagen. The medium (0.5-ml apical compartment, 1.5-ml basolateral compartment) was 
replaced daily. At day 6 post-seeding, the BeWo b30 cell layers were used for transport 
experiments. The barrier forming capacity of the BeWo cell layers was evaluated by 
measuring the transepithelial electrical resistance (TEER) of the cell monolayer using 
a Millicell ERS-2 Volt-Ohm Meter (Millipore, USA) at day 6 post-seeding as described 
previously [19]. Only the cell layers showing TEER values between 80 and 100 Ω∙cm2 
were used for transport experiments. 
Transport experiments were initiated by adding 0.5 ml of transport buffer HBSS 
containing the test compound, added from a 200 times concentrated stock solution 
in DMSO, to the apical compartment and 1.5 ml transport buffer to the basolateral 
compartment (final solvent concentration: 0.5% DMSO). Subsequently, the plate was 
incubated in a humidified atmosphere with 5 % CO2 at 37 °C. After 15, 30, 60 and 
90 min, a sample of 0.2 ml was taken from the basolateral compartment and replaced 
by an equal volume of transport buffer. At the end of each experiment, a 0.2 ml sample 
was also taken from the apical compartment. The amount of compound accumulated 
in the cells was determined and mass-balance calculations were performed as described 
previously [19]. The transport of each test compound was investigated at an apical amount 
of 50 nmol (0.5 ml of a 100 μM solution) to allow detection of compounds transported 
to the basolateral compartment. In each transport study, amoxicillin was included as 
a control for monolayer integrity since it is a compound known to be transported only 
to a limited extent and antipyrine was included as a control for optimal transport and 
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a reference compound to enable calculation of relative transport rates. The transport of 
the five test compounds, as well as the standards amoxicillin and antipyrine, through the 
permeable membrane of the transwell filter in the absence of BeWo cells was determined 
as well. It was shown to be equally fast among these compounds (data not shown), 
ensuring that any differences observed in the BeWo model were related to the BeWo 
cell system and not to the filter.
As described in the analysis certificate sheets from Sigma-Alltech, ketoconazole and 
propiconaozle have two isomers. For tebuconazole, prothioconazole and fenarimol, 
only one dominant form is present in the product with >99% purity. To determine 
transport rates of isomers of ketoconazole and propiconazole across BeWo cell layers, 
additional transport experiments were carried out and samples were taken at 60 min 
(during the linear phase of transport, as determined in the earlier assays) from both 
apical and basolateral compartment. At this time we also determined the intracellular 
accumulation in the BeWo cells as described previously [19]. 
high-performance liquid chromatography analysis
Samples were analyzed using high-performance liquid chromatography (HPLC) to 
quantify the amount of test compound in order to determine the transport rate and 
to perform mass-balance calculations. The HPLC system used consisted of a Waters 
(Milford, MA) 600 controller and a 600 pump, equipped with a photodiode array detector 
set to record absorption of wavelengths between 200 and 400 nm. A Waters 717 plus 
autosampler was used for sample injection. The temperature of the autosampler was 
kept at 7 °C. 
For analysis of all compounds, 50 μl sample was applied to a C18 5 μm reverse-
phase column (150 mm × 4.6 mm I.D.) with a guard column (7.5 mm × 4.6 mm I.D.) 
(Alltech, Bergen op Zoom, the Netherlands). The mobile phase used for analysis of 
all the test compounds consisted of (A) 0.1 % trifluoroacetic acid in nanopure water 
and (B) HPLC-grade acetonitrile. Elution was at a flow rate of 0.8 ml/min, starting 
at 22 % B with a linear increase to 100 % B in 8 min. Subsequently, the gradient 
returned linearly to the initial condition in 10 min and remained 2 min at this condition 
prior to the next injection. In each experiment, calibration curves were included for 
quantification. Using this HPLC method the two isomers of ketoconazole appeared 
as one peak, whereas the two isomers of propiconazole were separated as two peaks. 
Isomers of ketoconazole were identified and quantified as described in the analysis 
certificate sheets from Sigma-Alltech with small modifications. To this end, 50 μl 
sample was applied to a CYCLOBOND I 2000 HP-RSP 5 μm column (250 mm x 4.6 mm 
I.D.) (Alltech, Bergen op Zoom, the Netherlands). The mobile phase used for analysis 
consisted of (A) 0.1 % formic acid in nanopure water and (B) HPLC-grade acetonitrile. 
Two isomers were separated at a flow rate of 1 ml/min by using an isocratic elution 
system with 70% A and 30% B.
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data analysis
BeWo transport data
For each compound, the linear appearance rate in the basolateral compartment 
was determined. These linear appearance rates were used to calculate apparent 
permeability (Papp) coefficients (Papp coefficient (cm/s) = (ΔQ/Δt) / (A·C0)), where 
ΔQ is the amount of test compound (nmol) transported to the receiver chamber 
in a certain time span (Δt (s)), A is the cell surface area (cm2) and C0 is the initial 
concentration of the test compound (µM). To calculate ΔQ, a correction was made 
to compensate for the removal of compound when taking samples (ΔQ at tx+1 = 
amount measured at tx+1 (nmol) (basolateral concentration at tx+1 (μM) × 1.5 (ml)) 
supplemented with the amount removed at tx (nmol) (basolateral concentration 
sample at tx (μM) × 0.2 (ml))). Subsequently, relative Papp values were determined 
by expressing the Papp coefficient as a fraction of the Papp coefficient obtained for 
antipyrine. Amounts (nmol) of two isomers in the basolateral compartment, apical 
compartment and BeWo cell layer were analyzed at 60 min. Pairwise comparison of 
the isomers was performed using a two-sided student’s T-test considering differences 
statistically significant when p < 0.05.
In vitro data 
Different dichotomous concentration-response models were fitted to the developmental 
toxicity data obtained from the ES-D3 cell differentiation assay of the EST to calculate 
benchmark concentrations (BMC) using Environmental Protection Agency benchmark 
dose software (BMD) version 2.4. For each test compound, the BMCd50, representing 
the concentration for a 50% reduction in the number of differentiated EBs, was derived. 
Models included in the evaluation were the gamma, logistic, loglogistic, probit, 
logprobit, multistage, weibull and the quantal-linear model. Goodness-of-fit of the 
models was evaluated to accept a model, based on the P-values, the scaled residuals 
and the graphical displays obtained. The lowest BMCd50 value was chosen from the 
accepted models.
To combine in vitro developmental toxicity data obtained from the ES-D3 cell 
differentiation assay of the EST with placental transfer data obtained from the BeWo 
transport model, a corrected BMCd50 value was calculated by dividing the BMCd50 
values by the relative Papp values.
In vivo data
A literature study was performed to determine the in vivo developmental toxicity 
potencies of each test compound. Search terms included the name of test compound 
together with combinations of the search terms teratogenicity, developmental 
toxicity, malformation, embryotoxicity and cleft palate. For the purpose of this 
paper, the results of studies performed in rats were used, mostly published in reports 
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of the Food and Agriculture Organization (FAO), World Health Organization 
(WHO), Environmental Protection Agency (EPA), European Commission (EC) 
and the European Food Safety Authority (EFSA) or in published papers on 
developmental toxicity. A study was selected if it included at least one control group 
and two dose groups, which enables analysis by the BMD approach to derive a BMD 
value. The incidence of cleft palate or skeletal malformations was selected as the in 
vivo endpoint for developmental toxicity, as they have shown to be the profound 
developmental toxic effects caused by antifungal compounds. For fenarimol, 
hydronephrosis was used as the in vivo endpoint since data were not available 
on cleft palate or skeletal malformations. A benchmark response (BMR) for the 
BMD for each compound was defined as a 10% extra incidence of malformations. 
The BMD10 was calculated using dichotomous concentration-response models as 
described for the in vitro data. 
resulTs
cytotoxicity assay with es-d3 cells
WST-1 assays for both one-day and five-day exposure were performed to evaluate the 
cytotoxic effects of the compounds on the ES-D3 cells (Figure 1). For all compounds, the 
concentrations tested (up to 100 μM) were non-cytotoxic as determined in the one-day 
cytotoxicity assay. Among the five compounds, fenarimol was the most potent one in 
the five-day cytotoxicity assay, reducing the cell viability to 50% at 100 μM. Exposure 
of 100 μM ketoconazole, prothioconazole and tebuconazole to the ES-D3 cells resulted 
in 40%, 25%, and 20% decline in cell viability, respectively, reflecting lower cytotoxic 
properties of these compounds than of fenarimol. Propiconazole did not cause any 
reduction in cell viability up to 100 μM.
differentiation assay with es-d3 cells
To study the in vitro developmental toxicity of the antifungal compounds, the effects of 
the compounds on the differentiation of ES-D3 cells into contracting cardiomyocytes 
were evaluated. All test compounds induced a concentration-dependent inhibition of 
the differentiation of the ES-D3 cells into contracting cardiomyocytes (Figure 1). The 
BMCd50 values occurred at concentrations that did not cause cytotoxicity, indicating 
that inhibitory effects on the differentiation of EBs are not due to cytotoxicity of test 
compounds. BMCd50 values are summarized in Table 1, showing that ketoconazole 
was the most potent in inhibiting the differentiation of EBs, followed by tebuconazole, 
fenarimol, prothioconazole and propiconazole.
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Fig. 1 Concentration-dependent effects of test compounds ketoconazole (a), tebuconazole (b), propiconazole (c), prothioconazole 
(d) and fenarimol (e) on cell viability for one-day () and five-day (○) exposure and on inhibition of ES-D3 cell differentiation (△). 
Results represent at least three independent experiments and are presented as mean ± standard deviation (n = 3).   
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Fig. 1. Concentration-dependent effects of test compounds ketoconazole (a), tebuconazole 
(b), propiconazole (c), prothioconazole (d) and fenarimol (e) on cell viability for one-day 
(Î) and five-day (○) exposure and on inhibition of ES-D3 cell differentiation (△). Results 
represent at least three independent experiments and are presented as mean ± standard 
deviation (n = 3).  
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Table 1. BMCd50 and corrected BMCd50 values for in vitro developmental toxicity of test 
compounds in the ES-D3 cell differentiation assay and BMD10 values for in vivo developmental 
toxicity of test compounds in rats.
BMCd50
(µM)
Corrected BMCd50
(µM)
BMD10 (cleft palate or skeletal 
malformation) (µmol/kg bw/day)
Ketoconazole 10.63 13.46 20.14
Tebuconazole 18.85 21.92 27.55
Fenarimol 24.27 44.13 68.86
Propiconazole 38.64 55.19 90.99
Prothioconazole 35.42 88.55 212.4
in vitro beWo transport 
Ketoconazole, tebuconazole, propiconazole, prothioconazole and fenarimol were tested 
in the BeWo transport model to assess their transport across the placental barrier. For 
all transport experiments, the mass balances were between 91 and 99 %. Figure 2 shows 
the amount of test compounds in the basolateral compartment of the BeWo model 
with increasing time, after adding 50 nmol to the apical compartment. Antipyrine was 
included as a reference compound known to be efficiently transported across the BeWo 
cell layer [19] and amoxicillin was used as a control compound to check the integrity 
of the cell layer. The slow transfer of amoxicillin indicated an integrate BeWo cell 
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Fig. 2 Amount of amoxicillin (◊), prothioconazole (□), fenarimol (), ketoconazole (△), propiconazole (), tebuconazole (●) and 
antipyrine (+) in the basolateral compartment in the in vitro BeWo model with increasing time using initial concentrations of 100 
μM (50 nmol) in the apical compartment. Data are presented as mean ± standard deviation (n = 6). 
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Fig. 2. Amount of amoxicillin (◊), prothioconazole (□), fenarimol (), ketoco azole (△), propi-
conazole (Î), tebuconazole (●) and antipyrine (+) i  basolateral compartment in the in vitro 
BeWo model with increasing time using initial concentrations of 100 μM (50 nmol) in the apical 
compartment. Data are presented as mean ± standard deviation (n = 6).
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layer. Up to 60 min, the transport of all compounds to the basolateral compartment 
was linear in time. Therefore, the linear appearance rate of mass in the basolateral 
compartment could be determined using data at 60 min for the calculation of Papp 
coefficients (Table 2). The data in Table 2 show a wide range of Papp coefficients for 
the five test compounds, illustrating different placental transfer rates among them, 
with tebuconazole being transported at the highest rate and prothioconazole at the 
lowest rate. 
Table 2. Papp coefficients and relative Papp values of five test compounds and control compounds 
amoxicillin and antipyrine in the BeWo model. 
Papp coefficient 
(10−6 cm/s) Relative Papp value
Amoxicillin 6 ± 0.8a 0.15
Prothioconazole 16 ± 2.7 0.40
Fenarimol 21 ± 3.2 0.55
Propiconazole 27 ± 3.8 0.70
Ketoconazole 31 ± 2.4 0.79
Tebuconazole 33 ± 4.3 0.86
Antipyrine 39 ± 2.6 1.00
a Mean ± SD
Extra transport experiments were performed to study placental transfer of 
different isomers across BeWo cell layers. Table 3 shows the amount of isomers of 
ketoconazole and propiconazole in the basolateral and apical compartment, as well 
as the amount accumulated in the BeWo cell layer, at 60 min after adding 50 nmol to 
the apical compartment in the BeWo transport model. The results of the t-test show 
that the difference between the amounts (basolateral, apical and intracellular) of 
the two isomers for both ketoconazole and propiconazole is not significant (p>0.05), 
indicating the same degree of transport across the BeWo cell layer for the isomers 
of both test compounds.  
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combination of in vitro developmental toxicity data with beWo 
transport data
To combine in vitro developmental toxicity data obtained from the ES-D3 cell 
differentiation assay of the EST with placental transfer data obtained from the BeWo 
transport model, a corrected BMCd50 value was calculated by dividing the BMCd50 
values by the relative Papp values (Table 1). After the correction, the potency ranking 
was altered, with ketoconazole being the most toxic compound and prothioconazole 
the least potent one. 
bmd derivation from in vivo data
A literature study on in vivo developmental toxicity was performed to obtain a potency 
ranking of the test compounds in vivo. For this ranking, studies performed in rats 
with oral administration were used. Table 4 provides an overview of the details of the 
animal studies used to derive BMD values. BMD10 values that correspond with a 10% 
extra incidence of cleft palate or skeletal malformations on litters or on fetuses were 
derived. When the best fits of BMD10 values derived on both litters and fetuses for a 
test compound were determined, the lower value (relating to a more sensitive endpoint) 
of the two was selected as the final BMD10 value for the compound. Table 1 shows the 
results of BMD analysis of these in vivo data (for details see Supplementary file).
comparison of in vivo and in vitro developmental toxicity 
Both BMCd50 and corrected BMCd50 values were compared with in vivo BMD10 
values to assess the usefulness of taking into account BeWo transport data (Table 1). 
Based on the BMD10 values, ketoconazole was the most potent compound in vivo 
and prothioconazole was the least potent one. The data of these compounds in the 
ES-D3 cell differentiation assay of the EST correlate to some extent with the BMD10 
Table 3. Amount (nmol, mean ± SD) of isomers of ketoconazole and propiconazole in the 
basolateral compartment, apical compartment and BeWo cell layer at 60 min using initial 
concentrations of 100 μM (50 nmol) in the apical compartment.
Isomer 1 (nmol) Isomer 2 (nmol)
Ketoconazole Basolateral 5.1 ± 0.4 4.8 ± 0.6
Apical 17.4 ± 1.1 17.9±1.3
Intracellular 1.3± 0.1 1.1 ± 0.1
Propiconazole Basolateral 5.4 ± 0.8 5.2 ± 0.9
Apical 17.3 ± 0.9 17.7± 1.5
Intracellular 2.2± 0.2 2.1± 0.3
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Compound Days
Dose (mg/ 
kg bw/day)
No. of fetuses 
(litters) examined
Incidence of cleft palate or skeletal 
malformation on fetuses (litters)
Ketoconazolea PI
6-17 
0
25
75
- (22)
- (22)
- (3)
- (0)
- (3)
- (3)
Tebuconazoleb GD
6-15
0
30
60
120
144(24)
137(24)
127(22)
116(24)
29(14)
40(17)
38(17)
48(20)
Propiconazolec GD
6–15 
0
30
90
300
141(22)
148(21)
156(22)
148(22)
0(0)
1(1)
4(4)
53(16)
Prothioconazoled PC
6-19
0
20
80
750
-
-
-
-
23.5%(95.2%)
18.2%(77.8%)
27.6%(88.9%)
33.6%(95.7%)
Fenarimole GD
6-15
0
5
13
35
-
-
-
-
9%(25%)
0(0)
0(0)
30%(62%)
Note. PI = post-insemination; GD = gestational day; PC=post coitum
a data from [31] based on increased incidences of cleft palate.
b data from [32] based on increased incidences of skeletal variations.
c data from [33] based on increased incidence of skeletal malformations.
d data from [34] based on increased incidence of skeletal variations.
e data from [35] based on increased hydronephrosis, as no cleft palate or skeletal malformations were 
reported.
- data not available.
values derived from the in vivo data with R2 being 0.57 (Figure 3). When the ES-D3 
cell differentiation data are combined with the results obtained in the BeWo transport 
model to obtain corrected BMCd50 values, a better correlation with the in vivo BMD10 
values was obtained indicated by an increase of the R2 to 0.95 (Figure 3). These data thus 
demonstrate the power of including a component of kinetics when predicting relative 
in vivo toxicity potencies based on in vitro toxicity data. 
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Fig. 3. Correlation between in vivo BMD10 values of five test compounds ketoconazole, tebu-
conazole, propiconazole, prothioconazole and fenarimol, as derived based on data reported in 
the literature, with (A) in vitro BMCd50 values, obtained from the ES-D3 cell differentiation 
assay of the EST, and with (B) in vitro corrected BMCd50 values, obtained from combining in 
vitro BMCd50 values from the ES-D3 differentiation assay with relative Papp values from the 
BeWo transport model. 55  
Comparison of in vivo and in vitro developmental toxicity  
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Fig. 3 Correlation between in vivo BMD10 values of five test compounds ketoconazol , tebuconazole, propiconazole, 
prothioconazole and fenarimol, as derived based on data reported in the literature, with (A) in vitro BMCd50 values, obtained from 
the ES-D3 cell differentiation assay of the EST, and with (B) in vitro corrected BMCd50 values, obtained from combining in vitro 
BMCd50 values from the ES-D3 differentiation assay with relative Papp values from the BeWo transport model. 
Ketoconazole Tebuconazole
Fenarimol Propiconazole
Prothioconazoley = 5.0378x - 44.788R² = 0.57
0
80
160
240
0 10 20 30 40 50
In
 vi
vo
 B
M
D1
0 (
µm
ol/
kg
 bw
)
In vitro BMCd50 (µM)
A
Ketoconazole
Tebuconazole
Fenarimol
Propiconazole
Prothioconazoley = 2.549x - 29.824R² = 0.95
0
80
160
240
0 20 40 60 80 100
In
 vi
vo
 B
M
D1
0 (
µm
ol/
kg
 bw
)
In vitro corrected BMCd50 (µM)
B
discussion
Several in vitro studies have been performed with the ES-D3 cell differentiation assay of 
the EST to predict in vivo developmental toxicity potency ranking of series of structurally 
related compounds, and it has been suggested that the capacity of this assay to predict 
in vivo potency ranking could be improved by combining kinetic information with the 
in vitro ES-D3 cell differentiation data [9-11]. Therefore, in the present study, one of the 
important in vivo kinetic processes for developmental toxicity, i.e. placental transfer, 
was taken into account when in vivo developmental toxicity ranking of five antifungal 
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compounds was predicted based on in vitro toxicity data obtained in the ES-D3 cell 
differentiation assay of the EST. 
The in vitro BeWo transport model was used in the present study, as it was previously 
shown to be suitable to adequately characterize relative placental transfer rates of 
compounds [19, 23, 24]. Our intention was to determine the Papp values and to use 
relative Papp values to adjust the BMCd50 values, obtained from the differentiation assay, 
for placental transfer. We did not aim to test the transport mechanisms of the compounds 
in this study. The five test compounds showed different transfer rates through the placental 
barrier in the BeWo model, indicating that transport velocities to the fetus in vivo may 
differ as well. However, how this exactly translates to differences in fetal exposure is not 
known, due to the fact that in vivo experimentation of placental transport in humans is 
not feasible on a large scale for obvious ethical reasons and little has been published on 
the fetal bioavailability of antifungal compounds in human. Therefore, we hypothesize 
that the extent of fetal exposure would be positively correlated to the relative transport 
velocity in the BeWo model. This means that a compound with a relatively low Papp 
coefficient may cause a relatively low fetal exposure, whereas a compound with a relatively 
high Papp coefficient may cause a relatively high fetal exposure. Therefore, we investigated 
whether the correlation between in vitro BMCd50 values and in vivo developmental 
toxicity dose levels improved when we corrected the in vitro BMCd50 values for differences 
in placental transfer, by dividing these values for the five model compounds in the ES-D3 
cell differentiation assay of the EST by relative Papp values obtained in the BeWo model. 
The results obtained reveal that the corrected BMCd50 values correlated better than 
the uncorrected ones with the in vivo BMD10 values. This indicates that combining 
ES-D3 cell differentiation assay results with placental transfer kinetics improved the 
ability of this in vitro assay to predict relative in vivo developmental toxicity potencies 
of antifungal compounds. It should be noted that the BeWo cell model is not suitable to 
determine the absolute transport rates of compounds, given that the BeWo cell model is a 
simplification of the in vivo placental transfer system. This is related to several parameters 
that are different from the in vivo situation, e.g. circulation, flow rate and the volumes 
of maternal and fetal compartments. In those cases where it is important to use exact 
fetal bioavailability values, physiologically based kinetic (PBK) models which describe 
the in vivo absorption, distribution, metabolism, and excretion processes of a compound 
should be used. Other important in vivo kinetic processes than placental transfer, such 
as intestinal absorption, maternal metabolism and placental metabolism, were not taken 
into account in the present study. Therefore, incorporating more kinetic information is 
likely to further improve the predictive value of the ES-D3 cell differentiation assay of 
the EST. Therefore, a PBK model, should be the ultimate goal for the translation of in 
vitro toxicity data to the in vivo situation [25, 26]. The present study demonstrates that 
placental transfer should be one of the components in these PBK models. 
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In the ES-D3 cell differentiation assay of the EST, the developmental toxicity 
potency of test compounds is investigated by evaluating their inhibitory effects on 
the differentiation of mouse ES-D3 cells into contracting cardiomyocytes. The ES-D3 
cell differentiation assay of the EST is considered to represent the fetal component of 
developmental toxicity. As the (azole) antifungal compounds are also known for their 
abilities to inhibit cytochrome enzymes (Marotta and Tiboni 2010), and in particular 
may inhibit estrogen biosynthesis through CYP 19 aromatase inhibition, reducing 
the conversion of androgens to estrogens [27], this aspect, which takes place in the 
maternal organism, merits attention. The phenotypic analysis of the inhibition of 
cardiac differentiation in the ES-D3 cell differentiation assay of the EST cannot take 
this part of developmental toxicity into account. Therefore, other relevant in vitro assays, 
such as steroidogenesis assay, may be needed. In addition, although the ES-D3 cell 
differentiation assay of the EST combined with the BeWo transport assay shows to be 
an appropriate in vitro toxicological system to achieve an enhanced predictivity of the 
relative developmental toxicity for antifungal compounds, combined testing strategies 
based on in vitro assays should be used to provide relevant mechanistic information 
for human risk assessment. For example, the ES-D3 cell differentiation assay could be 
combined with transcriptomics to be able to get information on gene expression changes 
after exposure and the underlying mechanisms [28]. 
It is well known that the placental transfer rates of the compounds can be influenced 
by their physicochemical and molecular properties [29]. In fact, small molecules 
(molecular weight < 500) were reported to diffuse more readily than larger ones and 
low lipophilicity may exhibit restricted transport across the placental barrier [29]. It has 
also been found that the number of hydrogen bonding acceptor or donor sites was a very 
important descriptor that correlate negatively with the permeability values across the 
placental barrier. Moreover, a positive dependence of the placental transfer on log D has 
been reported [30]. Each of these physicochemical and molecular properties may provide 
useful information on evaluating permeability characteristic of compounds, but cannot 
be used independently to determine transport rate, as placental transfer is a complex 
process and the influence on the transfer of compounds is a conglomeration of different 
physicochemical and molecular properties. Therefore, a quantitative structure-activity 
relationship (QSAR) methodology for modeling transport across the human placental 
barrier was established using a multivariate data analysis approach on 84 compounds by 
Giaginis et al. [30]. The QSAR model used 16 descriptors and the predicted permeability 
values, relative to antipyrine, were compared with the relative transport values to 
antipyrine obtained from ex vivo human placental perfusion experiments compiled 
from numerous sources. A good correlation was found, with r2 being 0.73, showing that 
this model is an adequate and robust tool, providing an informative illustration of the 
contributing physicochemical, molecular and structural properties of the compounds 
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in placental transfer process. However, in their study, 4 compounds were defined as 
outliers and excluded from the model, rendering the prediction model less reliable due 
to its incapability to analyze the permeability of the compounds sharing the similar 
physicochemical and molecular properties with those 4 compounds [30]. In addition, 
this in silico model exhibits limited reflection on the interactions between compounds 
and biological systems, for example the interaction with the cell membrane transporters, 
which are essential information for compound’s permeation through a placental barrier. 
In contrast, the relative Papp values obtained our BeWo cell model were proven to 
correlate very well with the transport in the ex vivo placental perfusion model based 
on 9 model compounds, with an even higher r2 being 0.95 [19], and it allows the direct 
examination on the interaction of compounds with a biological system, indicating it 
outperforms a simple in silico membrane model. Although, as compared to an in silico 
model, the BeWo cell model is relatively more time-consuming and laborious, it can 
still be used in a high-throughput manner. 
Some of the compounds investigated are present in the form of different isomers 
(stereoisomerism), and each of these isomers may have different physical properties and 
biological effects. We therefore considered that it was important to know if different 
isomers could transfer through the placental barrier at different rates. Both ketoconazole 
and propiconazole have two isomers and each compound was tested in vivo and in the 
in vitro systems as a mixture of isomers. The results obtained with the BeWo model 
in the present study revealed that the isomers of both compounds transfer through 
BeWo cell layers at a comparable rate. Therefore, an equal exposure of the fetus to the 
isomers may be expected, which indicates that the exposure to the combination of the 
two isomers in the ES-D3 cell differentiation assay is expected to be relevant for the 
in vivo situation.
In conclusion, in the present study we showed, for the first time, that the ES-D3 cell 
differentiation assay of the EST, combined with the in vitro BeWo transport model, is able 
to better predict the in vivo developmental toxicity ranking of the antifungal compounds, 
than as a stand-alone assay, which could be a valuable alternative for developmental 
toxicity screening and prioritization. More compounds with different modes of action 
should be tested to further evaluate the capacity of this approach in predicting the 
developmental toxicity ranking of chemicals. At this stage the applicability domain of 
this combined in vitro toxico-dynamics and –kinetics approach is not known. From 
a conceptual point of view, it would seem that there is no reason why the value of this 
approach should be limited to the class of (azole) antifungal compounds. Since the 
method uses only in vitro assays to predict in vivo developmental toxicity ranking of 
chemicals, it can contribute to the 3Rs of animal testing. The predictive ability of the 
ES-D3 cell differentiation assay of the EST can most likely be further enhanced if it is 
combined with more kinetic data. 
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Table 1. Overview of BMD analysis performed using BMDS software version 2.4, a BMD of 10% 
extra risk and default settings. BMD10 values are derived from the incidence of cleft palate on 
litters in rats exposed to ketoconazole. The data used as input for the BMD analysis are presented 
in Table 3.
Model Name
No. of 
parameters Log Likelihood P-value Accepteda
BMD10
(µmol/kg bw/day)
Null 1 -14.548 - - -
Full 3 -8.762 - - -
Gamma 1 -8.763 1 Yes 44.82
Logistic 2 -8.763 0.99 Yes 45.96
LogLogistic 2 -8.762 0.99 Yes 46.12
LogProbit 2 -8.763 0.99 Yes 45.59
Multistage 1 -9.465 0.64 Yes 34.21
Probit 2 -8.763 0.99 Yes 45.01
Weibull 2 -8.763 0.99 Yes 43.51
Quantal-Linear 1 -11.193 0.16 Yes 20.14
a Fitted model not significantly different (worse) than the full model at p<0.05.
Table 2. Overview of BMD analysis performed using BMDS software version 2.4, a BMD of 
10% extra risk and default settings. BMD10 values are derived from the incidence of skeletal 
variation on litters in rats exposed to tebuconazole. The data used as input for the BMD analysis 
are presented in Table 3.
Model Name
No. of 
parameters Log Likelihood P-value Accepteda
BMD10  
(µmol/kg bw/day)
Null 1 -55.432 - - -
Full 4 -53.392 - - -
Gamma 2 -53.475 0.92 Yes 42.59
Logistic 2 -53.523 0.88 Yes 50.84
LogLogistic 3 -53.399 0.99 Yes 27.55
LogProbit 3 -53.597 0.81 Yes 77.63
Multistage 2 -53.475 0.92 Yes 42.59
Probit 2 -53.542 0.86 Yes 53.65
Weibull 2 -53.475 0.92 Yes 42.59
Quantal-Linear 2 -53.475 0.92 Yes 42.59
a Fitted model not significantly different (worse) than the full model at p<0.05.
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Table 3. Overview of BMD analysis performed using BMDS software version 2.4, a BMD of 
10% extra risk and default settings. BMD10 values are derived from the incidence of skeletal 
variation on fetuses in rats exposed to tebuconazole. The data used as input for the BMD analysis 
are presented in Table 3.
Model Name
No. of 
parameters Log Likelihood P-value Accepteda
BMD10  
(µmol/kg bw/day)
Null 1 -318.207 - - -
Full 4 -311.237 - - -
Gamma 2 -311.607 0.92 Yes 139.33
Logistic 2 -311.721 0.88 Yes 170.50
LogLogistic 3 -311.573 0.97 Yes 127.71
LogProbit 3 -311.613 0.98 Yes 214.94
Multistage 2 -311.607 0.92 Yes 139.33
Probit 2 -311.703 0.86 Yes 166.72
Weibull 2 -311.607 0.92 Yes 139.33
Quantal-Linear 2 -311.607 0.92 Yes 139.35
a Fitted model not significantly different (worse) than the full model at p<0.05.
Table 4. Overview of BMD analysis performed using BMDS software version 2.4, a BMD of 
10% extra risk and default settings. BMD10 values are derived from the incidence of skeletal 
malformation on litters in rats exposed to propiconazole. The data used as input for the BMD 
analysis are presented in Table 3.
Model Name
No. of 
parameters Log Likelihood P-value Accepteda
BMD10  
(µmol/kg bw/day)
Null 1 -48.081 - - -
Full 4 -27.342 - - -
Gamma 2 -27.397 0.95 Yes 161.95
Logistic 2 -28.511 0.44 Yes 282.92
LogLogistic 2 -27.466 0.88 Yes 165.46
LogProbit 2 -27.638 0.73 Yes 157.67
Multistage 2 -27.342 1 Yes 258.96
Probit 2 -28.252 0.53 Yes 163.14
Weibull 2 -27.363 0.98 Yes 90.99
Quantal-Linear 1 -28.490 0.56 Yes 161.95
a Fitted model not significantly different (worse) than the full model at p<0.05.
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Table 5. Overview of BMD analysis performed using BMDS software version 2.4, a BMD of 
10% extra risk and default settings. BMD10 values are derived from the incidence of skeletal 
malformation on fetuses in rats exposed to propiconazole. The data used as input for the BMD 
analysis are presented in Table 3.
Model Name
No. of 
parameters Log Likelihood P-value Accepteda
BMD10  
(µmol/kg bw/day)
Null 1 -185.075 - - -
Full 4 -115.666 - - -
Gamma 3 -116.191 0.35 Yes 283.20
Logistic 2 -116.449 0.62 Yes 367.70
LogLogistic 3 -116.123 0.36 Yes 283.06
LogProbit 3 -116.305 0.33 Yes 277.05
Multistage 1 -116.203 0.8 Yes 266.55
Probit 2 -116.143 0.76 Yes 337.06
Weibull 3 -116.051 0.36 Yes 284.61
Quantal-Linear 1 -126.274 0.0007 No 169.92
a Fitted model not significantly different (worse) than the full model at p<0.05.
Table 6. Overview of BMD analysis performed using BMDS software version 2.4, a BMD of 
10% extra risk and default settings. BMD10 values are derived from the incidence of skeletal 
variations on litters in rats exposed to prothioconazole. The data used as input for the BMD 
analysis are presented in Table 3.
Model Name
No. of 
parameters Log Likelihood P-value Accepteda
BMD10  
(µmol/kg bw/day)
Null 1 -33.807 - - -
Full 4 -31.199 - - -
Gamma 3 -32.976 0.06 Yes 486.86
Logistic 2 -33.020 0.17 Yes 222.31
LogLogistic 3 -32.976 0.06 Yes 431.27
LogProbit 3 -32.966 0.07 Yes 302.93
Multistage 2 -36.274 0.15 No 972.94
Probit 2 -33.016 0.17 Yes 238.49
Weibull 3 -32.982 0.06 Yes 1853.11
Quantal-Linear 2 -33.023 0.17 Yes 212.40
a Fitted model not significantly different (worse) than the full model at p<0.05.
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Table 7. Overview of BMD analysis performed using BMDS software version 2.4, a BMD of 
10% extra risk and default settings. BMD10 values are derived from the incidence of skeletal 
malformation on fetuses in rats exposed to prothioconazole. The data used as input for the BMD 
analysis are presented in Table 3.
Model Name
No. of 
parameters Log Likelihood P-value Accepteda
BMD10  
(µmol/kg bw/day)
Null 1 -57.016 - - -
Full 4 -56.179 - - -
Gamma 2 -56.442 0.77 Yes 1416.99
Logistic 2 -56.451 0.77 Yes 1541.92
LogLogistic 3 -56.421 0.49 Yes 1361.97
LogProbit 3 -56.408 0.50 Yes 1803.279
Multistage 2 -52.922 0.62 Yes 1321.42
Probit 2 -56.450 0.77 Yes 1527.41
Weibull 2 -56.442 0.77 Yes 1417.00
Quantal-Linear 2 -56.442 0.77 Yes 1417.00
a Fitted model not significantly different (worse) than the full model at p<0.05.
Table 8. Overview of BMD analysis performed using BMDS software version 2.4, a BMD of 10% 
extra risk and default settings. BMD10 values are derived from the incidence of hydronephrosis 
on litters in rats exposed to fenarimol. The data used as input for the BMD analysis are presented 
in Table 3.
Model Name
No. of 
parameters Log Likelihood P-value Accepteda
BMD10  
(µmol/kg bw/day)
Null 1 -52.372 - - -
Full 4 -30.66 - - -
Gamma 2 -38.122 0.001 no 72.91
Logistic 2 -42.276 0 no 37.05
LogLogistic 2 -38.114 0.001 no 91.76
LogProbit 3 -38.114 0.0002 no 81.73
Multistage 2 -40.622 0.0002 no 42.83
Probit 2 -42.851 0 no 33.91
Weibull 3 -38.114 0.0002 no 93.74
Quantal-Linear 2 -45.896 0 no 26.47
a Fitted model not significantly different (worse) than the full model at p<0.05.
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Table 9. Overview of BMD analysis performed using BMDS software version 2.4, a BMD of 10% 
extra risk and default settings. BMD10 values are derived from the incidence of hydronephrosis 
on fetuses in rats exposed to fenarimol. The data used as input for the BMD analysis are 
presented in Table 3.
Model Name
No. of 
parameters Log Likelihood P-value Accepteda
BMD10  
(µmol/kg bw/day)
Null 1 -31.956 - - -
Full 4 -22.835 - - -
Gamma 2 -25.378 0.098 Yes 88.48
Logistic 2 -26.787 0.02 no 67.42
LogLogistic 3 -25.377 0.03 no 98.37
LogProbit 3 -25.377 0.03 no 92.30
Multistage 2 -25.128 0.04 Yes 68.86
Probit 2 -27.051 0.02 no 64.042
Weibull 3 -25.377 0.03 no 99.11
Quantal-Linear 2 -28.520 0.02 no 60.54
a Fitted model not significantly different (worse) than the full model at p<0.05.
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absTracT  
The mouse embryonic stem D3 (ES-D3) cell differentiation assay is based on the 
morphometric measurement of cardiomyocyte differentiation and is a promising tool 
to detect developmental toxicity of compounds. The BeWo transport model, consisting of 
BeWo b30 cells grown on transwell inserts and mimicking the placental barrier, is useful 
to determine relative placental transport velocities of compounds. We have previously 
demonstrated the usefulness of the ES-D3 cell differentiation assay in combination with 
the in vitro BeWo transport model to predict the relative in vivo developmental toxicity 
potencies of a set of reference azole compounds. To further evaluate this combined in 
vitro toxicokinetic and toxicodynamic approach, we combined ES-D3 cell differentiation 
data of 6 novel triazoles with relative transport rates obtained from the BeWo model 
and compared the obtained ranking to the developmental toxicity ranking as derived 
from in vivo data. The data show that the combined in vitro approach provided a correct 
prediction for in vivo developmental toxicity, whereas the ES-D3 cell differentiation assay 
as stand-alone did not. In conclusion, we have validated the combined in vitro approach 
for developmental toxicity, which we have previously developed with a set of reference 
azoles, for a set of six novel triazoles. We suggest that this combined model, which takes 
both toxicodynamic and toxicokinetic aspects into account should be further validated 
for other chemical classes of developmental toxicants.
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inTroducTion
The EU REACH legislation requires the safety assessment for new and existing chemicals. 
At present, regulatory safety assessment is predominantly performed using animal 
models, with large numbers of animals needed particularly for developmental toxicity 
testing. Therefore, REACH stimulates the use of animal-free approaches wherever 
possible [1, 2]. Alternative test methods for in vivo developmental toxicity testing, 
accepted for use in regulatory toxicity testing, are urgently needed [3]. The mouse 
embryonic stem D3 (ES-D3) cell differentiation assay is a valuable tool that can be used 
to predict in vivo developmental toxicity potency rankings within selected chemical 
classes for most of the chemicals investigated so far [4-6]. However, as this assay does 
not take kinetic processes into account, it was suggested to combine the ES-D3 cell 
differentiation assay with data on kinetics, e.g. placental transfer of compounds, in 
order to better predict in vivo potency of the developmental toxicants [4-6]. We have 
previously shown that an in vitro BeWo transport model is capable of predicting relative 
placental transfer rates of a set of 9 model compounds with a good correlation to the 
relative transport rates observed in the ex vivo placental perfusion model (R2=0.95), 
indicating that the in vitro BeWo transport model is useful to obtain data with respect to 
placental transfer of compounds [7]. When combining the BeWo model with the ES-D3 
cell differentiation assay, for a set of reference azoles, the coefficient of determination 
(R2) for correlation of relative in vitro potency with relative in vivo potency increased 
from 0.57 to 0.95 [8], showing that the combined approach is able to better predict the 
in vivo developmental toxicity of azole antifungal compounds than the stand-alone 
ES-D3 cell differentiation assay.
Our first study included data on five reference antifungal compounds, with four 
of them being azoles. The azole family represents the largest family of antifungal 
compounds, which can be subdivided into the imidazole and triazole groups. We selected 
the class of azoles, because of their widespread use as antifungal agents in medicine and 
crop protection [9] and because they are known to cause developmental toxicity, for 
which an extensive toxicity data base is available, required for evaluation of predictions 
made. The reference azoles used demonstrated a varying degree of developmental toxicity 
[10, 11], allowing for a quantitative assessment of potency, which was the basis of the 
first validation of the combined ES-D3 and BeWo assay strategy. 
The aim of the present study is to further validate the combined ES-D3 cell 
differentiation assay and BeWo transport model for predicting in vivo potency of 
developmental toxicants. To this end, six novel triazoles (Table 1) were investigated 
in the combined in vitro approach and the obtained predictions for these compounds 
were compared with the in vivo data that are presented in this paper for the first time, 
not taken from the literature. 
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Table 1. Chemical information of six triazoles tested in the present study.
Code Name MW (g/mol)
0594 [5-(4-Chloro-2-fluoro-phenyl)-3-(2,4-difluoro-phenyl)-isoxazol-4-yl]-
pyridin-3-yl-methanol
416.8
0595 [2,4-Bis-(2,4-difluoro-phenyl)-thiophen-3-yl]-pyridin-3-yl-methanol 415.4
0596 4-{2-[2-(4-Fluoro-phenyl)-2-hydroxy-1-methyl-3-[1,2,4]
triazol-1-yl-propyl]-thiazol-4-yl}-benzonitrile
419.5
0599 4-[2-[2-(4-fluorophenyl)-2-hydroxy-3-imidazol-1-yl-1-methyl-propyl]
thiazol-4-yl]benzonitrile
418.5
0600 1-[[2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4,6-dimethyl-1,3-dioxan- 
2-yl]methyl]-1,2,4-triazole
434.3
0618 4-methyl-1,3-dioxolan-2-yl-methyl-1,2,4-triazole derivate 440.0
maTerials and meThods 
chemicals
BASF triazoles 0594, 0595, 0596, 0599, 0600 and 0618 were kindly provided by BASF 
SE (Ludwigshafen, Germany). Dimethyl sulfoxide (DMSO) was purchased from Acros 
Organics (Geel, Belgium).
beWo transport experiments
To study placental transfer of test compounds, BeWo transport experiments were 
performed as described previously [7]. Briefly, BeWo b30 cells (passages 27–45) were 
cultured in DMEM (Zwijndrecht, the Netherlands), supplemented with 10 % (v/v) heat-
inactivated FCS (HyClone-Perbio, Etten-Leur, the Netherlands), 10,000 U/ml penicillin, 
10 mg/ml streptomycin and 2 mM L-glutamine. The cells were seeded at a density of 1 x 
105 cells/cm2 on transwell® polycarbonate membranes (12 mm diameter, 0.4 μm pore size) 
(VWR International BV, Amsterdam, the Netherlands) coated with human placental 
collagen. The medium (0.5-ml apical compartment, 1.5-ml basolateral compartment) was 
replaced daily. At day 6 post-seeding, the BeWo b30 cell layers were used for transport 
experiments. The barrier forming capacity of the BeWo cell layers was evaluated by 
measuring the transepithelial electrical resistance (TEER) of the cell monolayer using 
a Millicell ERS-2 Volt-Ohm Meter (Millipore, USA) at day 6 post-seeding as described 
previously [7]. Only the cell layers showing TEER values between 80 and 100 Ω∙cm2 
were used for transport experiments. 
Transport experiments were initiated by adding 0.5 ml of transport buffer Hank’s 
balanced salt solution (HBSS, Invitrogen, Breda, the Netherlands) containing the 
test compound, being 0594, 0595, 0596, 0599, 0600 and 0618, dissolved in DMSO 
(final solvent concentration 0.5% DMSO), at concentration of 50 μM, to the apical 
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compartment and 1.5 ml transport buffer to the basolateral compartment. Subsequently, 
the plate was incubated in a humidified atmosphere with 5 % CO2 at 37 °C. After 15, 
30, 60 and 90 min, a sample of 0.2 ml was taken from the basolateral compartment and 
replaced by an equal volume of transport buffer. At the end of each experiment, a 0.2 ml 
sample was also taken from the apical compartment. Subsequently, the filters with the 
BeWo b30 cell layers were washed 3 times with PBS, cut out of the insert, dissolved in 
0.25 ml 65 % (v/v) methanol and sonificated for 15 min in a Bandelin Sonorex RK100 
(Berlin, Germany) in order to determine the amount of compound accumulated in 
the cells. After each experiment, mass-balance calculations were performed. In each 
transport study, amoxicillin and antipyrine were included as control and reference 
compounds. Amoxicillin transport was included to assess for monolayer integrity since 
it is a compound known to be transported only to a limited extent across the placenta, 
whereas antipyrine was included as a control for optimal transport and a reference 
compound to enable calculation of relative transport rates [7]. The transport of the 
six test compounds, as well as the reference compounds amoxicillin and antipyrine, 
through the permeable membrane of the transwell filter in the absence of BeWo cells 
was determined as well. The transport to the basolateral compartment was shown 
to be equally fast for all compounds (data not shown), ensuring that any differences 
observed in the transport studies were related to the BeWo cell layer and not to the 
filter. For each test compound, three independent experiments were performed, with 
three technical replicates per experiment.
high-performance liquid chromatography analysis
Samples were analyzed using high-performance liquid chromatography (HPLC) to 
quantify the amount of test compound in order to determine the transport rate and 
to perform mass-balance calculations. The HPLC system used consisted of a Waters 
(Milford, MA) 600 controller and a 600 pump, equipped with a photodiode array detector 
set to record absorption of wavelengths between 200 and 400 nm. A Waters 717 plus 
autosampler was used for sample injection. The temperature of the autosampler was 
kept at 7 °C. 
For analysis of all compounds, 50 μl sample was injected to a C18 5 μm reverse-
phase column (150 mm × 4.6 mm I.D.) with a guard column (7.5 mm × 4.6 mm I.D.) 
(Alltech, Bergen op Zoom, the Netherlands). The mobile phase used for analysis of 
all the test compounds consisted of (A) 0.1 % trifluoroacetic acid in nanopure water 
and (B) HPLC-grade acetonitrile. Elution was at a flow rate of 0.8 ml/min, starting at 
22 % B with a linear increase to 100 % B in 8 min. Subsequently, the gradient returned 
linearly to the initial condition in 10 min and remained 2 min at this condition prior to 
the next injection. In each analysis, calibration curves of all compounds were included 
for quantification. 
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es-d3 cell culture
The murine ES-D3 cell line was purchased from ATCC (Wesel, Germany). The cells were 
maintained in polystyrene cell culture flasks (Corning, the Netherlands) in Dulbecco’s 
Modified Eagle Medium (DMEM, Invitrogen, Breda, The Netherlands), supplemented 
with 20% heat-inactivated fetal calf serum (Lonza, BioWhittaker, Verviers, Belgium), 
50 U/ml penicillin with 50 μg/ml streptomycin (Invitrogen), 2 mM L-glutamine 
(Invitrogen), 0.1 mM β-mercaptoethanol (Sigma-Aldrich) and 1% (v/v) non-essential 
amino acids (Invitrogen), at 37°C and 5% CO2 in a humidified atmosphere. Cells were 
kept undifferentiated with 1000 U/ml murine leukemia inhibiting factor (LIF) (Sigma-
Aldrich) and subcultured every 2 to 3 days using non-enzymatic cell dissociation solution 
(Sigma-Aldrich) to detach the cells.
cytotoxicity assay with es-d3 cells
To determine cytotoxicity of the compounds, a WST-1 assay was performed. This assay 
measures the influence of test compounds on the formation of the water-soluble formazan 
reaction product from WST-1 by mitochondrial succinate-tetrazolium reductase 
enzymes. The cytotoxicity of a test compound inversely correlates to the absorbance 
of the produced formazan quantified spectrophotometrically as described previously 
[12]. ES-D3 cells were exposed to test compounds for the duration of one day or five 
days as described before [8]. Briefly, cells were seeded in 96-well plates (Greiner bio-one) 
at concentrations of 20 x 104 cells/ml (one-day exposure) or 1 x 104 cells/ml (five-day 
exposure) in 100 μL culture medium in the absence of LIF and incubated for one day to 
allow cell adherence. Then the cells were exposed to the test compounds at concentrations 
up to 60 μM (final solvent concentration: 0.2% DMSO) and subsequently cultured for 
one or five days at 37°C and 5% CO2 in a humidified atmosphere. Solvent DMSO (0.2%) 
was used as a negative control and 1% Triton X-100 served as a positive control in all 
cytotoxicity assays. After incubation of one or five days, 20 μL WST-1 reagent (Roche, 
Woerden, the Netherlands) was added to each well and the plates were incubated for 
another 3 hours. Then absorbance was measured at 450 nm using a SpectraMax M2 
(Molecular Devices, Sunnyvale, USA). Three wells were used per treatment in each 
independent experiment. Three independent experiments were done for each compound. 
The cell viability was expressed as % of the solvent control, with the solvent control set 
at 100% viability. Reproducible results were obtained from the treatments of negative 
and positive controls in all of the cytotoxicity assays.
differentiation assay with es-d3 cells
Differentiation assays were carried out to detect the effect of test compounds on the 
differentiation of ES-D3 cells into contracting cardiomyocytes using culture medium 
in the absence of LIF. On day 1, droplets of 20 μl cell suspension (3.75 x 104 cells/ml) 
were placed as hanging drops, to which the test compounds 0594, 0595, 0596, 0599, 
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0600 and 0618 were added at concentrations ranging from 0.2 to 60 μM (final solvent 
concentration: 0.2% DMSO), on the inner side of the lid of a 96-well plate. Sterile lids 
of eppendorf tubes were placed on the corner wells of the plates to prevent contact of 
the drops with the plate. The wells of the 96-well plate were filled with 250 μl phosphate 
buffered saline (PBS) (Invitrogen) and the plate was sealed with Micropore tape (3M, 
Neuss, Germany) to prevent evaporation of the hanging drops. Plates were incubated for 
three days at 37°C and 5% CO2 in a humidified atmosphere. In the drops, cells formed 
embryonic bodies (EBs), which were transferred to non-tissue culture treated Petri dishes 
(diameter 6 cm, Greiner) with 5 ml of medium with test compound. On day 5, the EBs 
were transferred to a 24-well plate (Corning) with 1 ml of medium with test compound, 
with one EB per well. On day 10, the number of wells containing contracting EBs was 
determined by visual inspection using a light microscope. Solvent control (0.2% DMSO 
in culture medium) was included in each experiment. The solvent control was also used 
to assess the quality of the batch of ES-D3 cells used in each individual test (cells being 
randomly distributed over test groups and solvent control). Tests were accepted for 
further analysis if at least 21 of the 24 wells of the solvent control contained contracting 
cardiomyocytes. For each test compound, three independent assays were performed. 
The results were expressed as “fraction of total”, with 1.0 implying all EBs in one 24-well 
plate differentiated into contracting cardiomyocytes.
in vivo experiments
The in vivo investigations of maternal and prenatal developmental toxicity were 
performed as a screening approach following the general principles of OECD 414 and 
OPPTS 870.3700 test guidelines, and the OECD and United States Environmental 
Protection Agency Good Laboratory Practice Standards [40 CFR Part 160 (FIFRA) and 
Part 792 (TSCA)]. The major differences to a full guideline study were the smaller sample 
size, using 9-10 instead of at least 16 pregnant rats, per test substance. Furthermore, 
the fetal evaluation was performed using 4 to 10 litters, the lower number being used 
if sufficient (i.e. positive) results were obtained to assess the prenatal developmental 
toxicological potential of the test compounds. The in vivo studies were performed 
according to the German Animal Welfare Act, the European Council Directive 2010/63/
EU and in an AAALAC-accredited facility. This screening study of developmental 
compounds was approved by the local authorizing agency for animal experiments 
(Landesuntersuchungsamt Koblenz, Germany) as referenced by the approval number 
23 177-07/G08-3-008).
Test animals
The animals were paired by the breeder (time-mated Wistar rats, Crl: WI [Han], 
Charles River Laboratories, Sulzfeld, Germany), between 10 and 12 weeks of age, and 
supplied on the day of evidence of mating; this day is referred to as gestational day 
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(GD) 0 and following day as GD 1. All animals showed no clinical signs of disease. 
This strain has been extensively used, both in our laboratory and elsewhere, and is 
sensitive to reproductive toxicants. All rats were housed individually in Makrolon 
cages with Lignocel PS 14 fibres dust-free bedding and wooden enrichment blocks. 
The cages were kept in climate controlled rooms at 20–24°C with a relative humidity 
of 30–70%, an air exchange rate of 15 times per hour, and a 12-hr light/dark cycle. 
Diet (Ground Kliba SA, Switzerland) and tap water were provided ad libitum. In-life 
data (mortality, clinical signs, body weights, and food consumption) were recorded 
throughout the study, but presented only if relevant for the interpretation of prenatal 
developmental effects. 
experimental Procedure
Studies were conducted with daily oral administration of test substances by gavage 
(test compounds 0594, 0595, 0596, 0599, and 0600) or via diet (test compound 0618) 
from GD 6 to GD 19 (Table 4). The individual dose levels were selected based on 
the results of a repeated exposure to non-pregnant female rats over 14 days (data 
not shown). According to the OECD 414 test guideline it was aimed to cause signs 
of maternal toxicity as recommended at the high dose level. The test compounds 
administered by gavage were administrated between 100 and 600 mg/kg bw/day 
using the vehicle 1% carboxymethylcellulose in deionized water. The standard dose 
volume was 10 mL/kg bw. The test compound 0618 was administered via the diet 
at dose levels of 300 ppm (dose was reduced from 2500 ppm on GD 6 and 7 causing 
severe clinical signs) and 1000 ppm in the diet. The exposures were corresponding 
to a substance intake of 28 mg/kg bw/day (GD 8-19) and 69 mg/kg bw/day (GD 
6-19), respectively. 
necropsy and fetus Preparation
On GD 20, the surviving dams were anesthetized with isoflurane, sacrificed by 
decapitation, and examined macroscopically. For each dam, the uterus was opened 
and the number, distribution, and classification of implantation sites (live fetus, early 
and late fetal resorptions, and dead fetus) were determined. The fetuses were removed, 
sexed and fetal body weight determined. Gross-pathological examination of the fetuses, 
including assessment of abnormalities of the fetal membranes, placentas, amniotic 
fluid and umbilical cord, was performed. Subsequently, all fetuses were sacrificed by 
injection of pentobarbital. About half of the fetuses of each dam were fixed in ethyl 
alcohol and after fixation, stained according to a modified method of Dawson (1926) 
to show the skeleton. The other half of the fetuses of each dam was fixed in Harrison´ s 
fluid. After fixation, the soft tissue of these fetuses was examined according to a modified 
microdissection method [13]. The glossary of [14] and its updated version of [15] was 
essentially used to describe findings in fetal morphology. Classification of these findings 
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was based on the terms and definitions proposed by [16] and [17, 18]. A permanent 
structural change that is likely to affect adversely the survival or health was assessed 
as malformation. A change that also occurs in the fetuses of control animals and/or is 
unlikely to affect adversely the survival or health was assessed as variation. This includes 
delays in growth or morphogenesis that have otherwise followed a normal pattern of 
development. 
data analysis
BeWo transport data
For each compound, the linear appearance rate in the basolateral compartment was 
determined. These linear appearance rates were used to calculate apparent permeability 
(Papp) coefficients (Papp coefficient (cm/s) = (ΔQ/Δt) / (A·C0)), where ΔQ is the amount 
of test compound (nmol) transported to the receiver chamber in a certain time span 
(Δt (s)), A is the cell surface area (cm2) and C0 is the initial concentration of the test 
compound (µM). To calculate ΔQ, a correction was made to compensate for the removal of 
compound when taking samples (ΔQ at tx+1 = amount measured at tx+1 (nmol) (basolateral 
concentration at tx+1 (μM) × 1.5 (ml)) supplemented with the amount removed at tx 
(nmol) (basolateral concentration sample at tx (μM) × 0.2 (ml))). Subsequently, relative 
Papp values were determined by expressing the Papp coefficient as a fraction of the Papp 
coefficient obtained for antipyrine. 
In vitro ES-D3 differentiation data 
Different dichotomous concentration-response models were fitted to the in vitro 
developmental toxicity data obtained from the ES-D3 cell differentiation assay to 
calculate benchmark concentrations (BMC) using Environmental Protection Agency 
benchmark dose (BMD) software version 2.4. For each test compound, the BMCd50, 
representing the concentration for a 50% reduction in the number of differentiated EBs, 
was derived. Models included in the evaluation were the gamma, logistic, loglogistic, 
probit, logprobit, multistage, weibull and the quantal-linear model. Goodness-of-fit of 
the models was evaluated to accept a model, based on the P-values, the scaled residuals 
and the graphical displays obtained. The lowest BMCd50 value was chosen from the 
accepted models. 
Figures of concentration-response curves for both differentiation and cytotoxicity 
were made using Graphpad Prism 5 using a 4-parameter logistic model. These curves 
were not used for the derivation of the BMDd50 values since BMDd50 values were derived 
as described above using BMD modeling.
To combine in vitro developmental toxicity data obtained from the ES-D3 cell 
differentiation assay with placental transfer data obtained from the BeWo transport 
model, a corrected BMCd50 value was calculated by dividing the BMCd50 values by the 
relative Papp values, as described in [8].
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In vivo data
Data obtained for food consumption, body weight, carcass weight, weight of unopened 
uterus, weight of placentas and fetuses, the number of implantations, number of late fetal 
resorptions, and percentage of postimplantation loss were analyzed by a simultaneous 
comparison of all dose groups with the control group using Dunnett s´ test [19, 20]. 
The number of pregnant animals at the end of the study, mortality rate of the dams, 
and number of litters with fetal findings was analysed by Fisher´ s exact test [21] and 
the proportion of fetuses with findings per litter by Wilcoxon signed-rank test [21, 22]. 
Maternal toxicity was classified as slight if body weight and/or carcass weight reduction 
is not above 10%, moderate if body weight and/or carcass weight reduction is between 
10% and 20% and severe if body weight and/or carcass weight reduction is above 20%. 
All the in vivo data are expressed as the affected fetuses/litter. 
resulTs
in vitro beWo transport 
For all transport experiments, the mass balances were between 91 and 99 %. Figure 1 shows 
the increasing amount of test compounds in the basolateral compartment of the BeWo 
model over time, after adding 25 nmol to the apical compartment. Antipyrine was included 
as a reference compound known to be efficiently transported across the BeWo cell layer 
and amoxicillin was used as a control compound to check the integrity of the cell layer [7]. 
The slow transfer of amoxicillin indicated an intact BeWo cell layer. For up to 60 min, the 
transport of all compounds to the basolateral compartment was linear in time. Therefore, the 
linear appearance rate of compound in the basolateral compartment could be determined 
using data at 30 min for the calculation of Papp coefficients. The data in Table 2 show a wide 
(up to 8-fold difference) range of Papp coefficients for the six test compounds, illustrating 
different placental transfer rates among them, with 0596 being transported at the highest 
rate and 0595 at the lowest rate. Besides the transport rate, intracellular accumulation of 
six test compounds and the control compounds at 90 min was quantified and the results 
obtained are shown in Table 2. The data show that all triazoles tended to accumulate in the 
BeWo cells and that amoxicillin and antipyrine did not. Higher amounts of 0595, 0600 and 
0618 were detected in the cells than of the other three triazoles.  
cytotoxicity assay with es-d3 cells
WST-1 assays for both one-day and five-day exposure were performed to evaluate the 
cytotoxic effects of the compounds on the ES-D3 cells (Figure 2). For all compounds, the 
concentrations tested (up to 60 μM) were non-cytotoxic as determined in the one-day 
cytotoxicity assay. Among the six compounds, 0618 was the most potent one in the five-
day cytotoxicity assay, reducing the cell viability to 10% at 60 μM. Exposure of 60 μM 
0599, 0596, and 0594 to the ES-D3 cells resulted in 80%, 70% and 30% decline in cell 
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viability, respectively, reflecting lower cytotoxic properties. The least cytotoxic triazoles 
were 0595 and 0600, which caused slight reduction in cell viability (20%) up to 60 μM.
differentiation assay with es-d3 cells
To study the in vitro developmental toxicity of the antifungal triazoles, the effect of 
the compounds on the differentiation of ES-D3 cells into contracting cardiomyocytes 
was evaluated. All test compounds induced a concentration-dependent inhibition of 
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up to 60 min, the transport of all compounds to the basolateral compartment was linear in time. Therefore, 
the linear appearance rate of compound in the basolateral compartment could be determined using data at 
30 min for the calculation of Papp coefficients. The data in Table 2 show a wide (up to 8-fold difference) 
range of Papp coefficients for the six test compounds, illustrating different placental transfer rates among 
them, with 0596 being transported at the highest rate and 0595 at the lowest rate. Besides the transport rate, 
intracellular accumulation of six test compounds and the control compounds at 90 min was quantified and 
the results obtained are shown in Table 2. The data show that all triazoles tended to accumulate in the BeWo 
cells and that amoxicillin and antipyrine did not. Higher amounts of 0595, 0600 and 0618 were detected in 
the cells than of the other three triazoles.   
 
Fig. 1 Amount of 0594 (○), 0595 (●), 0596 (), 0599 (), 0600 (□), 0618 (-), amoxicillin (△) and antipyrine (◊) in the basolateral 
compartment in the in vitro BeWo model with increasing time using initial concentrations of 50 μM (25 nmol) in the apical 
compartment. Data are presented as mean ± standard deviation (n = 3). 
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Fig. 1. Amount of 0594 (○), 0595 (●), 0596 (), 0599 (Î), 0600 (□), 0618 (-), amoxicillin (△) 
and antipy ine (◊) in the basolater l compartment in the in vitro BeWo model with increas-
ing time using initial concentrations of 50 μM (25 nmol) in the apical compartment. Data are 
presented as mean ± standard deviation (n = 3).
Table 2. Papp coefficients at 30 min and relative Papp values of six test compounds and the 
reference compounds amoxicillin and antipyrine in the BeWo model. 
Compounds
Intracellular accumulation  
(% of added amount)
Papp coefficient 
(10−6 cm/s) Relative Papp value
Amoxicillin 0% 6.5 ± 0.2a 0.16
0594 24% 11.5 ± 2.6 0.30
0595 79% 3.0 ± 0.4 0.08
0596 12% 24.4 ± 2.7 0.63
0599 22% 18.4 ± 1.1 0.47
0600 66% 7.9 ± 1.0 0.20
0618 56% 7.1 ± 0.2 0.18
Antipyrine 0% 38.9 ± 3.0 1.00
a Mean ± SD
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Fig. 2. Concentration-dependent effects of test compounds 0594 (a), 0595 (b), 0596 (c), 0599 (d), 
0600 (e) and 0618 (f) on cell viability for one-day (Î) and five-day (○) exposure and on inhibi-
tion of ES-D3 cell differentiation (△). Figures present data of three independent experiments.  
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the differentiation of the ES-D3 cells into contracting cardiomyocytes (Figure 2). The 
calculated BMCd50 values were at concentrations that did not cause cytotoxicity (after 
one and five days), indicating that inhibitory effects on the differentiation of EBs are not 
due to cytotoxicity of the test compounds. BMCd50 values are summarized in Table 3, 
showing that 0599 was the most potent in inhibiting the differentiation of EBs, followed 
by 0600 > 0618 > 0594 > 0595 > 0596.
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combination of in vitro developmental toxicity data with beWo 
transport data
To combine in vitro developmental toxicity data obtained from the ES-D3 cell 
differentiation assay with placental transfer data obtained from the BeWo transport 
model, a corrected BMCd50 value was calculated by dividing the BMCd50 values by the 
relative Papp values (Table 3). After the correction, the potency ranking was altered, 
being 0599 > 0596 > 0600 > 0594 > 0618 > 0595.
Table 3. BMCd50 values for in vitro developmental toxicity of test compounds in the ES-D3 
cell differentiation assay and corrected BMCd50 values obtained by combining the ES-D3 cell 
differentiation assay data with data on placental transfer from the BeWo transport model.
Novel triazoles
BMCd50
(µM)
Corrected BMCd50a
(µM)
0594 6.9 23.3
0595 11.0 141.8
0596 11.4 18.1
0599 1.8 3.8
0600 4.2 21.0
0618 4.3 23.7
acorrected BMCd50 value was calculated by dividing the BMCd50 values by the relative Papp 
values
Potency ranking derivation from in vivo data
In the in vivo studies, all tested compounds showed, to some degree, a potential to cause 
prenatal developmental toxicity. All statistically significant and toxicologically relevant 
alterations relative to controls are summarized in table 4. The potency of each of the test 
compounds to cause prenatal developmental toxicity was assessed based on the observed 
fetal findings, including teratogenic effects, taking into account the present or absence 
of maternal toxicity at the different dose levels. 
The highest potential to cause prenatal developmental toxicity, based on the results 
of the in vivo studies, was observed for the test compound 0599 (ranking 1). It caused 
teratogenic effects in 100% of fetuses, manifested in skeletal malformations on the 
tuberositas deltoidea and pterygoid bones as well as palate at 100 mg/kg bw/day. This 
dose level did not alter the overall development of the fetuses indicated by their body 
weight or in utero survival indicated by resorption rate. At this exposure, maternal 
toxicity was observed noted as decreased food consumption (74% GD 6-20), body weight 
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change (66% GD 6-8) and carcass weight (91%). Maternal toxicity is not considered to 
have contributed significantly to the fetal effects. 
The second highest potential to cause prenatal developmental toxicity was observed 
for the test compound 0596 (ranking 2). This compound also caused teratogenic effects 
in all fetuses, manifested in skeletal malformations, like the test compound 0599. The 
malformation observed at the highest incidences were observed in skull bones (including 
basisphenoid) and cervical arches. But this time all fetuses were only affected at a 6-time 
higher dose level of 600 mg/kg bw/day. Comparable to the test substance 0599, this dose 
level did not affect the overall development of the fetuses indicated by their weight or 
in utero survival indicated by resorption rate being comparable to the control. The 
teratogenic effects were observed at a dose level causing almost no maternal toxicity; 
only visible in an increased placental weight (133%). At 200 mg/kg bw/day the pattern 
of treatment-related effects was comparable to 600 mg/kg bw/day, but malformations 
being observed in 47% of fetuses per litter.  
The third highest potential to cause prenatal developmental toxicity was observed for 
the test compound 0600 (ranking 3). It was causing neither treatment related findings 
on fetuses nor on dams at 200 mg/kg bw/day. At 600 mg/kg bw/day the teratogenic 
potential of the test compound was manifested in an increased incidence of skeletal 
malformations (81% of fetuses per litter) without affecting the fetal growth or causing 
increased number of resorptions. The significantly increased malformation rate were 
observed in small or absent tuberositas deltoidea, misshapen pterygoid bones, and cleft 
palate. The maternal toxicity observed in lower body weight changes in the beginning of 
exposure (27% GD 6-8) and the increased placental weight (130%) might had enhanced 
the severity of teratogenic effects but could not be encountered for their occurrence only. 
The third lowest potential to cause prenatal developmental toxicity was observed 
for the test compound 0594 (ranking 4). Like the test compound 0600, it did not 
caused treatment-related findings in fetuses and dams at 200 mg/kg bw/day. At 600 
mg/kg bw/day only slight maternal toxicity was observed in minor alterations of food 
consumptions (86% GD 6-8) without any effect on the body weight development of the 
dams. A borderline increase of postimplantation loss was determined with 14.9% being 
only slightly above the spontaneous incidence of 14.7% given in the historical control 
data for this rat strain in our test facility. In comparison to test compound 0600, a 
weaker teratogenic potential of the test compound 0594 was observed manifested in an 
increased total skeletal malformation incidence of 12.5% fetuses per litter (bent femurs) 
at 600 mg/kg bw/day. This dose did not significantly affect number of fetuses alive per 
litter or the growth of the fetuses. 
The second lowest potential to cause prenatal developmental toxicity was observed 
for the test compound 0618 (ranking 5). It caused slight or moderate maternal toxicity 
at 300 and 1000 ppm manifested in significantly decreased body (87% at 1000 ppm) 
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and/or decreased carcass weight (95% at 300 ppm and 83% at 1000 ppm). The highest 
dose level tested also caused significantly increased placental weights (162%) and 
postimplantation loss (30.3%). The latter was based mainly on the increased number 
of late resorptions (23.2%). The observed decreased fetal development manifested in 
the lower fetal body weight (87% at 1000 ppm) could partially be explained by the 
moderate maternal toxicity observed. However, the skeletal malformations observed 
here, low incidences of bent femur, is a rare finding and is not in the historical control 
data. Thereby, the test compound 0618 still demonstrated a weak teratogenic potential.
The lowest potential to cause prenatal developmental toxicity was observed for the 
test compound 0595 (ranking 6). It has a relatively high general toxic potential leading 
to poor general state in 3 out of 10 rats after 10 to 11 days of exposure to 600 mg/kg bw/
day. These animals had been sacrificed moribund on GD 15 and 16. The surviving dams 
showed severe maternal toxicity in decreased body (74%) and carcass (89%) weight. At 
this dose level none of the embryos survived the in utero exposure leading to 100% early 
resorptions. At 200 mg/kg bw/day no maternal toxicity but still a significantly increase 
of postimplantation loss (24%) was observed mainly caused by an increase number of 
early resorptions (21.9%). The surviving fetuses did not show alterations on growth or 
malformations. Thereby, no teratogenic potential was observed for the test substance 
0595 in this in vivo study. 
Based on this assessment, a developmental potency ranking of the test compounds 
was obtained: 0599 > 0596 > 0600 > 0594 > 0618 > 0595. 
comparison of in vivo and in vitro developmental toxicity ranking
Both in vitro developmental toxicity potency rankings based on BMCd50 alone 
and the placental transfer corrected BMCd50 values were compared with in vivo 
potency ranking, to assess the usefulness of combining data from the ES-D3 cell 
differentiation assay with data from the BeWo transport model to predict in vivo 
potency ranking (Table 5). Based on the in vivo ranking, 0599 was the most potent 
compound in vivo and 0595 was the least potent one. The potency ranking of the 
six test compounds in the ES-D3 cell differentiation assay correlates to some extent 
with the in vivo ranking, with 0599 being the most potent one, however with clear 
differences for the less toxic ones. For 0596, especially, the relative potency is not 
well predicted in the ES-D3 assay, being least toxic in the ES-D3 cell differentiation 
assay, whereas almost most toxic in vivo. When the ES-D3 cell differentiation data 
are combined with the results obtained in the BeWo transport model to obtain 
corrected BMCd50 values, a better correlation with the in vivo ranking was obtained 
with no discrepancy (Table 5). These data thus demonstrate the power of including 
a component of kinetics when predicting relative in vivo toxicity potencies based 
on in vitro toxicity data. 
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Table 4. Developmental data on the incidence of cleft palate or skeletal malformation in rat
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3 most observed malformation c
0594 gavage
GD 6-19
600 mg/kg 10/10 FC (6-8) 
86%*
slight 116% 14.1% 0.8% 14.9%* 98 101% 19/4 Total 12.5% bent femur 12.5% 4
200 mg/kg 10/10 no no 110% 5.9% 1.9% 7.8% 99 107% - - -
0595 gavage 600 mg/kg 10/9 mortality 
30%
BW 74%**
CW 89%*
severe - 100.0%** 0.0% 100.0%** 0 - - - - 6
GD 6-19 200 mg/kg 10/9 NAD no 117% 21.9%* 2.0% 24.0%* 74 102% 18/4 Total 0% -
0596 gavage
GD 6-19
600 mg/kg 10/10 NAD no 133%** 7.7% 0.8% 8.6% 102 105% 57/10 Total 100%** severely malformed skull bones 
82.8%**
misshapen cervical arch 70.2%**
misshapen basisphenoid 13%
2
200 mg/kg 10/10 NAD no 127%** 2.9% 0.0% 2.9% 109 108% 54/10 Total 47%** misshapen basisphenoid 30.6%**
misshapen cervical arch 14.3%*
severely malformed skull bones 5.3%
0599 gavage
GD 6-19
250 mg/kg 10/10 mortality 
100%**
severe 110% - 0 - - - 1
100 mg/kg 10/10 FC(6-20) > 
74%**
BWC (6-8) 
66%**
CW 91%*
slight 116% 7.8% 0.8% 8.6% 99 102% 21/4 CP 10%
Total 100%**
Misshapen temporal bone 85.4%**
misshapen basisphenoid 74.2%**
small tuberositas deltoidea 66.3%**
0600 gavage
GD 6-19
600 mg/kg 10/10 BWC (6-8) 
27%**
slight 130%** 6.0% 1.0% 7.0% 104 102% 22/4 CP 5%
Total 81%**
small tuberositas deltoidea 48.1%**
absent tuberositas deltoidea 44.4%**
misshapen pterygoid bones 36.3%*
3
200 mg/kg 10/10 NAD no 105% 4.0% 0.0% 4.0% 99 102% 20/4 Total 0% -
0618 diet
GD 6-20
1000 ppm 10/10 BW 87%**
CW 83%**
moderate 162%** 7.2% 23.2%** 30.3%** 74 87%** 57/10 Total 2.5% bent femur 2.5% 5
300 /(2500) 
ppm a
10/10 CW 95% slight 111% 4.6% 0.8% 5.4% 110 101% 41/10 Total 1.4% misshapen basisphenoid 1.4%
Note: GD=gestation day; FC=food consumption; BW=body weight; CW=carcass weight; BWC=body 
weight change; CP=cleft palate; NAD=Nothing abnormal detected.
- Data not available
a 2500 ppm reduced to 300 ppm on GD 8 of first cohort (2 animals) and GD 7 of second cohort (8 animals)
b Statistics: Dunnett-test (two-sided)
c Statistics: Wilcoxon-test (one-sided)
* p<=0.05
** p<=0.01
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3 most observed malformation c
0594 gavage
GD 6-19
600 mg/kg 10/10 FC (6-8) 
86%*
slight 116% 14.1% 0.8% 14.9%* 98 101% 19/4 Total 12.5% bent femur 12.5% 4
200 mg/kg 10/10 no no 110% 5.9% 1.9% 7.8% 99 107% - - -
0595 gavage 600 mg/kg 10/9 mortality 
30%
BW 74%**
CW 89%*
severe - 100.0%** 0.0% 100.0%** 0 - - - - 6
GD 6-19 200 mg/kg 10/9 NAD no 117% 21.9%* 2.0% 24.0%* 74 102% 18/4 Total 0% -
0596 gavage
GD 6-19
600 mg/kg 10/10 NAD no 133%** 7.7% 0.8% 8.6% 102 105% 57/10 Total 100%** severely malformed skull bones 
82.8%**
misshapen cervical arch 70.2%**
misshapen basisphenoid 13%
2
200 mg/kg 10/10 NAD no 127%** 2.9% 0.0% 2.9% 109 108% 54/10 Total 47%** misshapen basisphenoid 30.6%**
misshapen cervical arch 14.3%*
severely malformed skull bones 5.3%
0599 gavage
GD 6-19
250 mg/kg 10/10 mortality 
100%**
severe 110% - 0 - - - 1
100 mg/kg 10/10 FC(6-20) > 
74%**
BWC (6-8) 
66%**
CW 91%*
slight 116% 7.8% 0.8% 8.6% 99 102% 21/4 CP 10%
Total 100%**
Misshapen temporal bone 85.4%**
misshapen basisphenoid 74.2%**
small tuberositas deltoidea 66.3%**
0600 gavage
GD 6-19
600 mg/kg 10/10 BWC (6-8) 
27%**
slight 130%** 6.0% 1.0% 7.0% 104 102% 22/4 CP 5%
Total 81%**
small tuberositas deltoidea 48.1%**
absent tuberositas deltoidea 44.4%**
misshapen pterygoid bones 36.3%*
3
200 mg/kg 10/10 NAD no 105% 4.0% 0.0% 4.0% 99 102% 20/4 Total 0% -
0618 diet
GD 6-20
1000 ppm 10/10 BW 87%**
CW 83%**
moderate 162%** 7.2% 23.2%** 30.3%** 74 87%** 57/10 Total 2.5% bent femur 2.5% 5
300 /(2500) 
ppm a
10/10 CW 95% slight 111% 4.6% 0.8% 5.4% 110 101% 41/10 Total 1.4% misshapen basisphenoid 1.4%
Note: GD=gestation day; FC=food consumption; BW=body weight; CW=carcass weight; BWC=body 
weight change; CP=cleft palate; NAD=Nothing abnormal detected.
- Data not available
a 2500 ppm reduced to 300 ppm on GD 8 of first cohort (2 animals) and GD 7 of second cohort (8 animals)
b Statistics: Dunnett-test (two-sided)
c Statistics: Wilcoxon-test (one-sided)
* p<=0.05
** p<=0.01
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Table 5. Comparison of the in vivo developmental toxicity ranking of test compounds with the 
ES-D3 cell differentiation alone or with the ES-D3 cell differentiation assay combined with the 
BeWo transport model. 
Methods
Toxicity ranking
         least toxic                                            →                                           most toxic         
ES-D3 0596 0595 0594 0618 0600 0599
ES-D3 + BeWo 0595 0618 0594 0600 0596 0599
in vivo 0595 0618 0594 0600 0596 0599
discussion
The ES-D3 cell differentiation assay has shown to be a promising method to assess the 
developmental toxicity potency ranking of series of structurally related compounds in 
vitro, and it has been suggested that the capacity of this assay to predict in vivo potency 
ranking could be improved by combining kinetic information with the in vitro data [4-6]. 
We have previously demonstrated that the ES-D3 cell differentiation assay combined 
with the in vitro BeWo transport model for placental transfer, is able to better predict 
the in vivo developmental toxicity of a set of reference azoles, than as a stand-alone assay 
[8]. In this study, we extended the dataset, to validate this combined model by testing 
more compounds within the series of antifungal triazoles. 
The in vitro BeWo transport model was used to obtain the relative transport rate in 
the present study, as it was previously shown to be suitable to adequately characterize 
relative placental transfer rates of compounds [7, 23, 24]. The six test compounds showed 
different transfer rates (up to 8-fold) through the placental barrier in the BeWo model, 
indicating that transport velocities to the fetus in vivo may differ as well. However, 
how this exactly translates to differences in fetal exposure is not known, due to the fact 
that in vivo experimentation of placental transport in humans is not feasible on a large 
scale for obvious ethical reasons and also because little has been published on the fetal 
bioavailability of antifungal compounds in vivo. We hypothesize that the extent of fetal 
exposure would be positively correlated to the relative transport velocity in the BeWo 
model. Therefore, we investigated whether the correlation between in vitro BMCd50 
values-based potency ranking and in vivo developmental toxicity potency ranking 
would improve when we corrected the in vitro BMCd50 values for differences in placental 
transfer, by dividing these BMCd50 values for the six test compounds in the ES-D3 cell 
differentiation assay by relative Papp values obtained in the BeWo model. 
With the ES-D3 cell differentiation assay alone, the predicted toxic concentrations 
among the six test compounds were within the same order of magnitude, but the combined 
assays resulted in a different ranking, with the most potent compound being about 
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30 times more toxic than the least potent one. The results obtained reveal that the ranking 
according to the corrected BMCd50 values correlated better than the uncorrected ones 
with the ranking that could be derived from in vivo developmental toxicity data. This 
shows that combining the ES-D3 cell differentiation assay results with placental transfer 
kinetic data improved the ability of this in vitro assay to predict in vivo developmental 
toxicity potencies of the tested compounds. It should be noted that other important in 
vivo kinetic processes than placental transfer, such as intestinal absorption, maternal 
metabolism and placental metabolism, were not taken into account, and that these will 
contribute to the amount of compound available in the fetus. Therefore, incorporating 
more kinetic information is likely to further improve the predictive value of the ES-D3 cell 
differentiation assay. Besides, the BeWo cell model may not be suitable to determine the 
absolute transport rates of compounds, given that the BeWo cell model is a simplification 
of the in vivo placental transfer system. In those cases where it is important to use exact 
fetal bioavailability values, physiologically based kinetic (PBK) models, which describe 
the in vivo absorption, distribution, metabolism, and excretion processes of a compound 
should be used for the translation of in vitro toxicity data to the in vivo situation [25-27]. 
We acknowledge that the increase in placental weight, noted for 0596 (at 200 and 600 
mg/kg bw/day), 0599 (at 600 mg/kg bw/day) and 0618 (at 1000 ppm) in the rat studies 
cannot be reflected in the ES-D3 assay, and therefore these effects were not taken into 
account when making the comparison among the different triazoles. The increased 
placental weight in pregnant rat may be the result of inhibition of aromatase enzyme 
activities [11]. The contribution of placental changes induced by azole compounds to 
fetal development, and its relevance to humans is currently under investigation [28]. 
In this study, intracellular accumulation of test compounds in the placental cells 
was investigated in the BeWo cell model. Triazoles 0595, 0600 and 0618 showed a high 
percentage of accumulation, up to 79% of the total mass added, in the BeWo cells. If this 
accumulation in placental cells is also occurring in vivo, the accumulated compounds 
may potentially affect the development or function of the placenta, given that the placenta 
is an entry organ to the fetus and vulnerable to the adverse effects of many toxicants. 
Structural or functional damage to the placenta can lead to adverse effects, such as 
abortion, birth defects, stillbirth, etc. We observed that triazole 0595, which showed the 
highest accumulation in the BeWo cells, induced the highest level of post-implantation 
loss, making it tempting to speculate that there might be a link between the BeWo cellular 
accumulation and the in vivo resorption rate. However, as BeWo cells only represent part 
of the placental tissue and since placental tissue changes over pregnancy, it is difficult 
to translate this in vitro finding to the exact in vivo situation. Results on placental 
accumulation of the six triazoles in vivo are not available, but it has been elucidated that 
some pesticides were found to accumulate in placental tissue [29, 30]. Therefore, it might 
be of interest to pay attention to possible placental toxicity, for which the in vitro BeWo 
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cell model might be useful for prioritization because as shown in the present study the 
model is able to provide information on the intracellular accumulation of compounds. 
The ES-D3 cell differentiation assay is considered to represent the fetal component 
of developmental toxicity. However, the (azole) antifungal compounds are found to have 
the ability to inhibit cytochrome enzymes (Marotta and Tiboni 2010), and in particular 
may inhibit estrogen biosynthesis through CYP19 aromatase inhibition, reducing the 
conversion of androgens to estrogens and exerting endocrine disrupting effects [31]. 
This process takes place in the maternal organism, and the phenotypic analysis of the 
inhibition of cardiac differentiation in the ES-D3 cell differentiation assay cannot take 
this part of developmental toxicity into account. Therefore, other relevant in vitro assays, 
such as the steroidogenesis assay [31, 32] may be needed. In addition, although we 
have proven in the previous and the present study that the ES-D3 cell differentiation 
assay combined with the BeWo transport assay shows to be an appropriate in vitro 
toxicological system to achieve an enhanced predictivity of the relative developmental 
toxicity for antifungal compounds, one should still note that one single alternative testing 
approach is not likely able to predict for the entire scope of developmental toxicants. 
To obtain information on mechanisms underlying developmental toxicity, the ES-D3 
cell differentiation assay could be combined with transcriptomics analyses, which can 
be used to group compounds in classes based on toxicity mechanisms [33]. A tool box 
which integrates different relevant in vitro assays into an integrated testing strategy may 
provide the best possible strategy to characterize both the toxicological profile and the 
relevant mechanistic information for human chemical risk assessment. 
When it comes to risk assessment, it should be remembered that many antifungal 
products contain mixtures of active substances, for example, for broad-spectrum disease 
control or for resistance management to obtain the broadest benefits possible [34]. 
Though current risk assessment approaches are predominantly based on individual 
azole fungicides, human exposure is in general to complex mixtures of pesticides. It is 
therefore of interest to investigate the developmental potency of the mixture of antifungal 
compounds in the future research. 
In conclusion, in the present study we provided further evidence that the ES-D3 cell 
differentiation assay, combined with the in vitro BeWo transport model, is able to better 
predict the in vivo developmental toxicity ranking of the antifungal compounds, than 
as a stand-alone assay. At this stage the applicability domain of this combined in vitro 
toxicodynamics and toxicokinetics approach is not known. Other series of compounds 
from different chemical classes should be tested to further evaluate the capacity of this 
approach in predicting developmental toxicity. Since the method uses only in vitro 
assays to predict in vivo developmental toxicity ranking of chemicals, it can contribute 
to the 3Rs (replacement, reduction and refinement) of animal testing. The predictive 
ability of the ES-D3 cell differentiation assay can most likely be further enhanced if it 
is combined with more kinetic data and PBK modeling. 
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absTracT  
We investigated the applicability of the ex ovo assay of chicken embryos to predict the 
teratogenic potential of five antifungal compounds and investigated if the combination 
of the assay with placental transfer information would improve its predictive capacity. 
The ex ovo assay assesses prenatal developmental toxic potential of compounds based 
on morphological endpoints. Each compound produced a characteristic pattern of 
alterations. Data on the relative placental transport velocity were taken from an earlier 
study, using the BeWo transport model. When the toxicity data from the ex ovo assay 
were combined with the relative transport rates from the BeWo model, the correlation 
with the in vivo data were better. In conclusion, the ex ovo assay of chicken embryos is 
able to assess the teratogenic potential of antifungal compounds, and, when combined 
with the in vitro BeWo transport model, is able to better predict the relative in vivo 
prenatal developmental toxicity.
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inTroducTion
The implementation of the REACH legislation results in the increased use of animals 
for toxicity testing, especially for developmental toxicity testing [1, 2]. Therefore, there 
is an urgent need to develop and validate in vitro and in silico alternative methods for 
in vivo developmental toxicity studies [3]. Several in vitro methods have been developed 
to evaluate the developmental toxic potential of chemicals, such as the embryonic stem 
cell test (EST), the rodent whole embryo culture test (WEC) and the ex ovo assay of 
chicken embryos [4-6]. Among these tests only the EST does not require the use of 
primary animal tissues, since it uses the blastocyst-derived mouse embryonic stem cell 
line D3 (ES-D3) that spontaneously differentiates into contracting cardiomyocytes. 
We have previously shown that the ES-D3 cell differentiation assay is able to predict 
the relative in vivo developmental toxicity potency of a series of selected antifungal 
compounds [7, 8]. 
The in vitro models mentioned above that are used to predict developmental 
toxicity do not contain a placental compartment. The placenta is an important organ 
required for the development of the embryo or fetus and it separates the maternal 
blood circulation from the fetal circulation. Different compounds transfer through 
the placenta at different rates, and this may influence the developmental toxicity 
outcome. Placental transfer can be studied in vitro using the BeWo transport model. 
The BeWo cell transport model, consisting of BeWo b30 cells grown on transwell 
inserts and mimicking the placental barrier, can be used to determine the relative 
placental transport velocity. We have previously shown that this model is suitable to 
adequately characterize relative placental transfer rates of chemicals [9]. We have also 
shown that the predictive ability of the ES-D3 cell differentiation assay was improved 
when it was combined with kinetic information on placental transfer determined using 
the BeWo transwell model [7, 8]. 
Although the ES-D3 cell differentiation assay, combined with the BeWo transport 
model, has been shown to be useful to predict the relative developmental toxicity 
potency of antifungal compounds, the ES-D3 cell differentiation assay is limited to 
the evaluation of only one endpoint, i.e. the differentiation of embryonic stem cells 
into contracting cardiomyocytes. Prenatal developmental toxicity studies in vivo 
have shown that many teratogenic compounds have specific manifestation patterns of 
adverse outcomes for different compound classes. Some antifungal compounds may 
induce specific morphological alterations [10]. The mechanism of action of antifungal 
compounds on skeletal development has been reported to result from alterations during 
hindbrain segmentation and branchial arches formation [11]. The phenotypic endpoint 
of cardiomyocytes differentiation, which is used as a sensitive readout for general 
embryotoxicity in the ES-D3 cell differentiation assay, cannot distinguish between 
different manifestation patterns of teratogenic compounds with different modes of action 
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by showing different phenotypes after exposure. Thus, the ES-D3 cell differentiation 
assay cannot indicate the specific type of effects that may potentially be induced. 
The ex ovo assay of chicken embryos assesses chemicals with regard to their prenatal 
developmental toxic potential based on morphological changes [12]. The culture duration 
of the chicken embryos covers major parts of organogenesis, offering the assessment 
of various morphological endpoints including specific development of different organ 
anlagen, i.e. head region with different brain -, eye -, and ear anlagen and branchial 
arches. Therefore, the ex ovo assay of chicken embryos is a suitable tool to study the 
teratogenic potential of antifungal compounds to gain additional information about the 
embryotoxic potential of test compounds. 
The aim of the present study was to investigate the teratogenic potential of 
five antifungal compounds, being ketoconazole, tebuconazole, propiconazole, 
prothioconazole and fenarimol, using the ex ovo assay of chicken embryos. The results 
obtained were compared to the in vivo teratogenic potential and to the developmental 
toxic potencies derived from the ES-D3 cell differentiation assay. Furthermore, it was 
investigated whether the combination of the ex ovo assay of chicken embryos with the 
BeWo model would improve its predictive capacity of the relative in vivo developmental 
toxicity of the test compounds.
maTerials and meThods 
chemicals
Ketoconazole, tebuconazole, propiconazole, prothioconazole, fenarimol (with purity for 
the five compounds all >98%) and dimethyl sulfoxide (DMSO) were purchased from 
Sigma-Aldrich (Munich, Germany). 
ex ovo assay of chicken embryos
The assay was performed according to a modified protocol of the ex ovo assay of chicken 
embryos described by Nagai et al.[12].
Preparation of the embryo
Specific pathogen free fertilized chicken eggs were obtained from either Valobiomedia 
(Osterholz-Scharmbeek, Germany) or Charles River (Sulzfeld, Germany). Their 
development was stopped immediately after laying by cooling to 12-16 °C. The embryonic 
development was restarted by a stepwise heating up procedure. Eggs were incubated in a 
humidified atmosphere at 38 ºC for 38-40 hours to reach the developmental stage of 5-8 
somites in the embryo (Fig. 1A). During transportation and incubation, the eggs were 
positioned with the embryos facing upwards. Embryo preparation was carried out in the 
Pannett-Compton solution (Quartett, Berlin, Germany) using a sterilized dissection kit 
(spoons, pincette and scissors), filter paper ring and pipette tips. The eggs were carefully 
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cracked open into a petri dish with the vitelline membrane being intact, covering the 
embryo facing upwards. Thin albumin was collected into a container to be kept for later 
use in the culture medium. A filter paper ring was placed on the vitelline membrane 
encircling the embryo (Fig. 1A). Then the vitelline membrane was cut along the outside 
edge of the filter paper to free the assembly. When cut free, both the membrane and paper 
along the edge of the assembly were picked up and transferred into Pannett-Compton 
solution in a petri dish. The yolk was flushed off by carefully lifting up the assembly in 
the Pannett-Compton solution. Subsequently, under the stereomicroscope (Stemi 2000, 
Zeiss), the blastoderm was peeled off the vitelline membrane (Fig. 1B). The free edge 
of the blastoderm was folded inwards and gently pulled until the blastoderm forms a 
fairly flat semicircle surface (Fig. 1C). Then the edge of the blastoderm was trimmed 
with scissors with care to obtain a closed semicircular blastoderm with the embryo 
lining along the diameter (Fig. 1D).
96 
 
 
Fig.1. Preparation of the chicken embryo. (A) Embryo with 5-8 pairs of somites covered by the filter ring, (B) isolated blastoderm 
peeled off the vitelline membrane, (C) flat semicircle surface formed by folding the free edge of the blastoderm inwards and gentle 
pulling, and (D) closed semicircular blastoderm with the embryo lining along the diameter.  
 
Exposure of the embryo to the test compounds 
After the semicircular blastoderm was prepared, it was placed to stand in Pannett-Compton 
solution for one hour to allow better adherence. Then the semicircular blastoderm disc was transferred to a 
six-well plate with 5 ml of culture medium per well containing the required concentration of the test 
compound or DMSO (solvent control), with one semicircular blastoderm per well. The culture media 
consisted of thin albumin and Pannett-Compton solution at a 2:1 ratio, supplemented with antibiotics and 
antimycotics solution, with the final dilution of antibiotics and antimycotics solution in the culture media 
being 1:300 of the stock concentration  (15240-062, Life technologies, Carlsbad). Test compounds were 
added to the culture media from 1000 times concentrated stock solutions in DMSO. Operated embryos were 
incubated at 38°C and 5% CO2 in a humidified atmosphere for 48 hours. At the end of the incubation period 
the embryos that had developed normally reached a developmental stage showing 25-30 somites. 
Range finding experiments were conducted prior to the main experiments to find the concentration 
range not causing embryonic death (data not shown). Embryos were exposed to the test compounds, 
ketoconazole, tebuconaozle, propicoanzole, prothiocoanzole and fenarimol, at 3 to 4 concentrations for 48 
hours to determine concentration-dependent effects. A solvent control of 0.1% DMSO was included in each 
single experiment.     
5-8 pairs of somites 
Fig. 1. Pr paration of th  chicken mbryo. (A) Embryo with 5-8 pairs of somites cov red by the 
filter ring, (B) isolated blastoderm peeled off the vitelline membrane, (C) flat semicircle surface 
formed by folding the free edge of the blastoderm inwards and gentle pulling, and (D) closed 
semicircular blastoderm with the embryo lining along the diameter. 
Exposure of the embryo to the test compounds
After the semicircular blastoderm was prepared, it was placed to stand in Pannett-
Compton solution for one h ur to allow better adh rence. Then  s m circular 
blastoderm disc was transferred to a six-well plate with 5 ml of culture medium per 
well containing the required concentration of the test compound or DMSO (solvent 
control), with one semicircular blastoderm per well. The culture media consisted of thin 
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albumin and Pannett-Compton solution at a 2:1 ratio, supplemented with antibiotics 
and antimycotics solution, with the final dilution of antibiotics and antimycotics 
solution in the culture media being 1:300 of the stock concentration  (15240-062, Life 
technologies, Carlsbad). Test compounds were added to the culture media from 1000 
times concentrated stock solutions in DMSO. Operated embryos were incubated at 
38°C and 5% CO2 in a humidified atmosphere for 48 hours. At the end of the incubation 
period the embryos that had developed normally reached a developmental stage showing 
25-30 somites.
Range finding experiments were conducted prior to the main experiments to find 
the concentration range not causing embryonic death (data not shown). Embryos 
were exposed to the test compounds, ketoconazole, tebuconaozle, propicoanzole, 
prothiocoanzole and fenarimol, at 3 to 4 concentrations for 48 hours to determine 
concentration-dependent effects. A solvent control of 0.1% DMSO was included in each 
single experiment.    
Morphological evaluation of the embryonic development
After 48 hours exposure, the embryos were transferred into a petri dish with Pannett-
Compton solution and the morphological changes of embryos were examined under the 
stereomicroscope. The evaluation was carried out based on a scoring system developed 
for rat embryos of Klug et al. [13] to assess the morphological parameters of chicken 
embryos during organogenesis (the scoring table is presented in the Supplementary data 
file 1). The evaluation included morphological endpoints representing differentiation 
endpoints, i.e. somite number, head-, ear-, and eye anlagen, branchial arches, 
neurulation, fore and hind limb, caudal part of trunk (referred to as tail), as well as 
representing growth parameters, i.e. crown-rump length and vessel-tail length. The 
embryos were considered to be viable when a beating heart and blood flow through 
the inflated yolk sac vessels were observed. The viable embryos were scored as 0 and 
the dead ones as -2. The development of different primordia during culture was scored 
with a number corresponding to the developmental stage. By adding the single score 
values of the different organ anlagen, the total morphological score of the embryo was 
obtained. The growth parameters were measured using an ocular micrometer. The 
somite numbers were counted. Dysmorphogenesis was distinguished from general 
embryotoxicity following the terminology of in vitro toxicology summarized in 
Flick et al. [14]: dysmorphogenesis was defined as disproportional development of 
single organ anlagen in comparison to the whole embryo development. A pattern 
of dysmorphogenesis in all tissues and organ anlagen, being rather homogeneously 
affected, indicated an unspecific general embryotoxicity of a compound rather than 
a specific, target-tissue related developmental effect. The pictures were taken with the 
stereomicroscope mounted with a Canon camera.  
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data analysis
Ex ovo assay of chicken embryos  
Statistical analysis was performed using the Jonkheere-Terpstra - asympt test (one-sided) 
for morphological endpoint scores and total morphological scores. The Dunnett test 
(one-sided) was used for analysis of growth parameter scores. The level of significance 
was set at p <0.05. The lowest test concentration at which the results were significantly 
different from those for the solvent control was determined as the lowest observed 
adverse effect concentration (LOAEC). 
Different dichotomous concentration–response models were fit to the morphological 
evaluation data on different endpoints obtained from the ex ovo assay of chicken embryos 
to calculate benchmark concentrations (BMC) using the Environmental Protection 
Agency benchmark dose (BMD) software version 2.4. For each test compound, the 
BMC50, representing the concentration for a 50% increase in the incidence of malformed 
embryos, was derived. Models included in the evaluation were the gamma, logistic, log 
logistic, probit, log probit, multistage, Weibull and the quantal-linear model. Goodness-
of-fit of the models was evaluated to accept or decline a model, based on the p-values, 
the scaled residuals and the graphical displays obtained. The lowest BMC50 value was 
chosen from the accepted models. 
To combine in vitro developmental toxicity data obtained from the ex ovo assay of 
chicken embryos with placental transfer data obtained from the BeWo transport model, 
corrected BMC50 and corrected LOAEC values were calculated by dividing the BMC50 
and LOAEC values by the relative permeability coefficient (Papp) values, obtained from 
the BeWo transport model as previously determined [8].
In vivo data
A literature study was performed to determine the in vivo developmental toxicity 
potencies of each test compound. Search terms included the name of the test compound 
together with combinations of the search terms teratogenicity, developmental toxicity, 
malformation, embryotoxicity, skeletal malformation and cleft palate. For the purpose 
of this paper, the results of studies performed in rats were used, mostly published in 
reports of the Environmental Protection Agency (EPA), European Commission (EC) and 
the European Food Safety Authority (EFSA) or in published papers on developmental 
toxicity (Table 1). A study was selected if it included at least one control group and two 
dose groups, which enables analysis by the BMD approach to derive a BMD value. A 
benchmark response (BMR) for the BMD for each compound was defined as a 10% 
extra incidence of structural alterations or of changes in the incidence of variations. The 
BMD10 was derived and chosen using dichotomous concentration–response models as 
described for the in vitro data. 
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Table 1. Literature data on developmental toxicity induced by antifungal compounds in rats 
with oral administration.
Compound
Dose (mg/kg 
bw/day)
Exposure 
duration Fetal effects References
Ketoconazole
25, 75 PI 6-17 Increased incidence of cleft palate [15] a
80 GD 6-15 Increased embryolethality, decrease of fetal 
body weights, and increase of fetal defects 
including cleft palate, frontal, parietal and 
interparietal incomplete ossification, limb 
anomalies, absent fibula and pubis, short 
femur, tibia and pubis. 
[16] b [17] b
Tebuconazole
30, 60, 120 GD 6-15 Increased incidences of skeletal variations. [18] a
10, 30, 100 PM 6-15 Facial alteration dysplacia of scapula and 
long bones, exencephaly + spinia bifida, 
encephalomeningocele + macroglossia and 
other external alterations.
[19] a
Propiconazole
30, 90, 300 GD 6–15 Increased incidence of rudimentary ribs, 
cleft palate, unossified sternebrae, as well 
as increased incidence of shortened and 
absent renal papillae. 
[20] a
Prothioconazole
20, 80, 750 PC 6-19 Marginal increase in the incidence of fetal 
supernumerary rudimentary (comma-
shaped) ribs.
[21] a
80, 500, 1000 PC 6-19 Increased incidence of microphthalmia. [21] a
Fenarimol
5, 13, 35 GD 6-15 Increased hydronephrosis without maternal 
toxicity (This minor effect of delayed 
development is not of particular concern).
[22] a
150, 300 GD 15–21 Increased neuromuscular and behavioral 
deficits in nursing pups. 
[23] b
Note. PI=post-insemination; GD=gestational day; PC=post coitum; PM=post mating
- Data not available
a Study used for BMD analysis
b Study not used for BMD analysis because not suitable for BMD analysis
If data were available on more than one endpoint, all available endpoints were 
analyzed to obtain, if possible, each an acceptable BMD10 value. Then from all accepted 
values for different endpoints, lowest BMD 10 values were chosen, and were used for the 
comparison with in vitro data. For tebuconazole, propiconazole and prothioconazole, the 
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lowest BMD10 values were related to endpoints of variation with high incidence number 
in the control treatment. In the available papers of the tested antifungal compounds no 
historical control data were reported that would enable the assessment of those variations 
in the control groups and potential dose-dependent increase of incidences as treatment-
related or not. If these variations are not treatment-related in reality, the lowest BMD10 
values may overestimate toxicity. Therefore, besides the lowest BMD10 values, we also 
included the median BMD10 values for the comparison with in vitro data. The median 
BMD10 values were calculated from all accepted BMD10 values for different endpoints.
resulTs
embryotoxic effects induced by the tested antifungal compounds
Table 2 shows the evaluation of chicken embryos on differentiation endpoints given in the 
morphological score, the somite number, as well as death and growth parameters, vessel-
tail length and crown-rump length, after exposure to the five antifungal compounds. 
At the tested concentrations, the compounds did not induce significantly increased 
mortality. Besides, the vessel-tail length and crown-rump length of the embryos were 
not significantly influenced at the tested concentrations, indicating there was no 
disturbance on the normal growth of the embryos. However, all test compounds induced 
concentration-dependent effects on the differentiation of the chicken embryos, with 
significant influence on neurulation, head, ear, eye, branchial arch, fore limb, hind limb 
development and/or somite number. For ketoconazole, propiconazole, prothioconazole 
and fenarimol, the LOAEC values were determined to be 0.1, 3, 3 and 3 µM, respectively, 
as there was no adverse effect shown at the next lower concentration tested. However, 
for tebuconazole, the tested concentrations were insufficient to determine the LOAEC, 
as even the lowest concentration tested, 3 µM, caused dysmorphogeneses on branchial 
arch differentiation. The LOAEC value for tebuconazole was therefore determined as 
≤3µM. All LOAEC values are presented in Table 4. 
As the test compounds did not induce general embryotoxic effects in the chicken 
embryos at the LOAEC levels, it was of interest to know whether these compounds 
induced a test substance specific dysmorphogenesis, or if there was a common pattern 
of morphological changes caused by this chemical class of antifungal compounds. The 
number of structurally altered embryos after treatment with the test compounds is 
shown in Table 3. Based on these data, BMC50 values of each endpoint induced by each 
compound were derived and the endpoint giving the lowest BMC50 value, was selected 
and is highlighted (bold) in Table 3. The lowest BMC50 values are presented in Table 4. 
Representative examples of the alterations representing the most affected endpoints 
are shown in Fig 2. 
Ketoconazole at the higher concentrations 0.1 and 0.3 µM induced specific 
dysmorphogenses on neurulation, head, eye, ear, branchial arch and hind limb. As 
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Table 2. Total morphological scoring (mean values) of chicken embryos exposed to antifungal 
compounds.
Concen-
tration 
(µM) N Deada Neua Heada Eyea Eara Brana FLa HLa Sa GSLb CRLb Scorea
Ket 0 11 0.0 4.9 2.4 4.6 4.3 2.4 2.7 2.4 27.3 1.4 4.1 36.1
0.03 13 0.0 4.9 2.4 4.7 3.8 2.2 2.6 2.3 26.8 1.7 4.1 35.3
0.1 12 0.0 4.0 1.8* 3.9* 2.9* 2.3 2.4 2.3 25.9 1.7 4.2 31.8
0.3 15 -0.1 3.3* 1.6** 3.7* 3.0* 2.3 2.6 2.2 23.2* 1.5 4.4 30.7*
Teb 0 12 -0.2 4.8 2.3 4.6 3.8 2.5 2.6 2.3 25.5 1.4 4.1 35.0
3 16 -0.1 5.0 2.5 4.9 3.8 1.9** 2.5 2.7 23.8 1.6 4.1 35.6
10 11 0.0 4.3 1.8 4.2 3.4 1.5** 2.3 2.2 25.6 1.6 4.2 32.6
30 14 0.0 4.1 1.9* 3.6** 2.7 1.6** 2.3 2.2 24.8 1.5 4.1 31.6
50 10 0.0 3.4* 1.3** 3.4** 3.3 1.4** 2.6 2.5 23.8 1.4 3.8 31.2
Prp 0 11 -0.2 3.7 2.6 4.6 4.4 2.4 2.8 2.7 28.4 1.5 4.2 35.2
1 12 0.0 4.0 2.4 4.7 4.8 2.6 3.1 2.8 30.1 1.6 4.3 36.8
3 11 -0.4 3.8 1.6** 4.2 4.1 2.6 2.8 2.3 27.4 1.7 4.2 34.4
10 12 -0.2 2.3* 1.7** 3.1** 2.5* 2.4 2.4* 2.1* 25.8 1.5 4.1 28.4**
Prt 0 11 -0.2 3.4 2.2 4.6 3.8 2.7 2.5 2.2 27.1 1.4 4.2 32.8
1 11 0.0 4.2 2.5 4.8 4.7 3.0 2.9 2.8 30.0 1.9 4.2 37.0
3 11 0.0 3.7 2.0 3.7 3.8 2.1* 2.5 2.5 26.8 1.5 4.1 32.6
10 10 -0.2 3.7 1.8 3.6* 2.8 2.6* 2.3 1.8 23.4 1.5 4.2 29.9
30 10 0.0 3.0 1.6* 2.2** 2.2** 2.4* 2.1 2.1 25.8 1.5 4.1 27.4
Fen 0 11 -0.4 4.0 2.1 5.0 4.1 2.7 2.6 2.0 25.9 1.4 4.1 34.1
0.3 12 -0.2 3.9 2.3 4.6 4.3 2.5 2.4 2.2 29.5 1.4 4.2 34.1
1 11 0.0 3.8 1.7 4.8 3.3 2.4 2.4 2.0 25.2 1.6 4.2 32.3
3 11 -0.4 2.8 1.3** 4.1 3.2* 2.2* 2.4 1.9 23.9* 1.3 4.1 29.9*
10 11 -0.2 2.2* 1.5** 3.5** 2.5** 2.2** 2.1 2.1 22.2** 1.3 3.9 28.0**
Note. Ket=ketoconazole, Teb=tebuconazole, Prp=propiconazole, Prt=prothioconazole, Fen=fenarimol, 
Neu=neurulation; Bran=branchial arch; FL=fore limb; HL=hind limb; S=somites number; GSL=vessel-
tail length (mm); CRL=crown-rump length (mm)
a Jonkheere-Terpstra - asympt (one-sided): * p≤ 0.05 ** p≤0.01
b Dunnett test (one-sided): * p≤0.05 ** p≤0.01
shown in Fig. 2b, as the most sensitive endpoint, the ear structure was disproportionally 
smaller than that in control embryos, and affected by ketoconazole at a concentration 
that did not influence any other endpoint. Some dysmorphogeneses were also found on 
the head region, with the metencephalon altered and the closure of neural tube at the 
cranial section delayed (Fig. 2c). 
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Table 3. Incidence of the number of malformed chicken embryos upon exposure to antifungal 
compounds
Concentration 
(µM) N Neu Head Eye Ear Bran FL HL
Ket 0 11 0 1 1 0 1 0 2
0.03 13 0 1 0 2 0 0 4
0.1 12 3 4 2 4 3 0 3
0.3 15 6 7 4 6 4 0 4
Teb 0 12 0 0 1 1 2 0 2
3 16 0 2 0 2 3 0 2
10 11 2 3 2 4 7 1 3
30 14 3 5 4 6 8 0 2
50 10 4 7 3 3 7 1 2
Prp 0 11 3 2 1 1 1 0 1
1 12 3 3 1 0 1 0 1
3 11 2 5 1 2 3 1 2
10 12 7 7 5 7 5 2 5
Prt 0 11 4 4 2 3 2 0 4
1 11 2 2 0 0 1 0 1
3 11 3 5 2 3 3 0 1
10 10 3 5 3 5 5 1 5
30 10 5 6 7 7 6 4 4
Fen 0 11 1 2 0 1 2 0 4
0.3 12 3 3 1 2 1 0 4
1 11 3 5 0 3 2 0 4
3 11 5 6 2 3 2 1 4
10 11 7 7 3 5 3 3 4
 Note. Ket=ketoconazole, Teb=tebuconazole, Prp=propiconazole, Prt=prothioconazole, Fen=fenarimol, 
Neu=neurulation; Bran=branchial arch; FL=fore limb; HL=hind limb; Dys=dysmorphogenesis   
Tebuconazole at the higher concentrations 10, 30 and 50 µM induced specific 
dysmorphogeneses on neurulation, head, eye, ear and branchial arch. As shown in Fig. 2d, 
the size of the three branchial bars were normal, but the upper lining tissue of the second 
branchial bar was severely ruptured, as compared to embryos of the control treatment. 
Propiconazole at the higher concentrations 3 and 10 µM induced specific 
dysmorphogeneses on neurulation, head, eye, ear, branchial arch, fore limb and hind 
limb. The head region was mostly affected by propiconazole, manifested by the malformed 
mesencephalon and metencephalon, as compared to control embryos (Fig. 2e). 
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Prothioconazole at the higher concentrations 10 and 30 µM induced specific 
dysmorphogeneses on neurulation, head, eye, ear, branchial arch and fore limb. The most 
sensitve dysmorphogenesis was found in the branchial arch. In contrast to tebucoanzole, 
prothiocoanzole induced a fusion between the second and the third branchial arch 
(Fig. 2f), as compared to embryos from the control treatment.    
Fenarimol at the higher concentrations 1, 3 and 10 µM induced specific 
dysmorphogeneses on neurulation, head, eye, ear, branchial arch and fore limb. As 
compared to embryos from the control treatment, fenarimol induced delayed closure 
of the neural tube in the cranial region, being the most sensitive endpoint (Fig. 2g). 
Each compound produced a characteristic pattern of alterations at the tested 
concentrations that were shown to be not generally toxic. We observed that all antifungal 
compounds tested significantly altered the development of neurulation, head, eye, ear 
and branchial arch reflecting some common dysmorphogeneses.
Fig. 2. Morphology of a chicken embryo exposed to solvent control (a) and morphology of 
chicken embryos exposed to different antifungal compounds showing the most affected malfor-
mation endpoints, being ear, head and neurulation affected by ketoconazole (b and c), branchial 
arch by tebuconazole (d) head by propiconazole (e), branchial arch by prothiocoanzole (f) and 
neurulation by fenarimal (g). Note. Neu=neurulation; Bran=branchial arch.
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Fig. 2. Morphology of a chicken embryo exposed to solvent control (a) and morphology of chicken embryos exposed to different 
antifungal compounds showing the most affected malformation endpoints, being ear, head and neurulation affected by 
ketoconazole (b and c), branchial arch by tebuconazole (d) head by propiconazole (e), branchial arch by prothiocoanzole (f) and 
neurulation by fenarimal (g). Note. Neu=neurulation; Bran=branchial arch. 
 
BMD derivation from in vivo data 
A literature study on in vivo developmental toxicity was performed to obtain developmental 
toxicity potencies of the test compounds in vivo (Table 1) (the BMD10 values derived from different 
endpoints are presented in the Supplementary data file 2). Table 4 shows that lowest and median BMD10 
values obtained for tebuconazole, propiconazole and prothioconazole. For ketoconazole and fenarimol, 
BMD10 values for only one endpoint were derived, as only data for one endpoint were available. Both 
lowest and median (if available) values were used for the comparison with in vitro toxicity potency values. 
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bmd derivation from in vivo data
A literature study on in vivo developmental toxicity was performed to obtain 
developmental toxicity potencies of the test compounds in vivo (Table 1) (the BMD10 
values derived from different endpoints are presented in the Supplementary data 
file 2). Table 4 shows that lowest and median BMD10 values obtained for tebuconazole, 
propiconazole and prothioconazole. For ketoconazole and fenarimol, BMD10 values 
for only one endpoint were derived, as only data for one endpoint were available. Both 
lowest and median (if available) values were used for the comparison with in vitro 
toxicity potency values.
comparison of antifungal compound-induced relative developmental 
toxicity potencies in vivo with the es-d3 cell differentiation assay and 
the ex ovo assay of chicken embryos   
The BMC50 and the LOAEC values, obtained from the ex ovo assay of chicken embryos, 
as well as the BMCd50 values, obtained from the ES-D3 cell differentiation assay of our 
earlier study [8], were compared with in vivo BMD10 values to evaluate the predictive 
ability for developmental toxicity of the two alternative assays. Fig. 3a, c and e show the 
correlation curves between in vivo and the in vitro assays when placental transfer was not 
taken into account. It illustrates that reasonable correlations were found when correlating 
the BMCd50 from the ES-D3 cell differentiation assay to the in vivo lowest and median 
BMD10 values ((Fig. 3a; R2=0.53 and R2=0.52, respectively), as well as when correlating 
the BMC50 from the ex ovo assay to the median BMD10 values (Fig. 3c; R2=0.50). 
To assess the usefulness of taking into account BeWo transport data for placental 
transfer, a correction was made on the in vitro effect concentrations, by dividing these 
values by the relative permeability coefficient (relative Papp) values obtained from 
the BeWo transport model (Table 4) [9]. When the ES-D3 cell differentiation data are 
combined with the results obtained in the BeWo transport model, a better correlation of 
the corrected BMCd50 values from the ES-D3 cell differentiation assay with the in vivo 
BMD10 values was obtained indicated by an increase of the R2 from 0.53 to 0.95 for the 
in vivo lowest BMD10 values and from 0.52 to 0.79 for the in vivo median BMD10 values 
(Fig. 3b). A similar increase in the R2 was found for the corrected BMC50 (Fig. 3d) and the 
corrected LOAEC (Fig. 3f) from the ex ovo assay of chicken embryos. For the corrected 
BMC50, R2 increased from 0.19 to 0.67 and from 0.50 to 0.88 for the in vivo lowest and 
median BMD10 values, respectively, compared to the correlations obtained for the 
non-corrected values (Fig. 3d). For the corrected LOAEC values, the R2 increased from 
0.23 to 0.76 and from 0.23 to 0.58, when it correlated to the lowest and median BMD10 
values, respectively (Fig. 3f), as compared to non-corrected values. These data thus 
demonstrate the power of including a component of kinetics when predicting relative 
in vivo toxicity potencies based on in vitro toxicity data. In addition, it is noteworthy 
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Fig. 3. Correlation between in vivo lowest (♦) and median (△) BMD10 values of the five test compounds ketoconazole (Ket), 
tebuconazole (Teb), propiconazole (Prp), prothioconazole (Prt) and fenarimol (Fen), as derived based on data reported in the 
literature, with (a) BMCd50 values, obtained from the ES-D3 cell differentiation assay, (c) BMC50 and (e) LOAEC, obtained from 
the ex ovo assay of chicken embryos, as well as with (b) the corrected BMCd50, obtained from the ES-D3 differentiation assay with 
relative Papp values from the BeWo transport model, (d) corrected BMC50 and (f) corrected LOAEC values, obtained from the ex 
ovo assay of chicken embryos with relative Papp values from the BeWo transport model. 
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Fig. 3. Correlation between in vivo lowest (♦) and medi n (△) D10 values of the five test 
compounds ketoconazole (Ket), tebuconazole (Teb), propiconazole (Prp), prothioconazole (Prt) 
and fenarimol (Fen), as derived based on data reported in the literature, with (a) BMCd50 values, 
obtained from the ES-D3 cell differentiation assay, (c) BMC50 and (e) LOAEC, obtained from 
the ex ovo assay of chicken embryos, as well as with (b) the corrected BMCd50, obtained from 
the ES-D3 differentiation assay with relative Papp values from the BeWo transport model, (d) 
corrected BMC50 and (f) corrected LOAEC values, obtained from the ex ovo assay of chicken 
embryos with relative Papp values from the BeWo transport model.
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that better correlation was obtained for the corrected BMCd50 and LOAEC values to the 
lowest BMD10 values than to the median BMD10 values; whereas, the corrected BMC50 
values correlated better to the median BMD10 values than to the lowest BMD10 values. 
discussion 
Developmental toxicity is of high concern and currently a number of animal free 
methods to evaluate developmental toxicity have been developed. Both the ES-D3 cell 
differentiation assay of the EST and the ex ovo assay of chicken embryos have been 
used to investigate the developmental toxic potential of compounds. For the ES-D3 
cell differentiation assay, we have previously shown its usefulness in predicting relative 
in vivo developmental toxicity potencies of five antifungal compounds, especially 
when combined with kinetic data on placental transfer. However, as the ES-D3 cell 
differentiation assay only focuses on the effect of compounds on a single endpoint, namely 
cardiomyocyte differentiation, as a sensitive indicator for general developmental toxicity 
[24], it may not be always suitable to assess specific teratogenic effects of compounds. 
In teratology, multiple and often interrelated events on the complex cells and tissues 
are thought to ultimately lead to dysmorphogenesis. These complex mechanisms may 
not be discovered in the ES-D3 cell differentiation assay when characterising only one 
differentiation endpoint. Therefore, in the present study, the ex ovo assay of chicken 
embryos was applied to evaluate the teratogenic potential of the same set of compounds, 
as previously tested in the ES-D3 cell differentiation assay, enabling a comparison of the 
predictive ability on developmental toxic potencies in the two assays.  
Antifungal compounds have shown to induce specific alterations, including 
craniofacial changes and inter alia cleft palate [10], with the mechanism of action of 
antifungal compounds on affecting skeletal development related to alterations during 
hindbrain segmentation and branchial arches formation [11]. The ex ovo assay of chicken 
embryos may be a suitable tool to study this characteristic of the teratogenic potential of 
the antifungal compounds as it assesses chemicals with regard to their developmental 
toxic potential based on morphological changes including changes of neural tube closure 
at the head region. As shown in Table 1, ketoconazole, tebuconazole, propiconazole and 
prothioconazole all induced skeletal defects in rats. The results of our ex ovo assay of 
chicken embryos support the critical effect expected for these antifungal compounds 
as all four compounds caused significant alterations on branchial arch and neurulation 
endpoints. 
Unlike these four compounds, fenarimol did not produce significant branchial 
arch dysmorphogenesis, although it exerted severe alteration on neurulation and head 
anlage. This is in accordance with the in vivo data that fenarimol may be developmental 
neurotoxic as increased neuromuscular and behavioral deficits in nursing pups after 
exposure at GD 15-21 was observed [23].
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It is noteworthy that in chicken embryos of the concurrent control treatment for 
prothioconazole, higher incidences of alterations (neurulation, head and hind limb) 
were observed than for the control embryos for other compounds. This phenomenon 
of variable incidences of alterations in controls, although unusual, can happen in 
the ex ovo assay of chicken embryos and thus indicates the need to have substantial 
experience with this assay to interpret study results. Clearly it is preferable to have a 
low rate of alterations in the control group to increase sensitivity to have a neat picture 
of the type of alterations induced. Whenever unusually high rates of alterations are 
observed in control groups, evaluation of the data should be performed with utmost 
care to avoid an incorrect assessment of the developmental toxicity potential of 
a chemical.
The power of including a component of kinetics, i.e. placental transfer, when 
predicting relative in vivo developmental toxicity potencies based on in vitro toxicity 
data, was also investigated in the present study. The results obtained reveal that the 
corrected BMCd50 of the ES-D3 cell differentiation assay, and the BMC50 and LOAEC 
values of the ex ovo assay of chicken embryos correlated better with the in vivo BMD10 
values than the uncorrected ones. This indicates that combining the in vitro toxicity data 
with placental transfer kinetics improved the ability of the ES-D3 cell differentiation 
assay and the ex ovo assay of chicken embryos to predict relative in vivo prenatal 
developmental toxicity potencies of the selected antifungal compounds. Other important 
in vivo kinetic processes than placental transfer, such as intestinal absorption, maternal 
metabolism and placental metabolism, were not taken into account in the present study. 
Therefore, incorporating more kinetic information is likely to further improve the 
predictive value of the two assays. It should be noted that the data from the BeWo 
cell model were used in a relative way. The assay is not suitable to determine absolute 
transport rates of compounds, given that the BeWo cell model is a simplification of the 
in vivo placental transfer system. In those cases where it is important to use exact fetal 
bioavailability values, physiologically based kinetic (PBK) models which describe the in 
vivo absorption, distribution, metabolism, and excretion processes of a compound should 
be used. Furthermore, in order to translate the in vitro concentration-response curves 
to in vivo dose-response curves, a so-called reverse dosimetry approach could be used. 
In this approach, in vitro toxic effect concentrations are considered as surrogate tissue 
(fetal) or blood concentrations that would cause adverse effect in the in vivo situation. 
The in vivo toxic dose levels can be predicted using a PBK model to calculate the doses 
that are needed to reach these internal effect concentrations. This PBK-model based 
reverse dosimetry approach will enable definition of reference values for risk assessment, 
e.g. BMD10 and BMDL10 values [25-28]. 
BMC50 and LOAEC values were obtained from the ex ovo assay of chicken embryos 
in the present study. The BMC50 values, in both original and corrected form, correlated 
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better to the in vivo BMD10 values, than the LOAEC values, indicating that the BMD 
approach is a scientifically more advanced method to the LOAEL approach for deriving 
a reference point, also because it makes full use of the available dose-response data and 
provides a quantification of the uncertainties in the dose-response data. 
In risk assessment, lowest BMD10 values derived from in vivo data were used as 
reference values from a conservative point of view. However, when the lowest BMD10 
values are given by the endpoints with high incidence number in control group and 
historical control data are not available, it is questionable if these endpoints are treatment-
related. When the endpoint is not treatment-related, it may result in a false BMD10 
value and the toxic potency of the compound is overestimated. Therefore, it is highly 
recommended, whenever possible, to take historical control data into consideration 
when doing the BMD analysis of in vivo data. In the present study, the historical control 
data were not available for some endpoints for which a high incidence is noted in the 
control group. Therefore we included also median BMD values for comparison with 
in vitro toxic concentrations. It was shown that the in vitro concentrations, obtained 
from the ES-D3 cell differentiation assay and the ex ovo assay of chicken embryos, when 
corrected for placental transfer data, correlated well to both lowest and median BMD 
values, showing a good predictive ability of both assays. 
The ex ovo assay of chicken embryos showed higher sensitivity than the ES-D3 cell 
differentiation assay to toxic antifungal compounds, indicated by the higher BMCd50, 
obtained from the ES-D3 assay, as compared to the BMC50 and LOAEC values obtained 
from the ex ovo assay of chicken embryos (Table 4). It is interesting to note that both 
assays have shown their own advantages and limitations. Advantages of the ex ovo 
assay of chicken embryos include higher sensitivity, shorter experimental procedure, 
the capability to evaluate more specific teratogenic endpoints and good predictivity 
of the toxic potency. However the assay is more labor intensive and requires special 
equipment and a well trained staff. Advantages of the ES-D3 differentiation assay are 
that it is animal free, cheaper, and showing good predictivity of the toxic potency. The 
assay is however not able to identify specific manifestation patterns or is less able to 
distinguish potential modes of action of different teratogenic compounds underlying 
the embryotoxicity. Based on the results of the present and our previous studies [7, 8] 
it can be suggested that a combined and tiered testing strategy based on the two assays 
could be used to predict teratogenic potential and developmental toxicity. As a simpler 
assay, the ES-D3 cell differentiation assay can be used in a first tier to predict toxicity 
potency of chemicals and to detect the compound(s) of high concern, i.e. showing high 
toxic potency. Then the ex ovo assay of chicken embryos can be applied to test chemical(s) 
of high concern in a second tier enabling identification of a more specific pattern of 
morphological changes, giving thereby more information on the structures affected by 
the developmental toxicant. 
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conclusion
In conclusion, the present study showed that the ex ovo assay of chicken embryos was 
able to detect the teratogenic potential and to predict relative developmental toxic 
potencies of antifungal compounds. When combined with the in vitro BeWo transport 
model, both the ex ovo assay of chicken embryos and the ES-D3 cell differentiation 
assay appeared to better predict the relative in vivo developmental toxicity potencies 
of the antifungal compounds. In combination, the three assays could provide a 
valuable tiered alternative approach for prenatal developmental toxicity screening 
and prioritization. More compounds with different modes of action should be tested 
to further evaluate the capacity of this approach in predicting the teratogenic potential 
and the developmental toxicity potency of chemicals. Since the method uses only in 
vitro assays to predict in vivo prenatal developmental toxicity ranking of chemicals, 
it can contribute to the 3Rs of animal testing. The predictive ability of the assays can 
most likely be even further enhanced when combined with more kinetic data and 
PBK modeling.
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suPPlemenTary maTerial 1
Table 1. Evaluation Scheme for calculating the morphological scores (modified according to 
Klug et al. [13]).
Primordium Evaluation
Posture of the embryo 5 = spiral bend
4 = U-shaped curve
3 = caudal trunk or tail portion are positioned at the right side of the 
embryo or embryo is stretched
2 = bend over the backs
1 = abnormality
Neurulation 5 = neuropore closed completely
4 = only caudal neuropore open
3 = cranial and caudal neuropore open
2 = only cranial neuropore open
1 = abnormality
Head 4 = rombencephalon with incipient division into hemispheres by media-
nelongitudinal furrow
3 = separated by transverse furrow telencephalon from the diencephalon
2 = no transverse furrow between telencephalon and diencephalon 
smooth transition between peak and neck hump
1 = abnormality
Eye 5 = lens bag
4 = invagination of the optic vesicle to the eye cup; cleft of the eye column
3 = optic vesicle
2 = no eye system
1 = abnormality
Ear 5 = endolymphatic duct visible
4 = bladder
3 = mine ears
2 = no ear system
1 = abnormality
Heart 4 = starting septa; heart appears as four chambers 
3 = S-shaped heart loop with thickened endocardial cushion between 
primitive atrium (atrium primitivum) and primitive main chamber 
(ventricle primitivum)
2 = U-shaped bulboventricular loop 
1 = abnormality
Branchial arches 2 = two branchial arches
1 = one branchial arch
0 = none / abnormality
Fore/hind limb 4 = limb stump, in which the height is ≥ the width of the base 
3 = limb stump, in which the height is < the width of the base
2 = no cusp extremities
1 = abnormality
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Table 1. Evaluation Scheme for calculating the morphological scores (modified according to 
Klug et al. [13]).
Primordium Evaluation
Caudal part of trunk 5 = tail bud, length > width (stretch)
4 = length > width
3 = length ≤ width
2 = no structure caudal to the hind limb system
1 = abnormality
suPPlemenTary maTerial 2
Table 1. BMD10 values derived from the incidence of malformation(s) in rats exposed 
to ketoconazole [15]. The lowest and the median (if possible) BMD10 values used for the 
comparison with in vitro data are presented in Table 4.
Dose (mg/kg bw/day)
BMD10(mg/kg bw/day)Control 25 73
No. litters examined 22 22 3
Cleft palate 0 3 3 10.7
Table  2. BMD10 values derived from the incidence of variation(s) in rats exposed to tebuconazole 
[18]. The lowest and the median (if possible) BMD10 values used for the comparison with in 
vitro data are presented in Table 4.
Dose (mg/kg bw/day)
BMD10(mg/kg bw/day)Control 30 60 120
No. pups examined 144 137 127 116
Cervical vertebra 1 18 21 24 48 48.1
Cervical vertebra 2 29 40 38 48 39.3
Cervical vertebra 3 9 10 12 16 134.5
Cervical vertebra 4 0 5 2 13 118.8
Cervical vertebra 5 3 3 3 10 131.2
Cervical vertebra 6 1 2 2 6 168.8
Vertebral arch 6, left 1 2 3 14 114.7
Vertebral arch 6, right 0 2 6 13 100.3
Vertebral arch 7, left 50 53 49 66 34.9
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Table  2. BMD10 values derived from the incidence of variation(s) in rats exposed to tebuconazole 
[18]. The lowest and the median (if possible) BMD10 values used for the comparison with in 
vitro data are presented in Table 4.
Dose (mg/kg bw/day)
BMD10(mg/kg bw/day)Control 30 60 120
Vertebral arch 7, right 45 53 51 65 30.8
Sternebra 2 4 3 3 15 118.5
Sternebra 6 0 0 1 4 150.6
Supernumerary ribs, left 14 20 18 26 90.0
Supernumerary ribs, right 15 23 19 24 113.6
Digit 2 proximal phalanx (l) 27 36 37 42 52.1
Digit 3 proximal phalanx (l) 0 3 5 9 133.5
Digit 4 proximal phalanx (l) 2 7 7 11 138.6
Metacarpal 5 (l) 0 0 2 4 157.5
Digit 2 proximal phalanx (r) 27 33 39 40 54.5
Digit 3 proximal phalanx (r) 0 3 4 8 141.0
Digit 4 proximal phalanx (r) 1 6 6 11 131.3
Metacarpal 5 (r) 0 0 2 5 147.4
Metatarsal (l) 18 24 18 31 84.9
Toe 2 proximal phalanx (l) 107 92 96 103 40.3
Toe 3 proximal phalanx (l) 81 70 78 87 23.6
Toe 4 proximal phalanx (l) 79 65 72 85 50.6
Metatarsal (r) 18 24 20 32 76.4
Toe 2 proximal phalanx (r) 110 96 105 105 37.6
Toe 3 proximal phalanx (r) 86 75 76 92 46.4
Toe 4 proximal phalanx (r) 81 71 74 91 45.3
No. litters examined 24 24 22 24
Cervical vertebra 2 14 17 17 20 8.5
Sacral vertebral arch 6 (r) 0 2 6 8 55.8
Digit 2 proximal phalanx (l) 14 14 16 18 45.8
Digit 3 proximal phalanx (l) 0 3 5 4 83.1
Digit 3 proximal phalanx (r) 0 3 4 4 91.3
Digit 4 proximal phalanx (r) 1 4 6 6 83.4
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Table 3. BMD10 values derived from the incidence of external alteration(s) in rats exposed 
to tebuconazole [19]. The lowest and the median (if possible) BMD10 values used for the 
comparison with in vitro data are presented in Table 4.
Dose (mg/kg bw/day)
BMD10(mg/kg bw/day)Control 10 30 100
No. pups examined 174 144 202 168
External alterations 3 1 4 12 126.3
Table 4. BMD10 values derived from the incidence of malformation(s) or of altered variation(s) 
in rats exposed to propiconazole [20]. The lowest and the median (if possible) BMD10 values 
used for the comparison with in vitro data are presented in Table 4.
Dose (mg/kg bw/day)
BMD10(mg/kg bw/day)Control 30 90 300
No. pups examined 141 148 156 148
Cleft palate 0 0 1 2 551.8
Renal papilla short 32 27 40 57 123.0
No. pups examined 129 136 146 137
Renal papilla missing 4 4 8 16 318.2
rudimentary ribs 0 1 4 53 141.7
sternebrae not ossified 49 54 83 99 29.0
No. litters examined 22 21 22 22
cleft palate 0 0 1 2 303.4
Renal papilla missing 4 3 3 12 62.2
rudimentary ribs 0 1 4 16 31.1
Table 5. BMD10 values derived from the incidence of malformation(s) or of altered variation(s) 
in rats exposed to prothioconazole [21]. The lowest and the median (if possible) BMD10 values 
used for the comparison with in vitro data are presented in Table 4. 
Dose (mg/kg bw/day)
BMD10(mg/kg bw/day)Control 20 80 750
No. litters examined 25 25 25 25
Rudimentary ribs (punctiform) 23 19 22 24 73.1
Rudimentary (comma-shaped) 13 16 9 17 268.8
Extra (full-size) 8 4 3 10 337.8
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Table 6. BMD10 values derived from the incidence of malformation(s) or of altered variation(s) 
in rats exposed to prothioconazole [21]. The lowest and the median (if possible) BMD10 values 
used for the comparison with in vitro data are presented in Table 4.
Dose (mg/kg bw/day)
BMD10(mg/kg bw/day)Control 80 500 1000
No. litters examined 26 25 22 24
Microphthalmia 0 6 3 11 306.5
Table 7. BMD10 values derived from the incidence (percentage) of malformation(s) or of altered 
variation(s) in rats exposed to fenarimol [22]. The lowest and the median (if possible) BMD10 
values used for the comparison with in vitro data are presented in Table 4.
Dose (mg/kg bw/day)
BMD10(mg/kg bw/day)Control 5 13 35
Hydronephrosis 9% 0 0 30% 29.3


Use of physiologically based kinetic 
modeling-facilitated reverse dosimetry of in vitro 
toxicity data for prediction of in vivo developmental 
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absTracT  
Toxicological hazard and risk assessment largely rely on animal testing. For economic 
and ethical reasons, the development and validation of reliable alternative methods for 
these animal studies, such as in vitro assays, are urgently needed. In vitro concentration-
response curves, however, need to be translated into in vivo dose-response curves for 
the risk assessment purposes. In the present study, we translated in vitro concentration–
response data of the antifungal compound tebuconazole, obtained in the ES-D3 cell 
differentiation assay and the ex ovo assay of chicken embryos, into predicted in vivo 
dose–response data for developmental toxicity using physiologically based kinetic (PBK) 
modeling-facilitated reverse dosimetry. The predicted in vivo dose–response data were 
used to derive BMD10 values for developmental toxicity in rat, which were compared 
with BMD10 values derived from toxicity data in rats as reported in the literature. The 
results show that the BMD10 values from predicted dose–response data from both 
assays are in concordance with BMD10 values derived from in vivo data (within 5-fold 
difference). It is concluded that PBK modeling-facilitated reverse dosimetry of in vitro 
toxicity data is a promising tool to predict in vivo dose-response curves and could be 
used to define a point of departure for deriving safe exposure limits in risk assessment.
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inTroducTion
The determination of safe human exposure levels of chemicals in toxicological risk 
assessments largely relies on animal toxicity data. In these toxicity studies, the majority 
of the animals are used for reproductive and developmental toxicity testing [1]. For 
economic and ethical reasons, there is large interest in the development of in vitro test 
systems as alternatives for the animal studies. A number of in vitro methods have been 
developed to screen compounds for potential developmental toxicity, using primary 
cultures of embryonic cells or embryonic stem cell lines, such as the embryonic stem 
cell test (EST), as well as test methods using whole embryos, such as the ex ovo assay 
of chicken embryos [2-4].
Among these alternative test systems for the assessment of developmental toxicity, the 
EST does not require the use of primary animal tissues and can therefore be considered 
as an animal-free test. The differentiation assay of the EST has been proven useful in 
the prediction of the in vivo potency ranking of structurally related compounds, such 
as glycol ethers, retinoids and phenols [5-7]. This assay uses the blastocyst-derived 
embryonic stem cell line D3 (ES-D3) that spontaneously differentiates into contracting 
cardiomyocytes when cultured as embryoid bodies, and it determines the concentrations 
of test compounds that inhibit this process as a measure of in vitro developmental 
toxicity. Recently, we have demonstrated that the ES-D3 cell differentiation assay is 
useful to predict the relative developmental toxicity potencies of antifungal compounds 
in vivo [8, 9]. Furthermore, we showed that the correlation between the in vitro effect 
concentrations and the in vivo effect doses improves when kinetic data on placental 
transfer are taken into account [8, 9]. 
A limitation of the ES-D3 cell differentiation assay is that it is an assay for general 
developmental toxicity and may not be predictive for specific morphological changes, 
since it assesses the effect of the chemical on the differentiation of stem cells into 
cardiomyocytes. The ex ovo assay of chicken embryos assesses chemicals with regard 
to their developmental toxic potential based on morphological changes [10]. The culture 
duration of the chicken embryos covers major parts of the organogenesis, thereby offering 
the assessment of various morphological endpoints including specific development of 
different organ anlagen, i.e. head region with different brain -, eye -, and ear anlagen 
and branchial arches. Therefore, the ex ovo assay of chicken embryos is a more suitable 
tool to study in a more specific way the potential interference of compounds with the 
embryo and fetal development. We have previously shown that the ex ovo assay of 
chicken embryos was able to predict the developmental toxicity potential of antifungal 
compounds, and, when combined with the in vitro BeWo transport model, was also 
able to better predict the relative in vivo developmental toxicity potencies of antifungal 
compounds than when the ex ovo assay of chicken embryos was used as a stand-alone 
assay [11]. 
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Although both the ES-D3 cell differentiation assay and the ex ovo assay of chicken 
embryos, in combination with data on placental transfer from the BeWo model, were 
shown to correctly predict relative in vivo potencies of antifungal compounds, these 
data cannot be used as such for risk assessment. An important reason is that the in 
vitro and ex ovo assays provide in vitro concentration–response curves on adverse 
effects on the cells and on the embryo, respectively, whereas in vivo dose–response 
curves are required for setting safe exposure levels in risk assessment. The application 
of so-called reverse dosimetry enables the translation of in vitro concentration–
response curves into in vivo dose–response curves using physiologically based kinetic 
(PBK) models, providing a platform to use in vitro toxicity data for risk assessment 
[4, 12-14]. PBK models quantitatively describe absorption, distribution, metabolism, 
and excretion processes of a compound in the body, and can relate external (toxic) 
doses to internal (toxic) concentrations [15]. In reverse dosimetry approaches aiming 
to predict in vivo toxic dose levels, in vitro toxic effect concentrations are considered 
as surrogate tissue or blood concentrations that would cause adverse effect in the 
in vivo situation. The in vivo toxic dose levels can be predicted using a PBK model 
to calculate the doses that are needed to reach these internal effect concentrations. 
PBK modeling-facilitated reverse dosimetry is the only method that enables the 
quantitative translation of in vitro data to the in vivo situation. Therefore, there is 
increased interest in using the PBK modeling-facilitated reverse dosimetry approach 
to derive points of departure (PoDs) for risk assessment, such as Benchmark Dose 
(BMD) values, based on the translation of in vitro concentration–response data 
obtained from in vitro toxicity assays [16, 17]. Our group has shown that reverse 
dosimetry of developmental toxicity data obtained in the ES-D3 cell differentiation 
assay resulted in the correct prediction of in vivo dose–response curves of glycol 
ethers, phenol and retinoic acid [4, 12, 13]. No proof-of-principles of chemicals from 
other chemical categories are available so far.
In the present study, we assessed whether the reverse dosimetry approach correctly 
predicts in vivo developmental toxicity of tebuconazole, a chemical belonging to 
the category of antifungal compounds. To this end we developed a PBK model for 
tebuconazole in the rat, based on in vitro- and in silico-derived parameter values, and 
used this model to translate data on tebuconazole-induced developmental toxicity 
obtained in the ES-D3 cell differentiation assay and the ex ovo assay of chicken embryos 
to predicted in vivo dose-response curves for developmental toxicity in rat. The predicted 
in vivo dose–response data were used to derive BMD10 values for rats, and were compared 
with BMD10 values derived from toxicity data in rats as reported in the literature, in 
order to evaluate the predictions made. 
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maTerials and meThods 
chemicals
Tebuconazole was purchased from Sigma-Aldrich (Steinheim, Germany). Dimethyl 
sulfoxide (DMSO) was purchased from Acros Organics (Geel, Belgium). Penicillin, 
streptomycin, L-glutamine, non-essential amino acids, phosphate-buffered saline 
(PBS) and Hank’s balanced salt solution (HBSS) were obtained from Invitrogen (Breda, 
the Netherlands).
high-performance liquid chromatography (hPlc) analysis
HPLC analysis was performed to quantify the amount of the test compound tebuconazole 
and its metabolites. The HPLC system used consisted of a Waters (Milford, MA) 600 
controller and a 600 pump, equipped with a photodiode array detector set to record 
absorption of wavelengths between 200 and 400 nm. A Waters 717 plus autosampler 
was used for sample injection. The temperature of the autosampler was kept at 7 °C. 
For analysis of all compounds, 50 μl sample was injected to a C18 5 μm reverse-phase 
column (150 mm × 4.6 mm I.D.) with a guard column (7.5 mm × 4.6 mm I.D.) (Alltech, 
Bergen op Zoom, the Netherlands). The mobile phase used for analysis consisted of (A) 
0.1% trifluoroacetic acid in nanopure water and (B) HPLC-grade acetonitrile. Elution 
was at a flow rate of 0.8 ml/min, starting at 22% B with a linear increase to 100% B in 8 
min. Subsequently, the gradient returned linearly to the initial condition in 10 min and 
remained 2 min at this condition prior to the next injection. 
Pbk modeling-facilitated reverse dosimetry approach
The PBK modeling-facilitated reverse dosimetry approach to predict in vivo developmental 
toxicity based on in vitro toxicity data (Figure 1) consists of six steps, being (1) the 
determination of in vitro concentration–response data for tebuconazole in the ES-D3 
cell differentiation assay and the ex ovo assay of chicken embryos, (2) the development 
of a PBK model for tebuconazole in rat, (3) the evaluation of the predictions made by 
the PBK model, (4) the translation of in vitro concentration–response data into in vivo 
dose–response data using the PBK model, (5) the derivation of a BMD value based on 
the predicted dose–response data and (6) the evaluation of the approach by comparison 
of the predicted BMD value with a BMD value derived from in vivo developmental 
toxicity data obtained from the literature.
1. determination of in vitro concentration–response data in the es-d3 
cell differentiation assay and the ex ovo assay of chicken embryos
The in vitro concentration–response data on the tebuconazole-induced inhibition of 
ES-D3 cell differentiation into contracting cardiomyocytes were obtained from our earlier 
study [8]. The data of three independent experiments of this study are presented in Fig. 1a. 
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The in vitro concentration-response data on the tebuconazole-induced branchial arch 
alteration (most sensitive endpoint for tebuconazole in the ex ovo assay), were obtained 
from another previous study [11]. The data of this study are presented in Fig. 1b.
2. development of a Pbk model for tebuconazole in rat 
The conceptual structure of the PBK model developed for tebuconazole is shown in Fig. 1c. 
Values for anatomical and physiological parameters are presented in supplementary 
material 1 Table 1 and were taken from literature [18]. The processes of stomach emptying 
(half-life in rat, liquid, 15 min) [19] and the small intestinal transition time (complete 
transition in rat, 1.5 h) [20] are included in the model. To describe small intestinal 
transition, the intestinal compartment was divided in 7 sub-compartments [12]. Values 
for kinetic parameters, including (1) intestinal absorption, (2) partitioning into tissues and 
(3) hepatic clearance, were determined in the present study using data obtained from in 
vitro and in silico methods as described below. The PBK model describes only the kinetics 
of tebuconazole and not of its metabolites, since we assume that the developmental toxicity 
is caused by the parent compound. The PBK model was coded and numerically integrated 
in Berkeley Madonna 8.3.18 (UC Berkeley, CA, USA), using the Rosenbrock’s algorithm 
for stiff systems. The PBK model code is presented in the supplementary material 3.
2.1 Determination of model parameter value for intestinal absorption
The parameter value for the intestinal absorption of tebuconazole was determined by 
using the following equation: absorption rate (µmol h−1) = Papp coefficient in vivo 
(cm h−1) Î surface area of the rat small intestine (cm2) Î luminal concentration of 
tebuconazole (mM) [21]. The value for the surface area of the rat small intestine was 
calculated to be 94 cm2 (radius of 0.18 cm and a small intestine length of 83 cm [22]). 
The small intestinal volume was calculated to be 8.4 ml. The luminal concentration of 
tebuconazole is calculated by the model by dividing the amount of tebuconazole by the 
small intestinal volume (ml). 
The Papp coefficient in vivo was estimated based on in vitro transport studies using 
Caco-2 cell layers in a transwell set-up. Sun et al. (2002) described the correlation between 
Papp values obtained in such Caco-2 studies and that obtained from ex vivo studies 
using human jejunum tissue (Papp,in vivo): Log (Papp,in vivo) = 0.6836 × Log (Papp,Caco-2) − 
0.5579. Caco-2 transport studies were performed as described below to determine the 
Papp,Caco-2, which was used to estimate the Papp,in vivo. It was assumed that the estimated 
Papp,in vivo value for humans is the same as the Papp,in vivo value for rats.  
For the Caco-2 transport studies, Caco-2 cells (P35-P40, obtained from ATCC) 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Breda, the 
Netherlands, cat. no. 61965), supplemented with 10 % (v/v) heat-inactivated fetal calf 
serum (FCS, HyClone-Perbio, Etten-Leur, the Netherlands), 10,000 U/ml penicillin, 
10 mg/ml streptomycin, 1 % non-essential amino acids and 2 mM L-glutamine. The cells 
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were seeded at a density of 2.24 x 105 cells/cm2 on transwell® polycarbonate membranes (12 
mm diameter, 0.4 μm pore size) (VWR International BV, Amsterdam, the Netherlands) 
and cultured in a humidified incubator at 5 % CO2 and 37 °C. Medium (0.5 ml apical 
compartment, 1.5 ml basolateral compartment) was changed every 2-3 days. Transport 
studies were performed at day 20 post-seeding. The barrier forming capacity of the 
Caco-2 cell layers was evaluated by measuring the transepithelial electrical resistance 
(TEER) of the cell layer using a Millicell ERS-2 Volt-Ohm Meter (Millipore, USA). The 
TEER value was determined after replacing culture medium with HBSS, showing TEER 
values between 700-900 Ω/cm2.
Transport experiments were initiated by adding 0.5 ml of transport buffer HBSS 
containing 50 μM tebuconazole, added from a 200 times concentrated stock solution 
in DMSO (final solvent concentration 0.5% DMSO) to the apical compartment and 
1.5 ml HBSS to the basolateral compartment. Subsequently, the plate was incubated in 
a humidified atmosphere with 5 % CO2 at 37 °C. After 15, 30, 60 and 90 min, a sample 
of 0.2 ml was taken from the basolateral compartment and replaced by an equal volume 
of HBSS. At the end of each experiment, a 0.2 ml sample was also taken from the apical 
compartment. Subsequently, the filters with the Caco-2 cell layers were washed 3 times 
with PBS, cut out of the insert, dissolved in 0.25 ml 65 % (v/v) methanol and sonificated 
for 15 min in a Bandelin Sonorex RK100 (Berlin, Germany) in order to determine the 
amount of compound accumulated in the cells and enabling mass-balance calculations. 
All samples were stored at −20 °C until HPLC analysis. In each transport study, amoxicillin 
was included as a control for monolayer integrity since it is a compound known to be 
transported only to a limited extent in the Caco-2 cell model [23] and antipyrine was 
included as a control for optimal transport [24]. The transport of tebuconazole, amoxicillin 
and antipyrine was also determined through the permeable membrane of the transwell 
filter in the absence of Caco-2 cells. It was shown to be equally fast among these compounds 
(data not shown), ensuring that any differences observed in the transport studies with 
Caco-2 cells were related to the Caco-2 cell layer and not to the filter.
For the test compound, the linear appearance rate in the basolateral compartment 
was determined to calculate the apparent permeability coefficient Papp,Caco-2 (Papp,Caco-2 
(cm/s) = (ΔQ/Δt)/(A·C0)), where ΔQ is the amount of test compound (nmol) transported 
to the receiver chamber in a certain time span (Δt (s)), A is the cell surface area (cm2) and 
C0 is the initial concentration of the test compound in the donor compartment (μM).
2.2 Determination of model parameter values for tissue/blood partitioning
Tissue/blood partition coefficients for tebuconazole were calculated using the algorithm 
reported in literature [25], requiring information on fraction unbound (fub) in blood, 
the pKa and log Kow of the compound as sole input parameters. The log Kow (at pH 7.4) 
reported for tebuconazole is 3.7 [26] and the pKa 5.0 [27]. The fub of tebuconazole in rat 
blood was determined using an approach described in literature [28] to determine protein 
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binding of chemicals. In short, protein binding parameters were estimated based on the 
assessment of the increase of EC50 values for tebuconazole cytotoxicity with increasing 
albumin concentrations, determined as described before [28] with slight modifications. 
A description of the cytotoxicity study is presented in the supplementary material 2. 
Obtained EC50 values of tebuconazole were determined from concentration–response 
relationships obtained in independent experiments with increasing concentrations of 
albumin and were plotted against the albumin concentration present in the exposure 
medium. A linear correlation was obtained between the EC50 values and the albumin 
concentration. Linear regression (Y = aX + b, Y= EC50, X= albumin concentration) was 
obtained with the slope (a) and intercept (b) for the best fit. The fub to albumin was 
estimated by using the following equation: fub = b / EC50 where b is the intercept of the 
linear regression equation, and EC50 is the value in the presence of a certain concentration 
of albumin [28]. Based on these equations, the fub in rat blood was determined, using 
albumin concentration in rat blood being 293 µM [29]. 
2.3 Determination of model parameter values for hepatic clearance
Tebuconazole body clearance was described by hepatic clearance of the parent compound. 
To determine parameter values for description of the hepatic clearance, the maximum 
enzyme reaction rate (Vmax) and the Michaelis–Menten constant (Km) for microsomal 
metabolism of tebuconazole were determined using incubations with female rat 
microsomes in Eppendorf vials. Conditions were optimized to obtain linear reaction rates 
with respect to incubation time and microsome concentration (data not shown). Final 
studies for the determination of the kinetic constants were performed using incubation 
mixtures consisting of 0.1 M Tris-HCl (pH 7.4), containing (final concentrations) 2 mM 
NADPH (Roche Diagnostics, Mannheim, Germany) and 1 mg/ml pooled female Wistar 
rat liver microsomes (XenoTech, Kansas, USA). The incubations were started, after 
a 1-min pre-incubation at 37 ºC, by the addition of the substrate tebuconazole from a 
100 times concentrated stock solution in DMSO and left in a shaking water bath of 37 ºC 
for 7 min. The reactions were terminated by the addition of ice-cold acetonitrile (20 % 
v/v). Subsequently, the Eppendorf vials were put on ice. All samples were centrifuged for 
5 min at 15000 rpm using a microcentrifuge (CT15RE, VWR, Leuven, Belgium), and the 
supernatant was stored at −20 °C until HPLC analysis. Blank incubation mixtures were 
included, in which NADPH was omitted. The intact masses of metabolites were identified 
by liquid chromatography–mass spectrometry (LC-MS) analysis as described below.
To obtain the kinetic parameters Vmax and Km, the in vitro data on the concentration 
dependent formation of metabolites were fit to the Michaelis–Menten equation using 
GraphPad Prism 5.0 software (San Diego, CA, USA). The in vitro-derived Vmax values 
(µmol/min/mg protein) were scaled to the in vivo situation using a microsomal protein 
concentration of 35 mg/g liver [30]. The in vivo Km values were assumed to equal the 
in vitro Km values. 
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2.4 Liquid chromatography–mass spectrometry (LC-MS) analysis
Separation and purification of the three major tebuconazole metabolites were performed 
by collecting the eluate of the HPLC column for the respective metabolite peaks. Then 
LC-MS analysis of each metabolite was conducted using a micrOTOF MS (Bruker) 
coupled to an Agilent LC (1200 Series) equipped with an Altima C18 column (150 x 
4.6 mm, 3 µm). The mobile phase used consisted of (A) nanopure water with 0.1 % formic 
acid and (B) HPLC-grade acetonitrile with 0.1 % formic acid. Elution was at a flow rate of 
0.8 ml/min, starting at 22 % B with a linear increase to 100 % B in 30 min. Subsequently, 
the gradient returned linearly to the initial condition in 2 min and remained 13 min at 
this condition prior to the next injection. 
3. Pbk model evaluation 
In order to assess the performance of the PBK model, the predicted blood concentrations of 
tebuconazole were compared with reported blood concentrations from an in vivo kinetic 
study as reported in the literature [31]. The model was also evaluated by comparison of the 
predicted cumulative excretion of metabolites (in % of the administered dose) to in vivo 
data on the cumulative excretion (urine and feces) of tebuconazole and its metabolites 
[32]). These in vivo kinetic data were not used to optimize model performance, but were 
solely used for model evaluation.
Sensitivity analysis 
Normalized sensitivity coefficients (SC) were determined to identify parameters that 
largely influence the prediction of the maximal blood concentrations (Cmax) by the PBK 
model, using the equation: SC = (C′−C)/(P′− P) × (P/C), where P and P′are the initial 
and modified parameter values respectively, and C and C′are the initial and modified 
values of the model output resulting from an increase in parameter value, respectively 
[33]. A 5% increase in parameter value was chosen to analyze the effect of a change 
in parameter on the Cmax of tebuconazole for 10-day exposure. Doses of 2, 12.5, and 
25 mg/kg bw/day were used for the sensitivity analysis as these cover the range of doses 
applied in the in vivo kinetic studies that were used for model evaluation. Each parameter 
was analyzed individually, keeping the other parameters to their initial values.
4. Translation of in vitro concentration–response data into predicted 
in vivo dose–response data using Pbk-modeling facilitated reverse 
dosimetry 
In the reverse dosimetry approach for the prediction of in vivo developmental toxicity, 
the in vitro effect concentrations of tebuconazole inducing inhibition of ES-D3 cell 
differentiation or inducing alterations of chicken embryos, were considered as surrogate 
in vivo concentrations in blood that could result in adverse effect of embryonic/fetal 
development. The PBK model is used to determine the oral dose levels that would result in 
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these concentrations in the blood. Differences may be expected in the fub of tebuconazole in 
the culture medium in the two assays compared with the fub in rat blood, because rat blood 
contains different protein levels than the culture medium. As it is assumed that the fub of 
the chemical is most likely to cause toxicity, corrections were made to take the differences 
in the fub in the culture medium compared with the rat blood into account. A description 
of the procedure for this correction is presented in the supplementary material 2.
Subsequently, translation of the in vitro concentrations into in vivo doses was made 
by relating the toxic effect (both in vitro and in vivo) to the Cmax of tebuconazole in blood. 
Then, it was determined which oral doses are required in the PBK model to reach the Cmax 
of tebuconazole in the blood compartment that would result in developmental toxicity. 
By performing this exercise for each concentration used in the in vitro assay, all in vitro 
concentration–response data were translated into predicted in vivo dose–response data. 
5. derivation of a bmd value on the predicted dose–response data 
BMD modeling was applied on the predicted in vivo dose–response data using all models 
for dichotomous data of the Environmental Protection Agency (EPA)’s Benchmark Dose 
Software (BMDS) version 2.4. BMD10 values that correspond with a 10% extra effect 
on the fraction of EBs inhibited or the fraction of chicken embryos with alterations 
were derived. Models included in the evaluation were the gamma, logistic, loglogistic, 
probit, logprobit, multistage, weibull and the quantal-linear model. Goodness of fit 
of the models was evaluated to judge if a model was accepted, using the p values with 
p>0.05, the scaled residuals and the graphical displays obtained as the criteria [34]. All 
models that met the requirements for acceptance of the model fit were considered for 
the determination of BMD10 values. Of the models that passed the criteria for model fit, 
the lowest BMD10 value was selected as the BMD10 value for developmental toxicity of 
tebuconazole. These values were used for comparison with BMD10 values derived from 
data of rat developmental toxicity studies reported in the literature.
6. evaluation of the predictive value of the approach
To evaluate the potential of the in vitro–in silico approach to obtain a PoD for risk 
assessment, the predicted BMD10 values for rat were compared with BMD10 values 
derived from data from rat developmental toxicity studies reported in the literature. To 
this end, a literature study was performed, with search terms including tebuconazole 
together with combinations of the search terms teratogenicity, developmental toxicity, 
(skeletal) alteration, (skeletal) variation, and embryotoxicity. The results of studies 
performed in rats were used. A study was selected if it included at least one control 
group and two dose groups, which enables BMD modeling to derive a BMD10 value. 
BMD10 values that correspond with a 10% extra incidence of developmental toxicity 
above background levels were derived. The BMD10 values were calculated as described 
above for the predicted dose-response data. 
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resulTs
development of a Pbk model for tebuconazole in rat
The PBK model code is presented in the supplementary material 3.
Determination of the model parameter value for intestinal absorption
Intestinal absorption was determined by multiplying the Papp,in vivo for intestinal 
absorption by the surface area of the intestine and the luminal concentration in the 
intestine. The Papp,in vivo coefficient was estimated based on Papp coefficients obtained 
in Caco-2 transport studies (Papp,Caco-2) using the formula reported by Sun et al. (2002) 
that relates Papp, Caco-2 to Papp, in vivo values. The obtained Papp,Caco-2 was 3.8 × 10−5 cm s−1, 
which resulted in a Papp,in vivo of 3.3 × 10−4 cm s−1 (equivalent to 1.2 cm h−1).
Determination of model parameter values for tissue/blood partitioning
Tissue/blood partition coefficients (supplementary material 1 Table 2) were obtained 
based on the algorithm reported in literature [25] using information on the fub in blood, 
the pKa and the logP. The fub in rat blood was estimated to be 0.34 (for more details on 
the calculation see the supplementary material 2). 
Determination of model parameter values for hepatic clearance 
Upon incubation of tebuconazole with female rat liver microsomes and NADPH, 
three metabolites (here called A, B and C) were detected (Fig. 2). Quantification of the 
formed metabolites was carried out by using the calibration curve for tebuconazole at 
a wavelength of 225 nm, which was shown to have the same UV spectrum for two of 
the three metabolites (metabolite B and C). The UV spectra of the three metabolites, as 
well as that of the parent compound tebuconazole are presented in the supplementary 
material 1 Fig. 1. The intact masses of the three metabolites were identified by LC-MS 
analysis and shown to amount in positive mode to mass values (m/z) of 324.16, 338.14 
and 324.16, for A, B and C, respectively, with the expected isotopic pattern for a single 
chlorine containing molecule. According to the reported in vivo metabolic profile of 
tebuconazole, three main phase I metabolites are formed in rat, being tebuconazole-o-
hydroxy, tebuconazole-1-hydroxy and tebuconazole–carboxylic acid, with exact mass 
values (m/z) of 324.16, 324.16 and 338.14, respectively [32]. The structures of tebuconazole 
and the three metabolites are presented in Fig. 2. Based on this information and the mass 
values obtained it is concluded that metabolite A and C represent the two hydroxylated 
compounds and that metabolite B represents the carboxylic acid. As the UV spectrum of 
metabolite A is different from that of tebuconazole, we tentatively identified metabolite 
A as tebuconazole-o-hydroxy, given that its hydroxyl group is attached to the benzene 
ring and therefore likely to modify the UV absorption spectrum. This implies that 
metabolite C corresponds to tebuconazole-1-hydroxy, which can be further metabolized 
to metabolite B (tebuconazole–carboxylic acid). 
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Fig. 3 shows the formation rate of the metabolites with increasing concentration 
of tebuconazole, indicating that the reactions follow Michaelis–Menten kinetics. In 
the PBK model, the clearance of the parent compound tebuconazole was described 
by modeling its metabolic conversion to the primary metabolites A and C. Given that 
metabolite C was partly further metabolized to form metabolite B, the amount of 
metabolite B was added to that of metabolite C for the determination of the kinetic 
parameter values for the formation of metabolite C (Fig. 3b). The apparent Km and 
Vmax values for formation of A and B+C are presented in Table 1 and were scaled to 
parameter values for rat liver in the PBK model as described in the Materials and 
Methods section. 
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Fig. 2 HPLC chromatogram (upper) and structures (lower) of tebuconazole and metabolites A 
(tebuconazole-o-hydroxy), B (tebuconazole–carboxylic acid) and C (tebuconazole-1-hydroxy).  
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Fig. 2. HPLC chromatogram (upper) and structures (lower) of tebuconazole and metabolites A 
(tebuconazole-o-hydroxy), B (tebuconazole–carboxylic acid) and C (tebuconazole-1-hydroxy). 
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Table 1. Apparent Km and Vmax values for the formation of metabolite A and B+C using female 
Wistar rat microsomes.
Metabolite A Metabolite B+C
Vmax (nmol/min/mg microsomal protein) 0.028 0.25
Km (µM) 3.27 8.12
133 
 
 
Fig. 3 Tebuconazole concentration-dependent rate of formation of metabolite A (a) and B+C (b) in incubations 
with female rat liver microsomes. Results represent data of three independent experiments. 
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PBK model evaluation 
To evaluate the performance of the PBK model, which was developed without the use of in 
vivo data, model predictions were compared with kinetic data from the literature on blood 
concentrations of tebuconazole and excretion of tebuconazole and its metabolites. Hass et al. (2012) 
reported tebuconazole blood concentrations in rats that were orally exposed to 12.5 or 25 mg/kg body 
weight (bw) of tebuconazole in a mixture with other compounds. Blood samples were taken from two or 
three female rats 1-5 hrs after tebuconazole exposure. The blood concentrations of tebuconazole for the 
two dams in the lower dose group was reported to be between 1.7 and 2.7 μM, and for the three dams in 
the higher dose group between 3.7 and 25 μM [31] (Table 2). Table 2 shows that the predicted blood 
concentrations of tebuconazole upon a dose of 12.5 and 25 mg/kg bw were between 1.0-4.4 μM and 
2.5-10.4 μM , respectively, and thus close to the in vivo data reported by Hass et al. (2012).  
In vivo data on the cumulative excretion (urine and faeces) of tebuconazole and its metabolites 
by female Wistar rats that were orally exposed to 2 or 20 mg tebuconazole/kg bw, was also used for 
model evaluation [32]. We predicted the cumulative excretion of tebuconazole and its metabolites by 
assuming that tebuconazole metabolites are excreted immediately and that unchanged tebuconazole is 
not excreted and compared the predicted cumulative excretion with the reported in vivo data (Fig. 4). 
Fig. 4 shows that for both doses, the in vivo excretion after 24 hours was well predicted with the PBK 
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Fig. 3. Tebuconazole concentration-dependent rate of formation of metabolite A (a) and B+C 
(b) in incubations with female rat liver microsomes. Results represent data of three independent 
experiments.
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Hass et al. (2012) reported tebuconazole blood concentrations in rats that were orally 
exposed to 12.5 or 25 mg/kg body weight (bw) of tebuconazole in a mixture with other 
compounds. Blood samples were taken from two or three female rats 1-5 hrs after 
tebuconazole exposure. The blood concentrations of tebuconazole for the two dams in 
the lower dose group was reported to be between 1.7 and 2.7 μM, and for the three dams 
in the higher dose group between 3.7 and 25 μM [31] (Table 2). Table 2 shows that the 
predicted blood concentrations of tebuconazole upon a dose of 12.5 and 25 mg/kg bw 
were between 1.0-4.4 μM and 2.5-10.4 μM , respectively, and thus close to the in vivo 
data reported by Hass et al. (2012). 
In vivo data on the cumulative excretion (urine and faeces) of tebuconazole and its 
metabolites by female Wistar rats that ere orally exp sed to 2 r 20 mg t buconazole/
kg bw, was also used for model evaluation [32]. We predicted the cumulative excretion 
of tebuconazole and its metabolites by assuming that tebuconazole metabolites are 
133
6
P
B
K
 m
o
d
e
lin
g
 -
 in
 v
it
ro
 d
at
a 
fo
r 
d
e
ve
lo
p
m
e
n
ta
l t
o
xi
ci
ty
excreted immediately and that unchanged tebuconazole is not excreted and compared 
the predicted cumulative excretion with the reported in vivo data (Fig. 4). Fig. 4 shows 
that for both doses, the in vivo excretion after 24 hours was well predicted with the PBK 
model (within 1.2-fold difference), whereas the excretion at earlier time points was 2- to 
7-fold over-predicted.  
Table 2. Tebuconazole blood concentration range between 1 and 5 hours after dosing 12.5 mg/kg 
bw or 25 mg/kg bw tebuconazole, reported by Hass et al. (2012) and predicted by the PBK model. 
12.5 mg/kg bw 25 mg/kg bw
reported blood concentration (µM) 1.7-2.7 3.7-25
predicted blood concentration (µM) 1.0-4.4 2.5-10
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Fig.4 Cumulative excretion (% of dosed amount) in rat predicted with the PBK model (solid line) and reported in 
vivo (filled diamonds) after a single oral dose of 2 (a) or 20 (b) mg/kg bw [32]. 
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Sensitivity analysis 
Figure 5 shows the most sensitive model parameters as indicated by the normalized 
sensitivity analysis. It shows that the predictions of Cmax in the PBK model is most 
sensitive to the stomach emptying rate (ksto) and, at low doses, also to the fraction 
of liver tissue (VLc) and the Km and Vmax values for the reaction of the formation of 
metabolites B+C (Km B+C and Vmax B+C). 
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Translation of the in vitro concentration–response data into predicted 
in vivo dose–response data, application of bmd modeling on predicted 
dose–response data, and evaluation of the predictive value of the 
approach 
The fub of tebuconazole in ES-D3 culture medium and in the ex ovo chicken embryo 
culture medium was calculated to be 1.6 times higher and 3.0 times lower than that 
in rat blood, respectively. Corrections were made to take this difference into account 
when applying reverse dosimetry. Fig. 6 shows predicted dose–response data for rat by 
applying reverse dosimetry on in vitro concentration-response data from the ES-D3 
cell differentiation assay or from the ex ovo assay of chicken embryos. The predicted 
BMD10 values obtained from these predicted dose-response data are 11.4 and 1.9 mg/
kg bw/day, respectively (Table 4). 
To evaluate the predictive value of the approach, BMD10 values determined from 
predicted dose-response data were compared with BMD10 values determined from in 
vivo dose-response data as reported in two studies (Table 3). Developmental toxicity data 
on the incidence of skeletal variations or fetal external alterations following tebuconazole 
exposure were used to derive BMD10 values. For each endpoint, the lowest value of 
the models that passed the criteria for model fit was selected as the BMD10 value for 
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flow to fat, QLc=fraction of blood flow to liver, ksto=stomach emptying rate, PF=fat/blood partition coefficient, 
PL=liver/blood partition coefficient, PR=rapidly perfused tissue/blood partition coefficient, PS=slowly perfused 
tissue/blood partition coefficient. 
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Fig. 5. Normalized sensitivity coefficients of PBK model parameters for the predicted Cmax of 
tebuconazole in blood after oral administratio  to 2 (white bars), 12.5 (light grey bars) or 25 
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135
6
P
B
K
 m
o
d
e
lin
g
 -
 in
 v
it
ro
 d
at
a 
fo
r 
d
e
ve
lo
p
m
e
n
ta
l t
o
xi
ci
ty
developmental toxicity of tebuconazole. These values are presented in the supplementary 
material 1, Tables 3 and 4. Table 4 shows the range of in vivo BMD10 values derived for 
all reported endpoints, based on litter incidence or fetus incidence. From the data on 
tebuconazole-induced alterations as reported in European Commission (2007b), one 
BMD10 value was obtained, being 126 mg/kg bw/day, which is based on fetus incidence. 
From the data on skeletal variations reported by EPA (1992), BMD10 values ranging from 
23.6-169 mg/kg bw/day were derived when considering effects on individual fetuses. 
When BMD10 values were derived from these data based on litter incidences, BMD10 
values ranged from 8.5-91.3 mg/kg bw/day. The lowest BMD10 value determined from 
all available data was 8.5 mg/kg bw/day (relating to increased variations, based on 
litter incidences), which was used to compare with the BMD10 values derived from the 
predicted dose-response data. The dose–response data for this endpoint are presented 
in Fig. 6 for comparison with our predicted dose-response data.
Table 3. Developmental toxicity studies of tebuconazole in rat upon oral exposure.
Ref. Exposure Dose (mg/kg bw/day) Developmental endpoint
[32] a PM 6-15 10, 30, 100 Increased incidences of external alterations
[35] b GD 6-15 30, 60, 120 Increased incidences of skeletal variations
GD=gestational day, PM=post mating day 
a see Supplementary Table 3 for details of toxicity data
b see Supplementary Table 4 for details of toxicity data
Table 4. BMD10 values for developmental toxicity of tebuconazole in rat derived from predicted 
in vivo data applying reverse dosimetry of ES-D3 cell differentiation assay data and ex ovo assay 
of chicken embryos data, based on Cmax, and BMD10 values derived from in vivo data in rat. 
BMD10
(mg/kg bw/day)
Predicted using reverse dosimetry of data from the ES-D3 cell differentiation assay 11.4
Predicted using reverse dosimetry of data from the ex ovo assay of chicken embryos 1.9
In vivo 
based on fetus incidence a 126
based on litter incidence b 8.5c-91.3
based on fetus incidence b 23.6-169
a Based on data reported in [32]. Only data on fetus incidence are available.
b Based on data reported in [35]. See Supplementary Table 4 for all BMD10 values obtained for different 
endpoints. 
c the full BMD analyses and all BMD10 values obtained by different model fits were reported in [8]
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The BMD10 value determined from predicted dose-response data based on the 
ES-D3 cell differentiation assay was 1.3-fold higher compared to the lowest BMD10 
value obtained from the in vivo data. The BMD10 value determined from predicted 
dose-response data based on the ex ovo assay of chicken embryos was 4.5-fold lower 
compared to the lowest BMD10 value obtained from the in vivo data. These results 
indicate that the differences between BMD10 values based on our predicted data and 
BMD10 values based on in vivo data were smaller than 5-fold, indicating that we could 
quite accurately predict in vivo developmental toxicity dose levels of tebuconazole using 
the combined in vitro-in silico approach. The results also indicate that lower BMD10 
values were obtained when applying reverse dosimetry on data from the ex ovo assay 
of chicken embryos than when applying reverse dosimetry on data from the ES-D3 cell 
differentiation assay (Table 4).
discussion
The aim of the present study was to assess whether in vivo developmental toxicity can 
be predicted by PBK modeling-facilitated reverse dosimetry of in vitro toxicity data 
obtained in the ES-D3 cell differentiation assay and the ex ovo assay of chicken embryos. 
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Fig. 6 Predicted (squares and circles) and reported (triangles) dose-response data for developmental toxicity of 
tebuconazole in rats with fitted dose-response curves obtained with BMDS. Predicted dose-response data were 
obtained using PBK modelling-facilitated reverse dosimetry of data from the ES-D3 cell differentiation assay 
(circles) and from the ex ovo assay of chicken embryos (squares). Reported dose–response data were on the most 
sensitive endpoint as reported by EPA (1992).  
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Fig. 6. Predicted (squares and circles) and reporte  (triangles) dos -response data for develop-
mental toxicity of tebuconazole in rats with fitted dose-response curves obtained with BMDS. 
Predicted dose-response data were obtained using PBK modelling-facilitated reverse dosimetry 
of data from the ES-D3 cell differentiation assay (circles) and from the ex ovo assay of chicken 
embryos (squares). Reported dose–response data were on the most sensitive endpoint as 
reported by EPA (1992). 
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We have previously shown that with this approach based on the ES-D3 cell differentiation 
assay, dose levels causing developmental toxicity could be predicted within one order 
of magnitude for glycol ethers, retinoic acid and phenol [4, 12, 13]. In the present study 
we show that for the antifungal compound tebuconazole the BMD10 value derived 
from predicted developmental toxicity dose levels differed less than 5-fold compared to 
BMD10 values obtained from in vivo studies, indicating that the use of our combined in 
vitro-in silico approach is also promising to predict developmental toxicity of chemicals 
belonging to other chemical categories. 
It is of interest to note that the PBK model developed in the present study that was 
used for the reverse dosimetry is solely based on kinetic parameter values derived from 
in silico and in vitro experimental data, without adjustment to fit the in vivo data. 
The PBK model-predicted tebuconazole blood concentrations upon dosing of 12.5 and 
25 mg/kg bw tebuconazole were within the range of blood concentrations reported in 
an in vivo kinetic study (Table 2), indicating a good prediction of tebuconazole blood 
concentrations by the PBK model. The PBK model was also evaluated by comparing the 
predicted cumulative excretion of tebuconazole metabolites with reported in vivo data 
on the excretion of tebuconazole metabolites in female rats. The model over-predicted 
the total excretion throughout 72 hours, especially in the first 24 hours (Figure 4). This 
may be explained by the fact that in vivo mainly phase II metabolites are excreted [32] 
and that the formation of phase II metabolites is not described in the model. For our 
reverse dosimetry-based predictions, lack of the description of phase II metabolism 
is not considered a problem, assuming that the parent compound causes the toxicity. 
Therefore, in such cases, description of phase I metabolism is sufficient to describe the 
body clearance of the parent compound.
For the prediction of developmental toxicity by PBK modeling-facilitated reverse 
dosimetry, we assumed that the concentrations in the embryo/fetus are the same as 
the concentrations in the mother, and did not take the possible effects of the placental 
transfer on fetal concentrations into account. Placental transfer may play an important 
role in fetal bioavailability of chemicals and may thereby affect the developmental toxicity 
outcome of a chemical. We have previously demonstrated that we better predicted 
relative developmental toxicity potencies of antifungal compounds based on in vitro 
data from the ES-D3 cell differentiation assay or the ex ovo assay of chicken embryos, 
by combining these data with information on placental transfer in the in vitro BeWo 
model, a useful model to predict relative placental transfer rates of compounds [8, 9]. 
This suggests that differences in placental transfer of the antifungal compounds may 
play an important role in their differences in developmental toxicity potencies in vivo. 
We have shown that the placental transport rate of tebuconazole as determined in the 
BeWo model is almost as high as the transport rate of antipyrine, a model compound 
known to easily cross the placenta [8]. Therefore, we assumed that the placenta does not 
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affect the levels of tebuconazole that reach the fetus, and we assumed that tebuconazole 
levels in fetal blood equal those in maternal blood, so we did not include a specific 
fetal compartment in the PBK model. However, this assumption cannot be made for 
the chemicals that have a low placental transfer rate. Therefore, for such compounds a 
fetal compartment should be incorperated in the PBK model when using it for reverse 
dosimetry of in vitro developmental toxicity data. 
The present study shows that PBK modeling-facilitated reverse dosimetry of both the 
ES-D3 cell differentiation assay data and the ex ovo assay of chicken embryos data closely 
predicted in vivo developmental toxicity data of tebuconazole, indicating that both assays 
are useful to predict developmental toxicity of antifungal compounds. However, each 
assay has its own advantages and limitations. For instance, the ES-D3 cell differentiation 
assay is a relatively easy assay, whereas the ex ovo assay of chicken embryos is more labor 
intensive and requires special equipment and a well trained staff. However, unlike the 
ex ovo assay of chicken embryos, the ES-D3 cell differentiation assay cannot be used to 
study specific alterations induced by chemicals. Since both assays have their advantages 
and limitations, a combined and tiered testing strategy could be followed. The ES-D3 
cell differentiation assay combined with PBK-modeling facilitated reverse dosimetry 
could be regarded in a first tier to define compounds of high concern. In the second 
tier, the ex ovo assay of chicken embryos could be applied to detect specific alterations 
that may be induced. Such a testing strategy may provide valuable early information 
for prioritization and potentially also for risk assessment. 
In conclusion, we showed that PBK modeling-facilitated reverse dosimetry allows 
translation of in vitro concentration-response curves of tebuconazole obtained in the 
ES-D3 cell differentiation assay and the ex ovo assay of chicken embryos to in vivo dose-
response curves for developmental toxicity, enabling the derivation of a PoD, such as 
BMD10 values, for risk assessment without the use of in vivo studies. Since the method 
uses only in vitro assays and in silico models to predict the in vivo developmental 
toxicity of chemicals, it contributes to the 3Rs (replacement, reduction and refinement) 
of animal testing. 
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Supplementary Table 1. Physiological parameter values used for the rat PBK model [18]. 
Physiological parameters Values
Tissue volumes 
(percentage of body weight)
    liver 3.4
    fat 7.0
    richly perfused tissue 5.6
    slowly perfused tissue 67.6
    blood 7.4
Cardiac output (L · h-1 · kg bw-0.74) 15.0
Tissue blood flows 
(percentage of cardiac output)
    liver 25.0
    fat 7.0
    richly perfused tissue 51.0
    slowly perfused tissue 17.0
Supplementary Table 2. Rat tissue/blood partition coefficients.
partition coefficients
liver 10.1
fat 131.6
richly perfused tissue a 10.1
slowly perfused tissue b 5.7
a partition coefficient of liver was used for richly perfused tissue
b partition coefficient of muscle was used for slowly perfused tissue
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Supplementary Fig. 1. UV spectra of tebuconazole and its metabolites A, B, C. 
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Supplementary Table 3. Incidences of external alterations in rats exposed to tebuconazole, including BMD10 
values derived from the data reported in [32].  
 
 Dose (mg/kg bw/day) BMD10 (mg/kg 
bw/day)  Control 10 30 100 
      
No. pups examined 174 144 202 168  
External alterations 3 1 4 12 126.3 
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Supplementary Table 3. Incidences of external alterations in rats exposed to tebuconazole, 
including BMD10 values derived from the data reported in [32]. 
Dose (mg/kg bw/day)
BMD10 (mg/kg bw/day)Control 10 30 100
No. pups examined 174 144 202 168
External alterations 3 1 4 12 126.3
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Supplementary Table 4. Incidences of skeletal variations in rats exposed to tebuconazole, 
including BMD10 values derived from the data reported [35]. (Continued)
Dose (mg/kg bw/day) BMD10 (mg/kg bw/day)
Control 30 60 120
No. pups examined 144 137 127 116
Cervical vertebra 1 18 21 24 48 48.1
Cervical vertebra 2 29 40 38 48 39.3
Cervical vertebra 3 9 10 12 16 134.5
Cervical vertebra 4 0 5 2 13 118.8
Cervical vertebra 5 3 3 3 10 131.2
Cervical vertebra 6 1 2 2 6 168.8
Vertebral arch 6, left 1 2 3 14 114.7
Vertebral arch 6, right 0 2 6 13 100.3
Vertebral arch 7, left 50 53 49 66 34.9
Vertebral arch 7, right 45 53 51 65 30.8
Sternebra 2 4 3 3 15 118.5
Sternebra 6 0 0 1 4 150.6
Supernumerary ribs, left 14 20 18 26 90.0
Supernumerary ribs, right 15 23 19 24 113.6
Digit 2 proximal phalanx (l) 27 36 37 42 52.1
Digit 3 proximal phalanx (l) 0 3 5 9 133.5
Digit 4 proximal phalanx (l) 2 7 7 11 138.6
Metacarpal 5 (l) 0 0 2 4 157.5
Digit 2 proximal phalanx (r) 27 33 39 40 54.5
Digit 3 proximal phalanx (r) 0 3 4 8 141.0
Digit 4 proximal phalanx (r) 1 6 6 11 131.3
Metacarpal 5 (r) 0 0 2 5 147.4
Metatarsal (l) 18 24 18 31 84.9
Toe 2 proximal phalanx (l) 107 92 96 103 40.3
Toe 3 proximal phalanx (l) 81 70 78 87 23.6
Toe 4 proximal phalanx (l) 79 65 72 85 50.6
Metatarsal (r) 18 24 20 32 76.4
Toe 2 proximal phalanx (r) 110 96 105 105 37.6
Toe 3 proximal phalanx (r) 86 75 76 92 46.4
Toe 4 proximal phalanx (r) 81 71 74 91 45.3
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Supplementary Table 4. Incidences of skeletal variations in rats exposed to tebuconazole, 
including BMD10 values derived from the data reported [35]. (Continued)
Dose (mg/kg bw/day) BMD10 (mg/kg bw/day)
Control 30 60 120
No. litters examined 24 24 22 24
Cervical vertebra 2 14 17 17 20 8.5
Sacral vertebral arch 6 (r) 0 2 6 8 55.8
Digit 2 proximal phalanx (l) 14 14 16 18 45.8
Digit 3 proximal phalanx (l) 0 3 5 4 83.1
Digit 3 proximal phalanx (r) 0 3 4 4 91.3
Digit 4 proximal phalanx (r) 1 4 6 6 83.4
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cytotoxicity study used to estimate the fraction unbound 
In order to estimate the tissue/blood partition coefficients, the fraction of unbound 
tebuconazole (fub) in rat blood was determined using an approach developed by Gülden 
et al. (2002) to determine protein binding of chemicals. The fub was estimated based 
on the assessment of the increase of the EC50 value for tebuconazole cytotoxicity with 
increasing albumin concentrations, as described by [28] with slight modifications. To 
this end, cytotoxicity assays using BeWo cells were performed. The BeWo cell line (clone 
b30) was kindly provided by the Institute of Public Health of the Faculty of Health 
Sciences of the University of Copenhagen (Denmark) with permission from Dr. Alan 
Schwartz (Washington University, St. Louis, MO). BeWo b30 cells were cultured in 
DMEM (D5671, Sigma-Aldrich, Zwijndrecht, the Netherlands) supplemented with 10% 
(v/v) heat-inactivated FCS, 10,000 U/ml penicillin, 10 mg/ml streptomycin, and 2 mM 
L-glutamine. The cells were maintained in polystyrene cell-culture flasks (Corning, USA), 
under a humidified atmosphere of 5% CO2 at 37 °C. The cells were harvested by exposing 
to a 0.05% trypsin-EDTA solution and transferred to 96-well plate (Greiner bio-one). 
Experiments were performed with passages 26−33. For the experiments, cells were 
seeded at concentrations of 20 x 104 cells/ml in 100 μL culture medium into the inner 60 
wells of the 96-well plate and incubated for one day at 37°C and 5% CO2 in a humidified 
atmosphere to allow cell adherence. Then the cells were exposed to tebuconazole at 
concentrations up to 1000 μM (final solvent concentration: 0.2% DMSO) for one day, by 
dissolving tebuconazole in exposure medium (DMEM supplemented with 1% (v/v) heat-
inactivated FCS, 10,000 U/ml penicillin, 10 mg/ml streptomycin, and 2 mM L-glutamine) 
alone or in exposure medium supplemented with bovine serum albumin (BSA, molecular 
weight/ 66500) at concentrations of 2, 5, 7.5, 10 or 12.5 mg/ml. After incubation of one 
day, 20 μL MTT-1 reagent (Sigma-Aldrich, the Netherlands) was added to each well and 
the plates were incubated for another 3 hours. Then absorbance was measured at 450 nm 
using a SpectraMax M2 (Molecular Devices, Sunnyvale, USA). Three wells were used 
per treatment in each independent experiment. 1% Triton X-100 served as a positive 
control in all cytotoxicity assays. The cell viability was expressed as percentage of the 
solvent control (0.2% DMSO), with the solvent control set at 100% viability. Reproducible 
results were obtained from the treatments of negative and positive controls in all of 
the cytotoxicity assays. EC 50 values were determined with Graphpad Prism 5 using a 
four-parameter logistic model.
Fig. 1. shows that EC50 value of tebuconazole-induced cytotoxicity increases with 
increasing albumin concentrations. A linear correlation was obtained between the 
EC50 value and the albumin concentration described by Y=1.7838X+267.74 (Y = aX 
+ b, with Y=EC50 and X=albumin concentration, and values given for the slope (a) 
and the intercept (b) being the best fit). The fraction of tebuconazole unbound to 
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albumin (fub) was estimated by using the following equation: fub = b / EC50 where b is 
the intercept of the linear regression equation, and EC50 is the value in the presence of 
a certain concentration of albumin [28], in this case described by Y=1.7838X+267.74, 
with X=albumin concentration. Based on the equation fub = b / EC50, which can also 
be written as fub = 267.74 / (1.7838X+267.74) with X being the albumin concentration 
in µM, the fub in rat blood (fub, rat blood) was estimated, using albumin concentration in 
rat blood being 293 µM [29]. The fub, rat blood was estimated to be 0.34, which was used as 
input for the calculation of partition coefficients parameters.
Fig. 1 Relation between albumin concentration and EC50 value obtained in cytotoxicity assays 
with tebuconazole. Results represent EC50 values determined from at least three independent 
experiments (average ± SD are shown). 
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Corrections made to take the differences between the fub in culture medium compared 
with the fub in rat blood into account 
The unbound concentration in the in vitro culture medium (Cub, in vitro) was estimated by using 
the following equation: Cub, in vitro = C, in vitro  fub, in vitro, where the C, in vitro is the nominal concentration 
applied in the in vitro assay and fub, in vitro is the fub of tebuconazole in the culture medium, which was 
derived using the equation fub = b / EC50, which can also be written as fub = 267.74 / (1.7838X+267.74) 
with X being the albumin concentration in µM. The albumin concentration was 134 µM in the in vitro 
ES-D3 cell culture medium and 1277 µM in the ex ovo chicken embryo culture medium, as determined 
using the PierceTM BCA protein assay kit (Thermo, Rockford, the USA). The fub, in vitro in ES-D3 cell 
culture medium was to be 0.53 and the fub, in vitro in ex ovo assay of chicken embryo culture medium was 
calculated to be 0.11. Then the effect concentration in rat blood (C, rat blood), used for reverse dosimetry, 
was estimated by using the following equation: C, rat blood = Cub, in vitro / fub, rat blood.  
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correctio   to take the diff rences between the fub in culture 
medium compared with the fub in rat blood into account
The unbound concentration in the in vitro culture medium (Cub, in vitro) was estimated 
by using t following equation: Cub, in vitro = C, in vitro Î fub, in vitro, where the C, in vitro is the 
nominal concentration applied in the in vitro assay and fub, in vitro is the fub of tebuconazole 
in the culture medium, which was derived using the equation fub = b / EC50, which can 
also be written as fub = 267.74 / (1.7838X+267.74) with X being the albumin concentration 
in µM. The albumin concentration was 134 µM in the in vitro ES-D3 cell culture medium 
and 1277 µM in the ex ovo chicken embryo culture medium, as determined using the 
PierceTM BCA protein assay kit (Thermo, Rockford, the USA). The fub, in vitro in ES-D3 
cell culture medium was to be 0.53 and the fub, in vitro in ex ovo assay of chicken embryo 
culture medium was calculated to be 0.11. Then the effect concentration in rat blood 
(C, rat blood), used for reverse dosimetry, was estimated by using the following equation: 
C, rat blood = Cub, in vitro / fub, rat blood. 
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Pbk model for tebuconazole, built with in vitro and in silico data; 
species: rat
;=====================================================================
;Physiological parameters
;=====================================================================
;tissue volumes
BW = 0.250 {Kg} ; body weight rat (variable, dependent on study)
VFc = 0.07 ; fraction of fat tissue  reference: [18].
VLc = 0.034      ; fraction of liver tissue  reference: [18].
VBc = 0.074  ; fraction of blood  reference: [18].
VRc = 0.09-VLc  ; fraction of richly perfused tissue  reference: [18].
VSc=0.746-VFc  ; fraction of slowly perfused tissue reference: [18].
VF = VFc*BW  {L or Kg} ; volume of fat tissue (calculated)
VL = VLc*BW  {L or Kg} ; volume of liver tissue (calculated)
VB = VBc*BW   {L or Kg} ; volume of blood (calculated)
VR = VRc*BW   {L or Kg} ; volume of richly perfused tissue (calculated)
VS = VSc*BW  {L or Kg} ; volume of slowly perfused tissue (calculated)
;-------------------------------------------------------------------------------------------------------------------- 
;blood flow rates
QC = 15*BW^0.74/60 {L/min} ; cardiac output    reference: [18].
QFc = 0.07 ; fraction of blood flow to fat   reference: [18].
QLc = 0.25  ; fraction of blood flow to liver   reference: [18].
QRc = 0.76 - QLc ; fraction of blood flow to richly perfused tissue reference: [18].
QSc = 0.24 - QFc  ; fraction of blood flow to slowly perfused tissue reference: [18].
      
QF = QFc*QC  {L/min} ; blood flow to fat tissue (calculated)
QL = QLc*QC  {L/min} ; blood flow to liver tissue (calculated)
QS = QSc*QC   {L/min} ; blood flow to slowly perfused tissue (calculated)
QR = QRc*QC   {L/min} ; blood flow to richly perfused tissue (calculated)
;-------------------------------------------------------------------------------------------------------------------- 
; Intestinal lumen volumes, surfaces, absorption rates, transfer rates 
Papp  = 2E-3      ; apparent intestinal permeability coefficient in vivo {dm/min}
ksto  = 0.047         ; stomach emptying rate {/min}
Vdd   = 0.0012   ; duodenum volume {L}
SAdd  = 0.134     ; surface area {dm2}
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kabdd  = Papp*SAdd     ; absorption rate constant {L/min}
kin   =  0.0695  ; transfer rate to jj1 {/min} 
kdd = kin
Vjj1  = 0.0012      ; jejunum 1 volume {L}
SAjj1 = 0.134       ; surface area {dm2}
kabjj1  = Papp*SAjj1     ; absorption rate constant {L/min}
kjj1  = kin     ; transfer rate to jj2 {/min} 
Vjj2  = 0.0012   ; jejunum 2 volume {L}
SAjj2 = 0.134    ; surface area {dm2}
kabjj2  = Papp*SAjj2       ; absorption rate constant {L/min}
kjj2  = kin       ; transfer rate to jj3 {/min} 
Vjj3  = 0.0012    ; jejunum 3 volume {L}
SAjj3 = 0.134      ; surface area {dm2}
kabjj3  = Papp*SAjj3     ; absorption rate constant {L/min}
kjj3  = kin          ; transfer rate to jj4 {/min} 
Vjj4  = 0.0012    ; jejunum 4 volume {L}
SAjj4 = 0.134     ; surface area {dm2}
kabjj4  = Papp*SAjj4     ; absorption rate constant {L/min}
kjj4  = kin      ; transfer rate to jj5 {/min} 
Vjj5  = 0.0012      ; jejunum 5 volume {L}
SAjj5 = 0.134       ; surface area {dm2}
kabjj5  = Papp*SAjj5     ; absorption rate constant {L/min}
kjj5  = kin           ; transfer rate to il {/min} 
Vil   = 0.0012     ; ileum volume {L}
SAil  = 0.134      ; surface area {dm2}
kabil  = Papp*SAil     ; absorption rate constant {L/min}
kil   = kin    ; transfer rate to co {/min} 
 
kfe = 0.00033   ; transfer rate to feces {/min}
;=====================================================================
;Partition Coefficients
;=====================================================================
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PF = 131.56  ; fat/blood partition coefficient                              calculated using QSAR 
of: [25]
PL = 10.14  ; liver/blood partition coefficient   calculated using 
QSAR of: [25] 
PR = 10.14  ; richly perfused tissue/blood partition coefficient calculated using QSAR of: [25]
PS = 5.69  ; richly perfused tissue/blood partition coefficient calculated using QSAR of: [25]
;=====================================================================
;Kinetic parameters 
;=====================================================================
;Metabolism liver
;metabolites of tebuconazole, scaled maximum rate of metabolism 
VmaxAc = 0.028 {nmol/min/mg}  ; data derived from incubation experiment with female 
rat microsomes
VMaxA = VMaxAc/1000*35*VL*1000  {umol/min}
VMaxBCc = 0.25 {nmol/min/mg}  ; data derived from incubation experiment with female 
rat microsomes
VMaxBC = VMaxBCc/1000*35*VL*1000 {umol/min} 
;metabolites of tebuconazole, affinity constants (umol/L)
KmA = 3.27 ; data derived from incubation experiment with female rat microsomes
KmBC = 8.115 ; data derived from incubation experiment with female rat microsomes
;=====================================================================
;Run settings
;=====================================================================
;Molecular weight
MW = 307.82 ; Molecular weight tebuconazole
   
;oral dose 
ODOSEmg = 12.5 {mg/kg bw} ; ODOSEmg = given oral dose in mg/kg bw
ODOSEumol2 = ODOSEmg*1E-3/MW*1E6  {umol/ kg bw} ; ODOSEumol2 = given oral dose 
recalculated to umol/kg bw
ODOSEumol=ODOSEumol2*BW;    ; ODOSEumol = umol given 
oral 
;time
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Starttime = 0  ; in min
Stoptime = 14400  ; in min
;=====================================================================
;Model calculations
;=====================================================================
;stomach
;ASt  = amount in stomach
Ast’  = -ksto*Ast+pulse(ODOSEumol, 0, 1440) - pulse(ODOSEumol,Tstop, 1440) ; Tstop stop time of dosing 
(min)
Tstop=14400
Init ASt =0
;-------------------------------------------------------------------------------------------------------------------- 
;intestines, divided in 7 compartments
;Add  = Amount tebuconazole in duodenum compartment (umol)
Cdd   = Add/Vdd
Add’  = ksto*Ast - kdd*Add - kabdd*Cdd
Init Add  =  0
;Ajj1 = Amount tebuconazole in jejunum compartment 1 (umol)
Cjj1  = Ajj1/Vjj1
Ajj1’ = kdd*Add - kjj1*Ajj1 - kabjj1*Cjj1
Init Ajj1  = 0
;Ajj2 = Amount tebuconazole in jejunum compartment 2 (umol)
Cjj2  = Ajj2/Vjj2
Ajj2’ = kjj1*Ajj1 - kjj2*Ajj2 - kabjj2*Cjj2
Init Ajj2  = 0
;Ajj3 = Amount tebuconazole in jejunum compartment 3 (umol)
Cjj3  = Ajj3/Vjj3
Ajj3’ = kjj2*Ajj2 - kjj3*Ajj3 - kabjj3*Cjj3
Init Ajj3  = 0
;Ajj4 = Amount tebuconazole in jejunum compartment 4 (umol)
Cjj4  = Ajj4/Vjj4
Ajj4’ = kjj3*Ajj3 - kjj4*Ajj4 - kabjj4*Cjj4
Init Ajj4  = 0
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;Ajj5 = Amount tebuconazole in jejunum compartment 5 (umol)
Cjj5  = Ajj5/Vjj5
Ajj5’ = kjj4*Ajj4 - kjj5*Ajj5 - kabjj5*Cjj5
Init Ajj5  = 0
;Ail = Amount tebuconazole in ileum compartment (umol)
Cil  = Ail/Vil
Ail’ = kjj5*Ajj5 - kil*Ail - kabil*Cil
Init Ail  = 0
;Aco = Amount tebuconazole in colon (umol)
Aco’ = kil*Ail - kfe*Aco
Init Aco  = 0
ACco’ = kil*Ail
Init ACco  = 0    ; cumulative amount reaching colon
;--------------------------------------------------------------------------------------------------------------------
;feces
;AFA = amount tebuconazole in feces (umol)
AFe’ = kfe*Aco
Init AFe  = 0
;-------------------------------------------------------------------------------------------------------------------- 
;liver compartment
;AL = Amount tebuconazole in liver tissue, umol
AL’ =  QL*(CB - CVL) + kabdd*Cdd + kabjj1*Cjj1 + kabjj2*Cjj2 + kabjj3*Cjj3 + kabjj4*Cjj4 + kabjj5*Cjj5 + 
kabil*Cil - AMA’  - AMBC’ 
Init AL = 0
CL = AL/VL
CVL = CL/PL
;AMA = amount tebuconazole metabolized to metabolite A
       AMA’ = VmaxA*CVL/(KmA + CVL)
       init AMA = 0
;AMBC = amount tebuconazole metabolized to metabolite B+C
       AMBC’ = VmaxBC*CVL/(KmBC + CVL)
       init AMBC = 0
;liver compartment
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CL = AL/VL
CVL = CL/PL
;formed metabolites
AMtotal= AMA+AMBC    ; total metabolites formed
PAMtotal = AMtotal/ODOSEumol*100  ; percentage of total metabolites formed 
;-------------------------------------------------------------------------------------------------------------------- 
;fat compartment
;AF = Amount tebuconazole in fat tissue (umol)
       AF’ = QF*(CB-CVF) 
       Init AF = 0
       CF = AF/VF
       CVF = CF/PF
;-------------------------------------------------------------------------------------------------------------------- 
;tissue compartment richly perfused tissue
;AR = Amount tebuconazole in richly perfused tissue (umol)
       AR’ = QR*(CB-CVR) 
       Init AR = 0
       CR = AR/VR
       CVR = CR/PR
;-------------------------------------------------------------------------------------------------------------------- 
;tissue compartment slowly perfused tissue
;AS = Amount tebuconazole in slowly perfused tissue (umol)
       AS’ = QS*(CB-CVS) 
       Init AS = 0
       CS = AS/VS
       CVS = CS/PS
;-------------------------------------------------------------------------------------------------------------------- 
; blood compartment      
;AB = Amount tebuconazole in blood (umol)
      AB’ = (QF*CVF +  QL*CVL  + QS*CVS + QR*CVR - QC*CB) 
      Init AB = 0
      CB = AB/VB
      AUC‘ = CB  ;umol*min/L
      Init AUC = 0
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;=====================================================================
;Mass balance calculations
;=====================================================================
Total = ODOSEumol 
Calculated = ASt + Add + Ajj1 + Ajj2 + Ajj3 + Ajj4 + Ajj5 + Ail + Aco+ AFe + AL + AMA + AMBC + AF 
+ AS + AR + AB

General discussion, future perspectives 
and conclusions
C H A P T E R  7
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main findinGs
Determination of safe human exposure levels of chemicals in toxicological risk 
assessments largely relies on animal toxicity data. In these toxicity studies, the highest 
number of animals are used for reproductive and developmental toxicity testing [1]. 
Because of economic and ethical reasons, there is large interest in the development of in 
vitro and/or in silico test systems as alternatives for the animal studies. The aim of the 
present thesis was to evaluate the applicability of combined in vitro approaches taking 
toxicokinetic and toxicodynamic aspects into account, as well as of an integrated in 
vitro and in silico approach for prediction of developmental toxicity using a series of 
antifungal compounds as the model compounds.
Transplacental transfer of compounds is highly likely to play an important role in 
developmental toxicity and should therefore be taken into account when predicting in 
vivo developmental toxicity based on in vitro toxicity data. In Chapter 2, we focused on 
the development and validation of an in vitro model to obtain kinetic information on 
placental transfer. Placental transfer of compounds has been studied using the human ex 
vivo placental perfusion model. However, this method is laborious and dependent on the 
availability of fresh human placenta, hampering its use for the assessment of large numbers 
of compounds. An in vitro placental barrier model using BeWo b30 cells was assessed as an 
alternative to the ex vivo system to predict placental transfer. To this end, BeWo b30 cells, 
derived from a human choriocarcinoma, were grown on transwell inserts to form a cell 
layer, separating an apical maternal compartment from a basolateral fetal compartment. 
For a set of nine selected model compounds, including the reference compound antipyrine, 
the transport velocity from the apical to the basolateral compartment was determined. 
Relative transport rates obtained were compared with the transfer indices (a measure for 
the transport relative to antipyrine) of these compounds obtained in ex vivo placental 
perfusion studies as reported in the literature. The relative transport rates in the in vitro 
BeWo model were in very good correlation (R2 = 0.95) with the transfer indices reported for 
the ex vivo placental model. This demonstrated that the BeWo model could be a valuable 
in vitro model to predict relative placental transfer of compounds.
In Chapter 3, we investigated the applicability of the ES-D3 cell differentiation 
assay combined with the in vitro BeWo transport model to predict the relative in vivo 
developmental toxicity potencies of five selected model antifungal compounds. To this 
end, the in vitro developmental toxicity of the five antifungal compounds was investigated 
by determining the effect concentrations that inhibit the differentiation of ES-D3 cells 
into beating cardiomyocytes. The BeWo transport model, consisting of BeWo b30 cells 
grown on transwell inserts and mimicking the placental barrier, was used to determine 
the placental transport velocity of the selected antifungal compounds relative to that of 
the reference compound antipyrine. In a next step the ES-D3 cell differentiation data were 
first compared to benchmark doses (BMDs) for in vivo developmental toxicity as derived 
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from data reported in the literature. Correlation between the benchmark concentration 
for 50% effect (BMCd50 values), obtained in the ES-D3 cell differentiation assay, with 
in vivo BMD10 values for developmental toxicity showed a reasonable correlation (R2 = 
0.57). When the ES-D3 cell differentiation data were combined with the relative transport 
rates obtained from the BeWo model, the correlation with the in vivo data increased 
profoundly (R2 = 0.95). This shows that the ES-D3 cell differentiation assay is able to 
better predict the in vivo developmental toxicity potencies of antifungal compounds 
when combined with the BeWo transport model, than as a stand-alone assay.
To validate this combined in vitro approach to predict in vivo developmental toxicity, 
we combined ES-D3 cell differentiation data of six novel triazole antifungal compounds 
with their relative transport rates obtained from the BeWo model and compared the 
obtained ranking to the developmental toxicity ranking as derived from in vivo data 
(Chapter 4). The data obtained show that the combined in vitro approach provided a 
correct prediction for the relative in vivo developmental toxicity, whereas the ES-D3 cell 
differentiation assay as stand-alone did not. It was concluded that these data validated 
the combined in vitro approach for developmental toxicity, previously developed with 
a set of reference azoles, for a set of six novel triazoles. We suggest that this combined 
model, which takes both toxicodynamic and toxicokinetic aspects into account, should 
be further validated for other chemical classes of developmental toxicants.
Although the ES-D3 cell differentiation assay, when combined with the BeWo 
transport model, has been shown to be useful to predict the relative developmental 
toxicity potency of the investigated compounds, it is limited to the evaluation of one 
phenotypic endpoint, i.e. the differentiation of embryonic stem cells into contracting 
cardiomyocytes, and can therefore not be used to detect specific structural alterations 
induced by chemicals. In Chapter 5, we investigated the applicability of the ex ovo assay 
of chicken embryos to predict the specific structural alterations induced by the five 
antifungal compounds that were used in Chapter 3 and investigated if the combination 
of the assay with placental transfer information would improve its predictive capacity. 
The ex ovo assay assesses developmental toxic potential of compounds based on well-
defined morphological endpoints. Each compound produced a characteristic pattern 
of alterations. The BMC50 values for the in vitro effect were compared with the in vivo 
BMD10 values to assess the potential of the ex ovo assay of chicken embryos to predict 
in vivo developmental toxicity. When the toxicity data from the ex ovo assay were 
combined with the relative transport rates from the BeWo model, the correlation with 
the in vivo data were better than when the toxicity data from the ex ovo assay were used 
without taking differences in placental transfer rates into account. This revealed that the 
ex ovo assay of chicken embryos is able to assess the teratogenic potential of antifungal 
compounds, and, when combined with the in vitro BeWo transport model, is able to 
better predict the relative in vivo prenatal developmental toxicity.
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With the help of the in vitro assays that assess kinetic processes, such as the BeWo 
cell transport model, the predictive value of in vitro developmental toxicity tests can 
be improved. However, the challenge of predicting developmental toxicity using in 
vitro assays still remains that the effect concentrations obtained from the in vitro 
assays cannot be used for risk assessment, because risk assessment requires in vivo 
dose response curves from which points of departure to define safe levels of exposure 
for humans can be derived. Therefore, in vitro concentration-response curves need to 
be translated into in vivo dose-response curves to enable the use of in vitro toxicity data 
in risk assessment. In Chapter 6, we translated in vitro concentration–response data 
of the antifungal compound tebuconazole, obtained in the ES-D3 cell differentiation 
assay and the ex ovo assay of chicken embryos, into predicted in vivo dose–response 
data using physiologically based kinetic modelling-facilitated reverse dosimetry. The 
predicted in vivo dose–response data were used to derive BMD10 values for rat, which 
were compared with BMD10 values derived from toxicity data in rats as reported in 
the literature. The results show that the BMD10 values from predicted dose–response 
data from both assays are in concordance with BMD10 values derived from in vivo data 
(within 5-fold difference). This revealed that physiologically based kinetic modeling is 
a promising tool to predict in vivo dose-response curves based on the results of in vitro 
toxicity assays, and may therefore be used to set a point of departure for deriving safe 
exposure limits in risk assessment.
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General discussion and fuTure PersPecTiVes
The present thesis shows, for antifungal compounds, the importance of taking placental 
transfer of compounds into account when predicting developmental toxicity with in vitro 
methods. The thesis also provided the proof-of-principle that for the selected antifungal 
compound tebuconazole, in vitro concentration‐response curves can be converted into 
in vivo dose‐response curves for developmental toxicity, in principal suitable for risk 
assessment, using PBK modeling with a reverse dosimetry approach. These results show 
the feasibility of combined in vitro approaches taking toxicokinetic and toxicodynamic 
aspects into account, and the potential of the integrated in vitro-in silico approach for 
predicting developmental toxicity of chemicals belonging to the antifungal class. The 
outcomes of the present thesis can be discussed in a wider perspective on what would be 
topics of interest to include and consider when applying the combined in vitro approaches 
and the integrated in vitro-in silico approach in predicting developmental toxicity for 
other chemicals of diverse nature, including both existing and new chemicals, in toxicity 
testing and risk assessment. The topics that are of relevance and importance to discuss 
in this respect in some more depth include 1) the in vitro developmental toxicity assay 
used, 2) the role of the placenta in contributing to developmental toxicity, 3) the use and 
development of PBK models, 4) the in vivo data available and their use for validation 
purposes and 5) future perspectives and conclusions. In the following sections these 
aspects are discussed in more detail. 
ad 1) The in vitro developmental toxicity assay used
In the present thesis two in vitro developmental assays were applied, i.e. the ES-D3 cell 
differentiation assay and the ex ovo assay of chicken embryos. The possibilities and 
limitations of the two assays for developmental toxicity testing are discussed in the 
present section. Besides, other in vitro assays that may be considered for characterizing 
developmental toxicity are presented. 
The ES-D3 cell differentiation assay
In the present thesis, the ES-D3 cell differentiation assay of the EST was used to 
determine the developmental toxicity potency of antifungal compounds. The EST is 
the only validated animal-free assay among in vitro tests for developmental toxicity 
that does not require the use of primary animal tissues. The readout parameter in this 
assay is the inhibition of the differentiation of ES-D3 cells into beating cardiomyocytes 
by tested chemicals, while in vivo studies in rats and mice have shown that antifungal 
compounds induce skeletal alterations of fetuses [2]. This indicates that the determination 
of inhibition of differentiation into beating cardiomyocytes may not be a direct endpoint 
for predicting developmental toxicity of antifungal compounds. However, it is not the 
intention of the ES-D3 cell differentiation assay to specifically predict concentrations 
affecting cardiac development, but rather to use this endpoint as a sensitive in vitro 
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readout parameter for developmental toxicity [3]. The present thesis shows the usefulness 
of chemical-induced inhibition of ES-D3 cell differentiation into beating cardiomyocytes 
as the readout parameter when predicting in vivo adverse effect concentrations of 
antifungal compounds. Based on the obtained in vitro adverse effect concentrations, the 
relative in vivo developmental toxicity potencies of series of antifungal compounds and 
even the in vivo developmental toxic dose level of the antifungal compound tebuconazole 
were well predicted. The usefulness of the ES-D3 cell differentiation assay using this 
classical readout parameter in the prediction of the in vivo developmental toxicity has 
also been reported for other classes of chemistry, such as valproic acid, glycol ethers, 
retinoids and phenols [4-10]. The results of the present thesis provide further support for 
the conclusion that the in vitro ES-D3 cell differentiation assay may also be appropriate 
to predict developmental toxicity of other classes of chemicals of diverse nature. 
One may argue that other developmental toxicity endpoints such as developmental 
neurotoxicity, developmental immune toxicity or developmental skeletal toxicity might 
not be well predicted using the inhibition of cardiomyocyte differentiation as readout 
parameter. Therefore, for the compounds that are known to induce other developmental 
toxicity endpoints, it could be evaluated whether in vivo potency rankings or in vivo toxic 
dose levels could be better predicted based on in vitro effect concentrations in in vitro 
assays characterizing other adverse endpoints [11-13]. However, for new compounds for 
which no upfront knowledge on the type of adverse effects is available, the investigation 
on the classical endpoint in the ES-D3 cell differentiation assay would provide a good 
starting point for predicting in vivo developmental toxicity.
Other than the phenotypic endpoints, such as the contraction of the cardiomyocytes, 
the ES-D3 cell differentiation assay has also been used to evaluate the effect of chemicals 
on the expression of specific genes for neuronal differentiation [14-16], osteoblast 
differentiation [17, 18], endothelial differentiation [18] or cardiac differentiation [19]. 
These readouts may be useful to predict the influence on specific developmental pathways, 
such as neurodevelopment, bone formation, vasculogenesis and/or angiogenesis, or heart 
development, respectively. When using transcriptome approaches, one has to take into 
consideration, however, that not all gene expression changes necessarily lead to an 
effect, deleterious or beneficial. One study compared the effect of a developmentally 
toxic compound, flusilazole, on gene expression regulation and on the ES-D3 cells 
differentiation into cardiomyocytes. Although transcriptomic profiling identified effects 
already at lower concentrations, reflecting a higher sensitivity than the phenotypic 
endpoint, it is difficult to establish adversity of a compound-induced effect based on 
gene expression alone [19], as the identification of regulation of gene expression does 
not necessarily represent an adverse biological response. Thus, an important challenge 
in the use of toxicogenomics for hazard characterization is to determine adversity of the 
observed compound-induced effect. Nevertheless, to obtain information on mechanisms 
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underlying developmental toxicity, the ES-D3 cell differentiation assay could be combined 
with transcriptomics analyses, which can be used to group compounds in classes based 
on toxicity mechanisms [20]. This may facilitate screening of compounds for possible 
developmental toxicity when no data are available. 
The ex ovo assay of chicken embryos
The second in vitro assay used in the thesis was the ex ovo assay of chicken embryos. In 
this assay, compound-induced specific structural alterations can be detected. Neural crest 
cells (NCCs) are the cells that migrate from the neural primordia throughout the embryo 
and contribute to morphogenesis. Malfunction of NCCs leads to dysmorphologies 
which are considered to result in in vivo skeletal alterations, such as cleft palate or 
other craniofacial changes [21]. Using chicken embryos, the investigation on NCCs 
and their migratory behavior in the avian embryos can be performed, which makes the 
assay suitable for studying developmental toxicity of compounds that my induce skeletal 
alterations, such as the antifungal compounds of the present thesis. In the present thesis, 
we have demonstrated that with the ex ovo assay of chicken embryos, we could discover 
different alteration patterns of different antifungal compounds, with good correlation 
to the in vivo findings. 
The exposure of chicken embryos can be conducted by injecting through the eggshell 
(in ovo) [23-27] or in a culture medium outside an egg (ex ovo). It has been reported that 
when performing toxicity assays using chicken eggs in ovo, there is limited visibility of 
the embryo and solubility of the tested chemicals may be a problem [28]. The exposure 
position in the egg is a critical factor and when the exposure is done by injection into 
the egg, the concentration of the chemical to be studied may not be evenly distributed. 
It has been shown that the toxicity of thiram injected in the yolk was two-times less 
than when it was injected in the air chamber, which is probably caused by a difference 
in distribution [27]. Therefore, the exposure route has been shifted to a so-called shell-
less (ex ovo) system in which embryos are exposed to a culture medium outside an 
egg [28-30]. When cultured ex ovo, in a developmental context, normal growth was 
shown with regard to weight and size as well as cartilage, bone, and myelinated nerves 
of embryos [28]. However, although the ex ovo technique used in the present assay is 
a more advanced method for exposure, it has also its limitations. In the present thesis, 
test compounds were added to the culture media from 1000 times concentrated stock 
solutions in DMSO (final DMSO concentration 0.1%). This DMSO concentration is 2.5 
times less than its concentration in most other in vitro assays, such as the ES-D3 cell 
differentiation assay. Using this final concentration of DMSO the concentrations we 
could reach for most antifungal compounds were above 300 µM, while it was 50 µM for 
tebuconazole, and in the present thesis these concentrations were high enough to allow 
the detection of adverse effects. However, for compounds that are less toxic and need 
higher concentrations to induce toxicity, this assay may appear inappropriate. To find 
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a solution to this issue, it should be studied whether a higher concentration of solvent 
has any influence on the normal growth of the embryo and can be used. 
Different studies have reported the usefulness of the chicken embryos test for 
detecting structural alterations of chemicals. Most available studies applied in ovo 
exposure by injecting through the eggshell, as the shift of exposure route to a shell-less 
system has only been introduced for a relatively short time. Salzgeber and Salaun (1965) 
and Jurand (1966) established that thalidomide produces in the chicken embryos in an 
in ovo assay essentially the same kind of limb alterations as it does in human and rabbit 
embryos [23, 24]. Another in ovo study has shown captopril to exert angiogenesis and 
vascular alterations in a chicken embryo model, and this model has been suggested to be 
a useful system to quantify the anti-angiogenic activity of compounds [31]. In addition, 
Verrett et al. investigated the toxicity of 80 chemicals that are used as food additives upon 
their administration to developing chicken embryos in ovo. Results obtained indicated 
that the chicken embryo test is capable of demonstrating the teratogenic potential of 
these compounds and that it is selective and does not respond nonspecifically to any 
agent introduced during development [25]. Given that the ex ovo system supports normal 
growth of chicken embryos as good as the in ovo system, with regard to weight and size 
as well as cartilage, bone, and myelinated nerves of embryos [28], it can be concluded 
that the ex ovo assay may be very likely to be able to observe the above mentioned 
structural alterations of the chemicals, although it may predict different toxicity potencies 
than the in ovo assay due to difference in solubility of chemicals in the two systems. 
Support for the ex ovo assay can be found in the results from a study showing that a 
variety of structural alterations such as retarded growth, abnormal heart development, 
macrosomia, exencephaly, etc. observed in chicken embryos exposed to glucose in an 
ex ovo assay, were similar to those reported in mammalian embryos as a consequence 
of diabetic pregnancy [29]. Based on these findings, the ex ovo assay of chicken embryo 
seems to be a valuable tool to predict developmental toxic and teratogenic potential of 
chemicals of diverse nature not being limited to the class of antifungal compounds. 
Other in vitro assays that may be considered for characterizing developmental toxicity
Given that in vitro assays represent only part of the complexity of the whole developing 
conceptus and its maternal environment, one may question the possibility to develop 
an in vitro assay that adequately captures all aspects of this important endpoint in 
toxicity studies. Although the present thesis focused on two toxicity assays, i.e. ES-D3 
cell differentiation assay and the ex ovo assay of chicken embryos, and proved their 
usefulness and applicability for predicting developmental toxicity, one should be aware 
that these two assays may not be the most relevant to study all characteristics that may 
relate to developmental toxicity. The applicability of a test may vary with the class of 
compounds tested, depending e.g. on the mechanism of toxic action and the window 
of exposure during which in a pregnancy the adverse effect is induced.
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An important mode of action underlying developmental toxicity can be endocrine 
disruption. Awareness about the long-term health consequences associated with 
exposure to endocrine disrupting chemicals (EDCs) during intrauterine life has 
been raised [32]. During particularly vulnerable stages of development, the course of 
development of many tissues is regulated by endogenous steroid hormones along with 
other endocrine and paracrine factors [32]. EDCs are likely to influence the critical 
steps of hormonal development of the fetus [33]. Besides, some EDCs are capable of 
altering the hormonal balance in the placenta. For instance, endosulfan has a slight 
inhibiting effect, while methomyl, pirimicarb, propamocarb, and iprodion have inducing 
effects on placental aromatase activity [34], and 2,3,7,8-tetrachloro-dibenzo-p-dioxin 
(TCDD) increases oestradiol secretion, which suggests that it also affects aromatase 
activity in placental tissue cultures [35]. The antifungal compounds used in this thesis 
are known for their abilities to inhibit cytochrome enzymes [2], and in particular may 
reduce estrogen biosynthesis through CYP19 aromatase inhibition. As estrogens are 
important in placental development, particularly in rats, reducing the conversion of 
androgens to estrogens may induce inappropriate development of the placenta [36, 37]. 
Moreover, some medicinal products to which pregnant women are commonly exposed 
affect placental steroidogenesis [38]. Smoking also affects placental steroidogenesis 
[39]. In animal and human studies offsprings affected by EDCs are not only born 
with congenital abnormalities but may also suffer from several health and behavioral 
problems throughout their lifespan, such as demonstrated for diethylstilbestrol (DES) 
and polychlorinated biphenyls (PCBs) [40]. 
A battery of different in vitro testing approaches have been established by the OECD, 
including receptor binding and transactivation assays, minced testis and aromatase assays 
[41], aiming to assess the risks associated with chemicals that have endocrine disrupting 
properties. These assays are not specifically developed for predicting developmental 
endocrine disruption during pregnancy, but these tests could be taken into consideration 
when considering in vitro assays for developmental toxicity [42]. 
ad 2) The role of the placenta in contributing to developmental toxicity
A second topic to consider in some more detail when applying the combined in vitro 
approaches and the integrated alternative approach of the present thesis is the role of 
the placenta and how that can be best taken into account. The placenta is a key organ 
in fetal growth and development because it controls the exchange of nutrients and 
hormones between the mother and the fetus. It also interferes with compound delivery 
to the fetus by expressing active membrane transporters and xenobiotic metabolism 
enzymes. Besides, chemical-induced toxicity in the placenta may contribute to the 
occurrence of developmental adverse effects [43]. Therefore, understanding the effect 
of xenobiotics on the placenta and also the effect of the placenta on the xenobiotics 
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increases insight in prediction of developmental toxicity. In the present thesis we have 
demonstrated the importance of including placental transfer information in predicting 
in vivo developmental toxicity using in vitro techniques. In this section, characteristics 
of i) placental transfer, ii) placental metabolism and iii) placental toxicity are discussed 
that may need future attention when developing novel and improved assays for in vitro 
and in silico toxicity testing of developmental toxicity.
Placental transfer
In the present thesis, we have proven that the BeWo transport model is capable of 
predicting relative placental transfer rates for a set of 9 heterogeneous compounds. 
Subsequently, for two groups of antifungal compounds, the usefulness of including 
relative placental transfer rates obtained in the BeWo transport model for predicting 
developmental toxicity based on in vitro assays was demonstrated. The BeWo transport 
model can be used as an appropriate model for placental transfer and can provide 
valuable information for improving the prediction of developmental toxicity, its use is 
limited, however, by the fact that it only predicts transport rates in a relative, but not an 
absolute way. It should also be noted that the BeWo transport model is a simplification 
of the in vivo placental transfer system, with several characteristics being different 
from the in vivo situation, e.g. circulation, protein binding, flow rate and the volumes 
of maternal and fetal compartments. As a result, the BeWo cell model may not be 
suitable to determine the absolute transport rates of compounds. The relative Papp 
value seems to be a “rough approximation” that can be used as an initial approach to 
estimate the relative placental transport and resulting fetal bioavailability. Placental 
transfer is a complex process, and a more sophisticated method may be needed for a 
more accurate quantitative determination of fetal bioavailability. However, our intention 
was to demonstrate, in a simple model and in a relative and not an absolute way, that 
placental transfer is important and that taking it into account can improve the quality 
of the predictions for the relative developmental toxicity based on in vitro assays. In the 
present thesis we, for the first time, combined the in vitro developmental toxicity values 
with relative placental transfer data obtained in the BeWo model, and showed that in 
this way adequate predictions could be made. 
Given the good correlation obtained between the placental transfer rates as 
determined from the BeWo transport model and as reported in the literature based on 
ex vivo human placental perfusion method that uses term placenta, it may be concluded 
that the BeWo model is especially relevant to model the last period of pregnancy. Since 
many structural abnormalities are induced at early stages of pregnancy [44], it seems 
important to predict placental transfer at these early stages. In this respect it must be 
noted that it is not clear how well the BeWo model and the ex vivo placental model 
predict placental transfer at early stages of pregnancy. Therefore, knowledge is needed 
on whether placental transfer in early stages of pregnancy differs from placental transfer 
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in the last period of pregnancy, in order to determine how well the BeWo model predicts 
placental transfer in these critical stages of pregnancy.  
The placenta expresses a number of transporter proteins. In the syncytiotrophoblast 
of the placenta, various transporters have been found both in the brush-border 
(apical membrane) facing maternal blood and the basolateral membrane close to 
fetal capillaries. Differential distribution of transporters between the maternal and 
fetal sides of the placental membrane might have profound effects on the behavior 
of compounds in transplacental transfer [45]. Multiple studies in several species 
including human suggest that several ABC (ATP binding cassette) transporters, 
and in particular P-glycoprotein (P-gp), multidrug resistance proteins (MRPs) and 
breast cancer resistance protein (BCRP), decrease fetal exposure to xenobiotics [46-
49]. It has also been shown that transporters mediating the transfer of amino acids, 
glucose (GLUTs) and fatty acids (FATPs) are expressed in plasma membranes of 
the syncytiotrophoblast. and mediate eff lux of specific nutrients from the placenta 
into the fetal circulation [50]. Several of these transporters are also expressed in 
BeWo cells. Inhibition studies reported that MRP1 and BCRP are expressed in 
these cells [51, 52]. BeWo cells also express the transporter of neutral amino acids 
including several essential amino acids as seen in human placental tissue [53]. One 
study showed that accumulation of P-gp substrates by BeWo cells was significantly 
enhanced in the presence of a typical P-gp inhibitor, cyclosporine, indicating the 
presence of P-gp in BeWo cells [54]. On the contrary, another study demonstrated 
that in BeWo cells the activity of P-gp transporter seems to be limited [51]. Obviously 
further studies are needed with a wider selection of substrates to further evaluate the 
transporter activity or expression in the BeWo cell model. Nevertheless, the BeWo 
cell model seems to exhibit several relevant transporter activities. Although in the 
present thesis it was not intended to determine transporters involved but rather to 
define relative Papp values for transport from the maternal to the fetal side, to be 
used to adjust the BMC50 values obtained from the toxicity assays, it would be of 
importance to characterise to a further extent whether the BeWo cell model is a 
suitable model to study the relative transport rate of compounds that are substrates 
of transporters.
Another factor that may influence placental kinetics and thus developmental 
toxicity is protein binding. Compounds that are protein bound, usually to albumin 
or α 1-acid glycoprotein, at the maternal or fetal side do not cross the placenta [55]. 
Therefore, plasma protein gradients between mother and fetus can also influence 
transfer. One example is propofol, which is highly protein bound, and in a human 
perfused placental system, the total propofol concentration in the fetal vein increased 
significantly with increasing albumin concentration in the fetal circulation, with 
the concentration of free propofol remaining unchanged [57]. Although the BeWo 
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transport model, as an in vitro system, seems suitable for studying the influence 
of protein binding on transfer by applying different albumin concentrations in the 
apical and basolateral chambers, we did not find a good correlation between relative 
transport rates in the BeWo model and in the ex vivo perfused placenta system when 
the same concentrations of albumin were used in both systems [58]. This may be related 
to the fact that the in vitro BeWo model is a static system, without flow of perfusates, 
whereas the ex vivo model is a dynamic system including flows of maternal and fetal 
perfusates controlled by peristaltic pumps. For antifungal compounds, we have shown 
that the BeWo transport model, with the absence of protein in the transport buffer, 
provided useful information on relative placental transfer, with which the predictive 
value of in vitro assays for developmental toxicity could be improved. However, for 
the compounds of other classes, one should be aware that protein binding may have 
impact on the transfer.  
Placental metabolism
In addition to transfer, metabolism of compounds may occur in the placenta, which 
would alter the concentrations of the parent xenobiotic and its metabolites to which 
the fetus is exposed [45, 59]. Therefore, we investigated the metabolic activity of the 
placenta for antifungal compounds as a potential further modifier of fetal exposure, 
which should be viewed as a further step to include the toxicokinetic aspects in 
in vitro models for developmental toxicity. Placental metabolism depends on the 
activities of the xenobiotic-metabolizing enzymes localized in the placenta. Although 
several studies have addressed the question whether such enzymes are expressed in 
the placenta of humans and experimental animals [59-61], quantitative data on the 
activities of placental xenobiotic-metabolizing enzymes are rare. We have therefore 
conducted a systematic quantification of seven major xenobiotic-metabolizing enzymes 
in the near-term placenta of untreated Wistar rats and also in the liver of untreated 
adult male Wistar rats for comparison [62]. Commonly accepted assays were used 
to quantify the enzyme activities, paying special attention to high sensitivity in 
order to be able to measure low activities. For some enzymes consisting of multiple 
isoforms, the activities of isoform families were determined. Moreover, the metabolic 
turnover of testosterone and four reference antifungal compounds, being ketoconazole, 
tebuconazole, propiconazole and prothioconazole, in incubations with liver and 
placental microsomes was compared to assess the relative contribution of placental 
metabolism [62]. 
This probing of xenobiotic-metabolizing enzyme activities in rat placenta and liver 
by commonly used assays has shown that most enzyme activities are either lacking 
in the placenta or are very low compared to the liver (Table 1). In order to confirm 
this finding for CYP-mediated activities, the disposition of testosterone and four 
reference antifungal compounds was studied in microsomal incubations fortified with 
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a NADPH-regenerating system for CYP-mediated metabolism. Testosterone is known to 
be hydroxylated at various positions of the steroid moiety by multiple isoforms of CYP, 
and the specific pattern of metabolites depends on the CYP isoforms present [63-65]. 
The antifungal compounds used in our study have multiple sites for hydroxylation. In 
order to simplify the analysis, no detailed pattern of metabolites but the recovery of the 
parent compounds from incubations with active and with heat-inactivated microsomes 
was determined by HPLC analysis, and the difference was assumed to represent the 
metabolic turnover. 
The results obtained are summarized in Table 2. For testosterone, virtually no 
turnover was observed with placental microsomes but a complete disappearance of the 
parent testosterone was noted with hepatic microsomes. For the reference antifungal 
compounds, turnover with liver microsomes under the conditions applied ranged 
from 24 to 100%, depending on the individual compound and demonstrating the 
clear contribution of the hepatic metabolism of these compounds to their systemic 
clearance. In contrast, the turnover of the azoles with placental microsomes was 
negligible (Table 2). This finding confirms the notion that the placenta is virtually 
devoid of CYP activity.
Although our study includes seven major enzymes of xenobiotic metabolism, the 
placental activities of a few other enzymes still need to be determined, e.g. epoxide 
hydrolases and sulfotransferases. Moreover, it is likely that enzyme activities change 
during gestation, and placentas at earlier and later stages should also be studied. 
For example, glutathione S-transferase (GST) activity was found to be higher in rat 
placenta on day 16 than on day 20 [66]. Furthermore, placental enzyme activities may 
be influenced by exposure to other chemicals. For instance, the activity of CYP1A1, 
which is very low in the placenta of non-smoking women in the first trimester of 
pregnancy and at full-term, is substantially increased by maternal cigarette smoking 
[61]. The results of the investigations reported here indicate that, at least for antifungal 
compounds, it is not necessary to take placental metabolism into consideration for 
describing clearance because its contribution is negligible in comparison to the liver. 
However, placental metabolism is still worth investigating, for especially compounds 
known to be converted to a reactive toxic metabolite, as the placenta is capable of 
metabolizing several drugs and foreign chemicals having impact on the developmental 
toxicity outcome. For instance, it was shown that B(a)P is metabolized to its ultimate 
carcinogenic metabolite, benzo(a)pyrene 7,8-diol-9,10-epoxide, capable of DNA binding 
by a placental CYP-dependent system [67]. Another example is the observation that 
human placenta can metabolize retinoids (isotretinoin and tretinoin) to both more 
and less toxic metabolites [68].
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Table 2.  Metabolic turnover of testosterone and four model azole fungicides in incubations of 
microsomes from rat placenta and liver [62].
Test compound m/z of [M+H]+ ion/daughter ion a
Turnover (%)
Placenta Liver
Testosterone n.a. b 5.9 ± 3.1 99.7 ± 8.3
Ketoconazole 531.0/489.0 2.8 ± 6.7 24.3 ± 13.6
Tebuconazole 308.1/124.6 n.d. c 45.3 ± 3.2
Propiconazole 342.0/158.9 0.2 ± 2.3 99.8 ± 0.1
Prothioconazole 344.0/153.9 n.d. 47.6 ± 1.6
a used for quantification in LC-MS/MS; b n.a., not applicable; c n.d., not detectable (< 0.2%)
Placental toxicity
In the present thesis, intracellular accumulation of test compounds was detected in the 
BeWo cell model and we discovered that some antifungal compounds showed a high 
percentage of accumulation in the BeWo cells, amounting to up to 79 % of the total 
mass added. However, as BeWo cells only represent part of the placental tissue and 
the placental tissue structure changes over pregnancy, it is difficult to translate this 
in vitro finding to the exact in vivo situation. If this accumulation in placental cells is 
also occurring in vivo, then because of the accumulation, high intracellular levels may 
be reached upon repeated dosing, potentially causing placental toxicity. Given that the 
placenta is an entry organ to the fetus and vulnerable to the adverse effects of many 
toxicants, this merits attention. Some toxicants, such as heavy metals and pesticides 
[43, 69, 70], have been shown to accumulate in the placenta and potentially affect its 
development or function. Structural or functional damage to the placenta can lead to 
adverse effects, such as abortion, birth defects and stillbirth [71]. Therefore, it might be 
of interest to pay attention to possible placental toxicity, for which the in vitro BeWo 
cell model might be useful for prioritization because as shown in the present study the 
model is able to provide information on the intracellular accumulation of compounds 
and detect possible resulting toxicity.
ad 3) The use and development of Pbk models
Another topic that needs to be considered to a further extent in the framework of using 
alternatives for prediction of in vivo developmental toxicity is the use of PBK model 
to extrapolate in vitro data into in vivo data that are needed in risk assessment. In the 
present section, discussion focuses on whether including a placental-fetal unit in a PBK 
model is needed and how to add such a unit in a PBK model. 
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The necessity of including a placental-fetal unit in a PBK model
Using the PBK model-facilitated reverse dosimetry approach, we extrapolated the in vitro 
concentration-response curves into in vivo dose-response curves and derived BMD10 
values that correlated well to in vivo data for developmental toxicity of one of the reference 
antifungal compounds tebuconazole. It should be noted that this PBK model developed for 
tebuconazole did not include a unit that describes placental-fetal exchange. For tebuconazole, 
we have demonstrated that a fast placental transfer rate was predicted in the BeWo transport 
model and that the contribution of placental metabolism is negligible in comparison to the 
liver. In this case, we assumed that the fetal concentration of tebuconazole is likely equal 
to its maternal concentration and it was not necessary to include a placental-fetal unit in 
the PBK model. However, placental transfer should be considered in PBK modelling if no 
evidence is available to support that the fetal exposure is comparable to internal maternal 
exposure and placental metabolism should be included in the PBK model if it contributes 
significantly to the overall metabolism or to the bioactivation of the xenobiotic.
How to include a placental-fetal unit in a PBK model  
Various compartmental structures have been used to describe the placental-fetal unit, as 
previously reviewed by Corley et al. [72]. The placental-fetal unit may include placenta, 
amniotic fluids, umbilical cord and fetus. The description of the fetus could be further 
extended to include additional compartments for tissues and organs if fetal tissue exposure 
is of interest. Fig.1 summarizes the model structures of the placental-fetal unit in the 
existing pregnancy-PBK (p- PBK) models [72] and they are discussed below in more detail.
For many of the chemicals evaluated to date, simple, blood flow-limited models 
have generally been used to describe the kinetics in placental-fetal tissue. As shown in 
Fig.1A, a simple approach on PBK modelling of the placental-fetal unit is to combine 
the placenta, embryos or fetuses, as well as amniotic fluid within a lumped homogenous 
compartment based on assumption on their similarities in blood perfusion and chemical 
partitioning [73-75]. However, this assumption may not be true for all types of chemicals, 
as tissue/blood partitioning depends on the physico-chemical properties of the chemical 
and the specific tissue undergoing changes during pregnancy. More importantly, in 
this simplistic approach, delays in appearance or the concentration of a chemical in 
embryo or fetal units cannot be explained by simple differences in partitioning and 
blood perfusion parameters. 
Alternatively, it is possible to consider the placental-fetal unit as diffusion-limited. 
Fig.1B shows the conceptual structure of a PBK model in which all tissues are modeled 
as well-stirred compartments with blood flow limitations except for the placental-fetal 
unit, which is modeled as diffusion limited. This model structure has been adopted 
by most p-PBK models, for example, the models developed by for morphine [76], 
theophylline [77], methadone [78] and pethidine [79], and  for retinoic acid and its 
metabolites [80]. Moreover, some p-PBK models have modelled the amniotic fluid as a 
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compartment separated from the embryo/fetus, as shown in Fig. 1C, for example, the 
models developed for 2-methoxyethanol and 2-methoxyacetic acid and methanol [74, 
81, 82]. Such separation would benefit model validation, on the basis of the possibility 
to get in vivo data from the amniotic fluid sampling. 
The most complex approach, as shown in Fig.1D, is to model the fetus using a flow-
limited, or diffusion-limited (as well as their combination) compartmental structure of 
the fetus similar to the maternal part, with mass communication with the maternal PBK 
model via the placental-barrier [83]. This approach could be used to study the exposure 
to specific tissues/organs within the fetus. The use of this approach is restricted to 
modelling the part of the gestation period after the fetal blood circulation and tissues/
organs have been established. 
As the levels of complexity are added to the p-PBK models, a corresponding increase 
in the data requirements (and costs) associated with the development of parameters 
and validation of the models occurs. The simple models provide little insight into the 
role of embryo or fetal tissue-specific internal doses in developmental toxicity and 
does not take diffusional transfer into account, which may play an important role in 
determining fetal concentration. However, the more complex the model applied, the 
lower the number of chemicals for which data for model verification and validation 
are available. Therefore, based on the available data, a balanced complexity should be 
incorporated into PBK models in order to balance the need for reducing uncertainty 
against the need for refinement of the definition of target tissue doses. Such refinements 
are dependent on the development of reasonable hypotheses for modes of action and 
the availability of biological and chemical-specific data [72]. 
With respect to compounds with low placental transfer rates, e.g. as measured in 
the BeWo transport model, the incorporation of a placental-fetal unit in a PBK model 
is needed and for such compounds model B or C are preferable among the 4 models, as 
these two models take diffusional transfer into account and are less complex than model 
D. Importantly, parameters for diffusional transfer are needed in model B and model C. 
However, these parameters are difficult to measure and are generally inferred from in vivo 
kinetic studies [72]. For most of chemicals, including antifungal compounds, limited in 
vivo data are available on their diffusional transfer for placenta-embryo/fetus, embryo/
fetus-amniotic fluid, or placenta-amniotic fluid. Alternatively, it seems useful to use the 
ex vivo placental perfusion systems for determining these diffusional transfer parameters, 
as the ex vivo perfusion systems allows for good control of the physiological environment 
and can provide an opportunity for studying rate of chemical diffusion across the placenta. 
However, given that the ex vivo placental perfusion systems are laborious and dependent 
on the availability of fresh placenta, research is needed to identify the feasibility of using 
in vitro techniques or in silico methods, such as (Q)SAR models, to determine diffusional 
transfer parameters for building a placental-fetal unit in a PBK model.  
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ad 4) The in vivo data available and their use for validation purposes -- 
skeletal malformation or skeletal variation? litter data or fetus data?
To validate results of the relative developmental toxicity potencies obtained from the in 
vitro toxicity assays and the predicted dose-response data as determined using the PBK 
modelling-facilitated reverse dosimetry, in the present thesis the results were compared 
to available in vivo data from rat studies for developmental toxicity. These in vivo studies 
are designed to identify chemicals that are potentially hazardous to the developing 
conceptus, with the ultimate aim to provide appropriate data for the extrapolation to 
human health hazard and risk assessment. For antifungal compounds studied in the 
present thesis, in vivo data on skeletal alterations were used in order to validate the 
results obtained from in vitro and/or in silico results. 
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Skeletal alterations in development include both malformations and variations. In 
prenatal developmental toxicity studies, interpretation of skeletal alterations is a difficult 
area. Part of the difficulty lies in the historic definitions of malformations versus variations 
and the interpretation of their relevance to human risk assessment [84]. According to 
the EPA guidelines for developmental toxicity risk assessment: “A malformation is 
usually defined as a permanent structural change that may adversely affect survival, 
development, or function. The term teratogenicity is used in these guidelines to refer only 
to malformations. The term variation is used to indicate a divergence beyond the usual 
range of structural constitution that may not adversely affect survival or health” [85]. 
However, this distinction is occasionally blurred, given that there is a continuum ranging 
from variations to malformations since there exists a continuum of responses from the 
normal to the extremely deviant [84]. There have been several workshops held in which 
standardization of the classification of malformations and variations have been discussed 
[86, 87]. Nevertheless, this area remains highly disputed and depends on species and even 
strain distribution of abnormalities in the developmental process. For instance, some 
investigators would classify extra ribs as either variations or malformations depending on 
the length of the structure [84]. This historic distinction of malformations and variations 
has often affected the interpretation of the relative importance in predicting risks to 
humans [85, 88]. In the present thesis, data on both endpoints were chosen to derive 
BMD10 values for the comparison with the predicted toxicity values, as both endpoints 
were considered to represent adverse effects on the developing organism. In addition, 
where it comes to the use of in vivo data, one should be aware that appropriate historical 
control data can be helpful in the interpretation of malformations and variations, especially 
those that normally occur at very low incidences, to be able to evaluate whether these 
adverse findings are relevant indicators of developmental toxicity. When no historical 
control data are available, the data should be interpreted with caution particularly when 
a high background incidence in control animals is reported. 
In developmental toxicity studies, data can be calculated as proportion of offspring or 
implants affected per litter (fetus data), but can also be expressed as number and percent 
of litters with particular endpoints (litter data). Generally, in reproduction toxicity, liter 
data are considered to be the experimental unit on which (e.g. statistical) evaluations are 
based. In the evaluation of available in vivo developmental toxicity data to derive BMD10 
values for validation purposes of the work presented here, no upfront selection has been 
made whether litter- or fetus-data are more appropriate to use. The fetal incidence is 
often a more sensitive indicator of toxic effects than the litter incidence. However, when 
a high incidence of skeletal alterations is observed in just one litter that is due to dam 
specific (and not necessarily treatment related) effects, such as genetic background 
and environmental factors, using fetal incidence as developmental endpoint would be 
incorrect.. Therefore, it may be inappropriate to only consider one type of incidence data 
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when analyzing the in vivo data. In the present thesis, data on both litter incidence and 
fetus incidence were considered for the evaluation in order to derive reference values 
for validation of values predicted from the in vitro/in silico models.
ad 5) future perspectives and conclusions
The present thesis focuses on the use of alternative methods to predict in vivo 
developmental toxicity. Based on the results obtained in the present thesis, a framework 
of using in vitro or/and in silico methods for developmental toxicity testing could be 
proposed for antifungal compounds. As a simpler assay, the ES-D3 cell differentiation 
assay, when combined with the BeWo cell transport model, can be used in a first tier to 
predict toxicity potency of chemicals and to detect the compound(s) of high concern, 
i.e. showing high toxic potency. Then the ex ovo assay of chicken embryos can be applied 
to test chemical(s) of high concern in a second tier enabling identification of potential 
structural alterations. In combination, the three in vitro assays could provide a valuable 
tiered alternative approach for developmental toxicity screening and prioritization. 
Further on, in vitro concentration-response curves obtained from the two in vitro 
developmental toxicity assays could be extrapolated into in vivo dose-response curves 
using the PBK modelling facilitated reverse dosimetry approach. From the predicted in 
vivo dose-response curve a PoD could be derived which can be used in risk assessment. 
The present thesis provides the proof‐of‐principle that, with the help of PBK-model 
facilitated reverse dosimetry approach, in vitro concentration response curves can be 
converted into in vivo dose‐response curves for developmental toxicity of antifungal 
compounds. In order to gain more confidence on the use of this approach as input in 
risk assessment, further proof‐of‐principle studies with a wide set of chemicals from 
diverse nature for developmental toxicity are needed, especially the ones for which human 
data are available enabling validation of the predictions made for human. So far reverse 
dosimetry-based predictions have been made for the developmental toxicity of different 
classes of compounds, including glycol ethers, phenol and retinoic acid [5, 8, 89] and it 
has been possible to accurately predict a PoD for the risk assessment of these compounds 
for developmental toxicity, using in vitro and in silico data only. Besides, to increase the 
impact and applicability of using this PBK-model facilitated reverse dosimetry approach 
in risk assessment procedures, one should consider to define proofs of principle for other 
endpoints. Research gaps have been identified in the applicability of in vitro tests for 
systemic endpoints for regulatory purposes. Therefore, being able to predict PoDs for a 
broad range of endpoints would allow to assess the level of confidence of using the reverse 
dosimetry approach in risk assessment. So far, apart from developmental toxicity, this 
approach has been tested valid in extrapolating in vitro toxicity results to the in vivo 
situation for other endpoints, including kidney toxicity [90], neurotoxicity [91, 92], acute 
oral toxicity and repeated dose toxicity [93] and genotoxicity [94] of chemicals of interest. 
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From a conceptual point of view, it would seem that there is no reason why the value of 
this approach should be limited to the above mentioned toxicity endpoints. Therefore, it 
seems reasonable that the applicability of this approach could be extended towards other 
systemic endpoints. Then the use of alternative methods for risk assessment could even be 
brought to a new stage, in which based on the PoD values predicted for different endpoints, 
one could determine what would be the target tissue/organ of a chemical. All in all, this 
approach is in accordance with the concept recommended by the National Research 
Council (NRC) for Toxicity Testing in the 21st Century [95], a landmark report stating 
that scientists must embrace new technologies transitioning from current expensive 
and lengthy in vivo testing with qualitative and quantitative endpoints to in vitro assays 
evaluating cellular responses upon chemical exposure, combined with PBK modeling to 
equate in vitro effect concentrations with tissue doses expected in humans. 
Although the PBK modelling-facilitated reverse dosimetry approach has been possible 
to enhance the applicability of in vitro methods in risk assessment, the application of such 
an approach will ultimately also depend on the validation of both in vitro assays and PBK 
models and their acceptation by regulatory authorities [96]. As more and more research 
activities have been conducted on the PBK modelling-facilitated reverse dosimetry, the 
possibility of using this approach in risk assessment will increase. When implementing 
this approach in risk assessment practice, one should consider whether uncertainty 
factors would be required to account for uncertainties in the accuracy of predicted 
dose‐dependent effects. For the compound studied in the present thesis, differences in 
predicted BMD10 values and those values derived from reported rat studies were within 
5-fold, indicating that an uncertainty factor of 5 may be necessary for uncertainties in the 
predictions. With earlier reverse dosimetry-based predictions made for the developmental 
toxicity of glycol ethers, phenol, and retinoic acid [5, 8, 89], the BMD(L)10 values from 
predicted dose–response data were all within one order of magnitude of the BMD(L)10 
values obtained from in vivo data, indicating that so far a factor of 10 seems appropriate for 
uncertainties in the reverse dosimetry-based predictions. As more examples of the proof‐
of‐principle for other chemicals and other endpoints will be provided, an appropriate 
overall value for this uncertainty factor may be determined.
In conclusion, the present thesis demonstrates for antifungal compounds, the 
importance of taking placental transfer of compounds into account when predicting 
developmental toxicity with in vitro methods. It also shows that in vivo developmental 
toxicity dose levels can be closely predicted using a PBK modelling-facilitated reverse 
dosimetry approach. This reverse dosimetry approach could contribute to an increased 
acceptance and further implementation of in vitro toxicity data in risk assessment 
procedures. The combined in vitro approaches and the integrated in vitro-in silico 
approaches appear to be promising for the screening and prioritization of chemicals 
and to provide reference values, such as BMD10 values, without using animals, therefore 
contributing to the 3R principle of animal testing. 
177
7
G
e
n
e
ra
l d
is
cu
ss
io
n,
 f
u
tu
re
 p
e
rs
p
e
ct
iv
e
s 
an
d
 c
o
n
cl
u
si
o
n
s
reference
1. Van der Jagt, K., et al., Alternative 
Approaches Can Reduce the Use of Test 
Animals under REACH. Addendum to the 
Report “Assessment of addtional testing 
needs under REACH. Effects of (Q)SARs, 
risk based testing and voluntary industry 
initiatives”. 2004.
2. Marotta, F. and G. Tiboni, Molecular 
aspects of azoles-induced teratogenesis. 
Expert Opinion on Drug Metabolism & 
Toxicology, 2010. 6(4): p. 461-482.
3. Genschow, E., et al., Validation of the 
embryonic stem cell test in the international 
ECVAM validation study on three in vitro 
embryotoxicity tests. ATLA Alternatives 
to Laboratory Animals, 2004. 32(3): p. 209-
244.
4. Strikwold, M., et al., Relative embryotoxic 
potency of p-substituted phenols in 
the embryonic stem cell test (EST) and 
comparison to their toxic potency in vivo 
and in the whole embryo culture (WEC) 
assay. Toxicology Letters, 2012. 213(2): p. 
235-242.
5. Strikwold, M., et al., Combining in vitro 
embryotoxicity data with physiologically 
based kinetic (PBK) modelling to 
define in vivo dose–response curves for 
developmental toxicity of phenol in rat and 
human. Archives of Toxicology, 2013. 87(9): 
p. 1709-1723.
6. Louisse, J., et al., Relative developmental 
toxicity potencies of retinoids in the 
embryonic stem cell test compared with their 
relative potencies in in vivo and two other 
in vitro assays for developmental toxicity. 
Toxicology Letters, 2011. 203(1): p. 1-8.
7. Louisse, J., et al., The Use of In Vitro Toxicity 
Data and Physiologically Based Kinetic 
Modeling to Predict Dose-Response Curves 
for In Vivo Developmental Toxicity of 
Glycol Ethers in Rat and Man. Toxicological 
Sciences, 2010. 118(2): p. 470-484.
8. Louisse, J., et al., Prediction of in vivo 
developmental toxicity of all-trans-retinoic 
acid based on in vitro toxicity data and 
in silico physiologically based kinetic 
modeling. Archives of Toxicology, 2014: p. 
1-14.
9. De Jong, E., et al., Relative Developmental 
Toxicity of Glycol Ether Alkoxy Acid 
Metabolites in the Embryonic Stem Cell 
Test as compared with the In Vivo Potency 
of their Parent Compounds. Toxicological 
Sciences, 2009. 110(1): p. 117-124.
10. de Jong, E., et al., Potency ranking of 
valproic acid analogues as to inhibition 
of cardiac differentiation of embryonic 
stem cells in comparison to their in vivo 
embryotoxicity. Reproductive Toxicology, 
2011. 31(4): p. 375-382.
11. Breier, J.M., et al., Neural progenitor cells 
as models for high-throughput screens of 
developmental neurotoxicity: State of the 
science. Neurotoxicology and Teratology, 
2010. 32(1): p. 4-15.
12. Mainali, E.S. and J.G. Tew, Dexamethasone 
selectively inhibits differentiation of cord 
blood stem cell derived-dendritic cell (DC) 
precursors into immature DCs. Cellular 
Immunology, 2004. 232(1–2): p. 127-136.
13. Heuer, J., et al., An in vitro embryotoxicity 
assay using the differentiation of embryonic 
mouse stem cells into haematopoietic cells. 
Toxicology in Vitro, 1994. 8(4): p. 585-587.
14. Stummann, T.C., L. Hareng, and S. Bremer, 
Embryotoxicity hazard assessment of 
methylmercury and chromium using 
embryonic stem cells. Toxicology, 2007. 
242(1–3): p. 130-143.
15. Theunissen, P.T., et al., Time-Response 
Evaluation by Transcriptomics of 
Methylmercury Effects on Neural 
Differentiation of Murine Embryonic Stem 
Cells. Toxicological Sciences, 2011. 122(2): 
p. 437-447.
16. Zimmer, B., et al., Coordinated waves of gene 
expression during neuronal differentiation 
of embryonic stem cells as basis for novel 
approaches to developmental neurotoxicity 
testing. 2011. 18(3): p. 383-395.
17. zur Nieden, N.I., L.A. Davis, and D.E. 
Rancourt, Comparing three novel 
178
7
G
e
n
e
ra
l d
is
cu
ss
io
n,
 f
u
tu
re
 p
e
rs
p
e
ct
iv
e
s 
an
d
 c
o
n
cl
u
si
o
n
s
endpoints for developmental osteotoxicity 
in the embryonic stem cell test. Toxicology 
and Applied Pharmacology, 2010. 247(2): p. 
91-97.
18. zur Nieden, N.I., L.A. Davis, and D.E. 
Rancourt, Monolayer cultivation of 
osteoprogenitors shortens duration of the 
embryonic stem cell test while reliably 
predicting developmental osteotoxicity. 
Toxicology, 2010. 277(1–3): p. 66-73.
19. Doss, M.X., et al., Global transcriptome 
analysis of murine embryonic stem cell-
derived cardiomyocytes. Genome Biology, 
2007. 8(4): p. R56-R56.
20. van Dartel, D.A.M. and A.H. Piersma, The 
embryonic stem cell test combined with 
toxicogenomics as an alternative testing 
model for the assessment of developmental 
toxicity. Reproductive Toxicology, 2011. 
32(2): p. 235-244.
21. Hall, B.K., The Neural Crest and Neural 
Crest Cells in Vertebrate Development and 
Evolution. 2009, Springer: New York. p. 
269–293.
22. Marotta, F. and G.M. Tiboni, Molecular 
aspects of azoles-induced teratogenesis. 
Expert Opinion on Drug Metabolism & 
Toxicology, 2010. 6(4): p. 461-482.
23. Jurand, A., Early changes in limb buds of 
chick embryos after thalidomide treatment. 
Development, 1966. 16(2): p. 289-300.
24. Salzgeber, p.B. and J. Salaün, Action de 
la thalidomide sur l’embryon de poulet. 
Development, 1965. 13(2): p. 159-170.
25. Verrett, M.J., et al., Toxicity and 
teratogenicity of food additive chemicals in 
the developing chicken embryo. Toxicology 
and Applied Pharmacology, 1980. 56(2): p. 
265-273.
26. Griffin, G.F. and F.S. Chu, Toxicity of 
the Alternaria metabolites alternariol, 
alternariol methyl ether, altenuene, and 
tenuazonic acid in the chicken embryo assay. 
Applied and Environmental Microbiology, 
1983. 46(6): p. 1420-1422.
27. Gebhardt, D.O.E. and M.J. van Logten, The 
chick embryo test as used in the study of 
the toxicity of certain dithiocarbamates. 
Toxicology and Applied Pharmacology, 
1968. 13(3): p. 316-324.
28. Schomann, T., et al., Improved Method for 
Ex Ovo-Cultivation of Developing Chicken 
Embryos for Human Stem Cell Xenografts. 
Stem Cells International, 2013. 2013: p. 9.
29. Datar, S. and R.R. Bhonde, Shell-less chick 
embryo culture as an alternative in vitro 
model to investigate glucose-induced 
malformations in mammalian embryos. 
The review of diabetic studies : RDS, 2005. 
2(4): p. 221-227.
30. Hamamichi, S. and H. Nishigori, 
Establishment of a chick embryo shell-
less culture system and its use to observe 
change in behavior caused by nicotine 
and substances from cigarette smoke. 
Toxicology Letters, 2001. 119(2): p. 95-102.
31. PEIFER, C. and G. DANNHARDT, A Novel 
Quantitative Chick Embryo Assay as an 
Angiogenesis Model Using Digital Image 
Analysis. Anticancer Research, 2004. 
24(3A): p. 1545-1552.
32. Bellingham, M. and R.M. Sharpe, Chemical 
Exposures During Pregnancy: Dealing with 
Potential, but Unproven, Risks to Child 
Health. 2013.
33. WHO, Endocrine disrupters and child 
health. Possible developmental early effects 
of endocrine disrupters on child health. 
2012.
34. Raun Andersen, H., et al., Effects of 
Currently Used Pesticides in Assays 
for Estrogenicity, Androgenicity, and 
Aromatase Activity in Vitro. Toxicology 
and Applied Pharmacology, 2002. 179(1): 
p. 1-12.
35. Augustowska, K., et al., Effects of dioxin 
(2,3,7,8-TCDD) and PCDDs/PCDFs 
congeners mixture on steroidogenesis in 
human placenta tissue culture. Endocr 
Regul, 2003. 37(1): p. 11-9.
36. Kjærstad, M.B., et al., Endocrine disrupting 
effects in vitro of conazole antifungals 
used as pesticides and pharmaceuticals. 
Reproductive Toxicology, 2010. 30(4): p. 
573-582.
179
7
G
e
n
e
ra
l d
is
cu
ss
io
n,
 f
u
tu
re
 p
e
rs
p
e
ct
iv
e
s 
an
d
 c
o
n
cl
u
si
o
n
s
37. Stinchcombe, S., et al., Effects of Estrogen 
Coadministration on Epoxiconazole 
Toxicity in Rats. Birth Defects Research 
Part B: Developmental and Reproductive 
Toxicology, 2013. 98(3): p. 247-259.
38. Paakki, P., et al., Antepartum 
Glucocorticoid Therapy Suppresses 
Human Placental Xenobiotic and Steroid 
Metabolizing Enzymes. Placenta, 2000. 
21(2–3): p. 241-246.
39. Paakki, P., et al., Maternal drug abuse 
and human term placental xenobiotic and 
steroid metabolizing enzymes in vitro. 
Environmental Health Perspectives, 2000. 
108(2): p. 141-145.
40. Crinnion, W.J., Maternal levels of 
xenobiotics that affect fetal development 
and childhood health. Alternative medicine 
review : a journal of clinical therapeutic, 
2009. 14(3): p. 212-222.
41. Charles, G.D., In Vitro Models in Endocrine 
Disruptor Screening. ILAR Journal, 2004. 
45(4): p. 494-501.
42. Hecker, M. and H. Hollert, Endocrine 
disruptor screening: regulatory 
perspectives and needs. Environmental 
Sciences Europe, 2011. 23(1): p. 1-14.
43. Myllynen, P., M. Pasanen, and O. Pelkonen, 
Human placenta: a human organ for 
developmental toxicology research and 
biomonitoring. Placenta, 2005. 26(5): p. 
361-371.
44. Macklon, N.S., J.P.M. Geraedts, and B.C.J.M. 
Fauser, Conception to ongoing pregnancy: 
the ‘black box’ of early pregnancy loss. 
Human Reproduction Update, 2002. 8(4): 
p. 333-343.
45. Myllynen, P. and K. Vähäkangas, Placental 
transfer and metabolism: An overview of 
the experimental models utilizing human 
placental tissue. Toxicology in Vitro, 2013. 
27(1): p. 507-512.
46. Myllynen, P., M. Pasanen, and K. 
Vähäkangas, The fate and effects of 
xenobiotics in human placenta. Expert 
Opinion on Drug Metabolism & Toxicology, 
2007. 3(3): p. 331-346.
47. Kalabis, G.M., et al., Breast Cancer 
Resistance Protein (Bcrp1/Abcg2) in Mouse 
Placenta and Yolk Sac: Ontogeny and its 
Regulation by Progesterone. Placenta, 2007. 
28(10): p. 1073-1081.
48. Mölsä, M., et al., Functional role of 
P-glycoprotein in the human blood-
placental barrier. Clinical Pharmacology & 
Therapeutics, 2005. 78(2): p. 123-131.
49. Pávek, P., et al., Influence of P-glycoprotein 
on the transplacental passage of 
cyclosporine. Journal of Pharmaceutical 
Sciences, 2001. 90(10): p. 1583-1592.
50. Lager, S. and T.L. Powell, Regulation of 
Nutrient Transport across the Placenta. 
Journal of Pregnancy, 2012. 2012: p. 14.
51. Magnarin, M., et al., Role of ABC 
Transporters in the BeWo Trophoblast 
Cell Line. Toxicology Mechanisms and 
Methods, 2008. 18(9): p. 763-769.
52. Ceckova, M., et al., Expression and functional 
activity of breast cancer resistance protein 
(bcrp, abcg2) transporter in the human 
choriocarcinoma cell line bewo. Clinical 
and Experimental Pharmacology and 
Physiology, 2006. 33(1-2): p. 58-65.
53. Jin, C.J., et al., Functional characterization 
of L-type amino acid transport in human 
choriocarcinoma cell BeWo cell. . FASEB J., 
2009.
54. Utoguchi, N., et al., Functional expression 
of P-glycoprotein in primary cultures of 
human cytotrophoblasts and BeWo cells☆. 
Reproductive Toxicology, 2000. 14(3): p. 
217-224.
55. Pacifici, G. and R. Nottoli, Placental 
Transfer of Drugs Administered to the 
Mother. Clinical Pharmacokinetics, 1995. 
28(3): p. 235-269.
56. Boréus, L.-O., Placental Transfer of 
Ampicillin in Man. Acta Pharmacologica et 
Toxicologica, 1971. 29: p. 250-254.
57. He, Y.L., et al., Effects of protein binding 
on the placental transfer of propofol in the 
human dually perfused cotyledon in vitro. 
British Journal of Anaesthesia, 2000. 85(2): 
p. 281-286.
180
7
G
e
n
e
ra
l d
is
cu
ss
io
n,
 f
u
tu
re
 p
e
rs
p
e
ct
iv
e
s 
an
d
 c
o
n
cl
u
si
o
n
s
58. Li, H., et al., Assessment of an in vitro 
transport model using BeWo b30 cells to 
predict placental transfer of compounds. 
Archives of Toxicology, 2013. 87(9): p. 1661-
1669 
59. Syme, M., J. Paxton, and J. Keelan, Drug 
Transfer and Metabolism by the Human 
Placenta. Clinical Pharmacokinetics, 2004. 
43(8): p. 487-514.
60. Juchau, M.R., Drug biotransformation in 
the placenta. Pharmacology & Therapeutics, 
1980. 8(3): p. 501-524.
61. Hakkola, J., et al., Expression of xenobiotic-
metabolizing cytochrome P450 Forms in 
human full-term placenta. Biochemical 
Pharmacology, 1996. 51(4): p. 403-411.
62. Fabian, E., et al., Activities of xenobiotic 
metabolizing enzymes in rat placenta and 
liver in vitro. 2015 submitted.
63. Waxman, D.J., Interactions of hepatic 
cytochromes P-450 with steroid hormones. 
Biochemical Pharmacology, 1988. 37(1): p. 
71-84.
64. Waxman, D.J., A. Ko, and C. Walsh, 
Regioselectivity and stereoselectivity of 
androgen hydroxylations catalyzed by 
cytochrome P-450 isozymes purified from 
phenobarbital-induced rat liver. Journal 
of Biological Chemistry, 1983. 258(19): p. 
11937-11947.
65. Pfeiffer, E. and M. Metzler, Effect of 
bisphenol A on drug metabolising enzymes 
in rat hepatic microsomes and precision-
cut rat liver slices. Archives of Toxicology, 
2004. 78(7): p. 369-377.
66. Ilio, C.D., et al., Glutathione-S-transferase 
activity from rat placenta. Placenta, 1986. 
7(2): p. 155-162.
67. Namkung, M.J. and M.R. Juchau, On the 
capacity of human placental enzymes 
to catalyze the formation of diols from 
benzo[a]pyrene. Toxicology and Applied 
Pharmacology, 1980. 55(2): p. 253-259.
68. Miller, R.K., et al., The Role of the Human 
Placenta in Embryonic Nutrition. Impact of 
Environmental and Social Factorsa. Annals 
of the New York Academy of Sciences, 1993. 
678(1): p. 92-107.
69. Kantola, M., et al., Accumulation of 
Cadmium, Zinc, and Copper in Maternal 
Blood and Developmental Placental Tissue: 
Differences between Finland, Estonia, and 
St. Petersburg. Environmental Research, 
2000. 83(1): p. 54-66.
70. Graf, R., R. Gossrau, and H.G. Frank, 
Placental toxicity in rats after administration 
of synthetic glucocorticoids. Anatomy and 
Embryology, 1989. 180(2): p. 121-130.
71. Magnarelli, G. and N. Guiñazú, Placental 
Toxicology of Pesticides. (2012: InTech.
72. Corley, R.A., et al., Evaluation of 
Physiologically Based Models of Pregnancy 
and Lactation for Their Application in 
Children’s Health Risk Assessments. Critical 
Reviews in Toxicology, 2003. 33(2): p. 137-211.
73. Gargas, M.L., et al., A Toxicokinetic Study 
of Inhaled Ethylene Glycol Ethyl Ether 
Acetate and Validation of a Physiologically 
Based Pharmacokinetic Model for Rat 
and Human. Toxicology and Applied 
Pharmacology, 2000. 165(1): p. 63-73.
74. Clarke, D.O., et al., Pharmacokinetics of 
2-Methoxyethanol and 2-Methoxyacetic 
Acid in the Pregnant Mouse: A 
Physiologically Based Mathematical Model. 
Toxicology and Applied Pharmacology, 
1993. 121(2): p. 239-252.
75. Hays, S.M., et al., Development of a 
Physiologically Based Pharmacokinetic 
Model of 2-Methoxyethanol and 
2-Methoxyacetic Acid Disposition in 
Pregnant Rats. Toxicology and Applied 
Pharmacology, 2000. 163(1): p. 67-74.
76. Gabrielsson, J. and L. Paalzow, A 
physiological pharmacokinetic model for 
morphine disposition in the pregnant rat. 
J Pharmacokinet Biopharm. , 1983 11(2): p. 
147-63.
77. Gabrielsson, J., L. Paalzow, and L. Nordström, 
A physiologically based pharmacokinetic 
model for theophylline disposition in the 
pregnant and nonpregnant rat. Journal of 
Pharmacokinetics and Biopharmaceutics, 
1984. 12(2): p. 149-165.
78. Gabrielsson, J., et al., Analysis of methadone 
disposition in the pregnant rat by means of a 
181
7
G
e
n
e
ra
l d
is
cu
ss
io
n,
 f
u
tu
re
 p
e
rs
p
e
ct
iv
e
s 
an
d
 c
o
n
cl
u
si
o
n
s
physiological flow model. J Pharmacokinet 
Biopharm.  , 1985. 13(4): p. 355-72.
79. Gabrielsson, J., et al., Analysis of pethidine 
disposition in the pregnant rat by means of a 
physiological flow model. J Pharmacokinet 
Biopharm, 1986. 14(4): p. 381-95.
80. Clewell Iii, H.J., et al., A physiologically 
based pharmacokinetic model for retinoic 
acid and its metabolites. Journal of the 
American Academy of Dermatology, 1997. 
36(3, Supplement): p. S77-S85.
81. Ward, K.W., et al., Development of a 
Physiologically Based Pharmacokinetic 
Model to Describe the Disposition of 
Methanol in Pregnant Rats and Mice. 
Toxicology and Applied Pharmacology, 
1997. 145(2): p. 311-322.
82. Welsch, F., G.M. Blumenthal, and R.B. Conolly, 
Physiologically based pharmacokinetic 
models applicable to organogenesis: 
extrapolation between species and potential 
use in prenatal toxicity risk assessments. 
Toxicology Letters, 1995. 82–83: p. 539-547.
83. Luecke, R.H., et al., A computer model and 
program for xenobiotic disposition during 
pregnancy. Computer Methods and Programs 
in Biomedicine, 1997. 53(3): p. 201-224.
84. Daston, G.P. and J. Seed, Skeletal 
malformations and variations in 
developmental toxicity studies: 
Interpretation issues for human risk 
assessment. Birth Defects Research Part 
B: Developmental and Reproductive 
Toxicology, 2007. 80(6): p. 421-424.
85. EPA, Guidelines for Developmental Toxicity 
Risk Assessment. U.S. Environmental 
Protection Agency, Risk Assessment Forum 
1991: Washington, DC,.
86. Solecki, R., et al., Harmonisation of rat fetal 
skeletal terminology and classification. 
report of the third workshop on the 
terminology in developmental toxicology: 
Berlin, 14–16 September 2000. Reproductive 
Toxicology, 2001. 15(6): p. 713-721.
87. Paumgartten, F., et al., Harmonization of 
terminology in developmental toxicology: 
The quest for a more precise description 
and a harmonized classification of fetal 
observations. Reproductive Toxicology, 
2009. 27(1): p. 8-13.
88. OECD, Test No. 414: Prenatal Development 
Toxicity Study,OECD Guidelines for the 
Testing of Chemicals, Section 4,. 2001.
89. Louisse, J., et al., The use of in vitro toxicity 
data and physiologically based kinetic 
modeling to predict dose-response curves 
for in vivo developmental toxicity of 
glycol ethers in rat and man. Toxicological 
Sciences, 2010.
90. Abdullah, R., et al., Combining in vitro 
cytotoxicity data with physiologically based 
kinetic (PBK) modeling to define in vivo 
dose-response curves for kidney toxicity of 
aristolochic acid I in rat, mouse and human. 
. Submitted., 2015.
91. DeJongh, J., et al., Estimation of Systemic 
Toxicity of Acrylamide by Integration 
of in Vitro Toxicity Data with Kinetic 
Simulations. Toxicology and Applied 
Pharmacology, 1999. 158(3): p. 261-268.
92. Forsby, A. and B. Blaauboer, Integration of 
in vitro neurotoxicity data with biokinetic 
modelling for the estimation of in vivo 
neurotoxicity. Human & Experimental 
Toxicology, 2007. 26(4): p. 333-338.
93. Gubbels-van Hal, W.M.L.G., et al., An 
alternative approach for the safety evaluation 
of new and existing chemicals, an exercise 
in integrated testing. Regulatory Toxicology 
and Pharmacology, 2005. 42(3): p. 284-295.
94. Paini, A., et al., A physiologically based 
biodynamic (PBBD) model for estragole 
DNA binding in rat liver based on in 
vitro kinetic data and estragole DNA 
adduct formation in primary hepatocytes. 
Toxicology and Applied Pharmacology, 
2010. 245(1): p. 57-66.
95. Council, N.N.R., Toxicity Testing in the 
21st Century: A Vision and A Strategy. 
2007: Washington, D.C.
96. Punt, A., et al., Evaluation of research 
activities and research needs to increase 
the impact and applicability of alternative 
testing strategies in risk assessment 
practice. Regulatory Toxicology and 
Pharmacology, 2011. 61(1): p. 105-114.

Summary
C H A P T E R  8

185
8
S
u
m
m
ar
y
summary
For the determination of safe human exposure levels of chemicals in toxicological 
risk assessments, there is large interest in the development of in vitro and/or in silico 
test systems as alternatives for animal studies. The aim of the present thesis was to 
evaluate the applicability of an integrated in vitro-in silico approach for prediction of 
developmental toxicity using a series of antifungal compounds as the model compounds.
In Chapter 2, we developed and validated an in vitro placental barrier model using 
BeWo b30 cells to predict placental transfer. For a set of nine selected model compounds, 
the relative transport rates obtained in the in vitro model were in very good correlation 
(R2 = 0.95) with the transfer indices reported for the ex vivo placental transfusion model 
in the literature. This demonstrated that the BeWo model could be a valuable in vitro 
model to predict relative placental transfer of compounds.
In Chapter 3, the in vitro developmental toxicity of five selected model antifungal 
compounds was investigated by determining the effect concentrations that inhibit 
the differentiation of ES-D3 cells into beating cardiomyocytes. When the ES-D3 cell 
differentiation data were combined with the relative transport rates obtained from the 
BeWo transport model, the correlation with the in vivo data (R2 = 0.95) was better than 
using the ES-D3 cell differentiation data alone (R2 = 0.57). This shows that the ES-D3 
cell differentiation assay is able to better predict the in vivo developmental toxicity 
potencies of antifungal compounds when combined with the BeWo transport model, 
than as a stand-alone assay. To validate this combined in vitro approach to predict in 
vivo developmental toxicity, we combined ES-D3 cell differentiation data of six novel 
triazole antifungal compounds with their relative transport rates obtained from the 
BeWo model and compared the obtained ranking to the developmental toxicity ranking 
as derived from in vivo data (Chapter 4). The data obtained show that the combined 
in vitro approach provided a correct prediction for the relative in vivo developmental 
toxicity, whereas the ES-D3 cell differentiation assay as stand-alone did not. We suggest 
that this combined model, which takes both toxicodynamic and toxicokinetic aspects 
into account, should be further validated for other chemical classes of developmental 
toxicants.
In Chapter 5, we investigated the applicability of the ex ovo assay of chicken embryos 
to predict the specific alterations induced by the five antifungal compounds that were 
used in Chapter 3 and investigated if the combination of the assay with placental 
transfer information would improve its predictive capacity. The ex ovo assay assesses 
the developmental toxic potential of compounds based on well-defined morphological 
endpoints. Each compound produced a characteristic pattern of alterations. When the 
toxicity data from the ex ovo assay were combined with the relative transport rates 
from the BeWo model, the correlation with the in vivo data were better than using the 
toxicity data from the ex ovo assay alone. This revealed that the ex ovo assay of chicken 
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embryos is able to assess the teratogenic potential of antifungal compounds, and, when 
combined with the in vitro BeWo transport model, is able to better predict relative in 
vivo prenatal developmental toxicity potencies.
In Chapter 6, we translated in vitro concentration–response data of the antifungal 
compound tebuconazole, obtained in the ES-D3 cell differentiation assay and the ex ovo 
assay of chicken embryos, into predicted in vivo dose–response data using physiologically 
based kinetic modelling-facilitated reverse dosimetry. The results show that the BMD10 
values from predicted dose–response data from both assays are in concordance with 
BMD10 values derived from in vivo data (within 5-fold difference). This revealed that 
physiologically based kinetic modeling is a promising tool to predict in vivo dose-
response curves based on the results of in vitro toxicity assays, and may therefore be 
used to set a point of departure for deriving safe exposure limits in risk assessment.
In Chapter 7 we presented a discussion of the data obtained and also future 
perspectives. It is concluded that it is important to take placental transfer of compounds 
into account when predicting developmental toxicity with in vitro methods. The results 
obtained also show that in vivo developmental toxicity dose levels can be closely predicted 
using a PBK modelling-facilitated reverse dosimetry approach. This reverse dosimetry 
approach could contribute to an increased acceptance and further implementation of 
in vitro toxicity data in risk assessment procedures. The combined in vitro approaches 
and the integrated in vitro-in silico approaches appear to be promising for the screening 
and prioritization of chemicals and to provide reference values, such as BMD10 values, 
without using animals, therefore contributing to the 3R principle of animal testing.
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